#FORMAT=WebAnno TSV 3.3
#T_SP=webanno.custom.ConceptLayer|identifier


#Text=Elevated peripheral cytokines characterize a subgroup of people with schizophrenia displaying poor verbal fluency and reduced Broca's area volume
#Text=Previous studies on schizophrenia have detected elevated cytokines in both brain and blood, suggesting neuroinflammation may contribute to the pathophysiology in some cases.
1-1	0-8	Elevated	_
1-2	9-19	peripheral	_
1-3	20-29	cytokines	_
1-4	30-42	characterize	_
1-5	43-44	a	_
1-6	45-53	subgroup	_
1-7	54-56	of	_
1-8	57-63	people	_
1-9	64-68	with	_
1-10	69-82	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
1-11	83-93	displaying	_
1-12	94-98	poor	_
1-13	99-105	verbal	_
1-14	106-113	fluency	_
1-15	114-117	and	_
1-16	118-125	reduced	_
1-17	126-133	Broca's	_
1-18	134-138	area	_
1-19	139-145	volume	_
1-20	146-154	Previous	_
1-21	155-162	studies	_
1-22	163-165	on	_
1-23	166-179	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
1-24	180-184	have	_
1-25	185-193	detected	_
1-26	194-202	elevated	_
1-27	203-212	cytokines	_
1-28	213-215	in	_
1-29	216-220	both	_
1-30	221-226	brain	_
1-31	227-230	and	_
1-32	231-236	blood	_
1-33	236-237	,	_
1-34	238-248	suggesting	_
1-35	249-266	neuroinflammation	_
1-36	267-270	may	_
1-37	271-281	contribute	_
1-38	282-284	to	_
1-39	285-288	the	_
1-40	289-304	pathophysiology	_
1-41	305-307	in	_
1-42	308-312	some	_
1-43	313-318	cases	_
1-44	318-319	.	_

#Text=We aimed to determine the extent to which elevated peripheral cytokine messenger RNA (mRNA) expression: (1) characterizes a subgroup of people with schizophrenia and (2) shows a relationship to cognition, brain volume and/or symptoms.
2-1	320-322	We	_
2-2	323-328	aimed	_
2-3	329-331	to	_
2-4	332-341	determine	_
2-5	342-345	the	_
2-6	346-352	extent	_
2-7	353-355	to	_
2-8	356-361	which	_
2-9	362-370	elevated	_
2-10	371-381	peripheral	_
2-11	382-390	cytokine	_
2-12	391-400	messenger	_
2-13	401-404	RNA	_
2-14	405-406	(	_
2-15	406-410	mRNA	_
2-16	410-411	)	_
2-17	412-422	expression	_
2-18	422-423	:	_
2-19	424-425	(	_
2-20	425-426	1	_
2-21	426-427	)	_
2-22	428-441	characterizes	_
2-23	442-443	a	_
2-24	444-452	subgroup	_
2-25	453-455	of	_
2-26	456-462	people	_
2-27	463-467	with	_
2-28	468-481	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
2-29	482-485	and	_
2-30	486-487	(	_
2-31	487-488	2	_
2-32	488-489	)	_
2-33	490-495	shows	_
2-34	496-497	a	_
2-35	498-510	relationship	_
2-36	511-513	to	_
2-37	514-523	cognition	_
2-38	523-524	,	_
2-39	525-530	brain	_
2-40	531-537	volume	_
2-41	538-541	and	_
2-42	541-542	/	_
2-43	542-544	or	_
2-44	545-553	symptoms	_
2-45	553-554	.	_

#Text=Forty-three outpatients with schizophrenia or schizoaffective disorder and matched healthy controls were assessed for peripheral cytokine mRNAs (interleukin (IL)-1β, IL-2, IL-6, IL-8 and IL-18), intelligence quotient, memory and verbal fluency, symptom severity and cortical brain volumes integral to language (that is, Broca's and Wernicke's areas).
3-1	555-566	Forty-three	_
3-2	567-578	outpatients	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[1]
3-3	579-583	with	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[1]
3-4	584-597	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[1]
3-5	598-600	or	_
3-6	601-616	schizoaffective	http://maven.renci.org/NeuroBridge/neurobridge#SchizoaffectiveDisorder[2]
3-7	617-625	disorder	http://maven.renci.org/NeuroBridge/neurobridge#SchizoaffectiveDisorder[2]
3-8	626-629	and	_
3-9	630-637	matched	_
3-10	638-645	healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[3]
3-11	646-654	controls	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[3]
3-12	655-659	were	_
3-13	660-668	assessed	_
3-14	669-672	for	_
3-15	673-683	peripheral	_
3-16	684-692	cytokine	_
3-17	693-698	mRNAs	_
3-18	699-700	(	_
3-19	700-711	interleukin	_
3-20	712-713	(	_
3-21	713-715	IL	_
3-22	715-716	)	_
3-23	716-717	-	_
3-24	717-719	1β	_
3-25	719-720	,	_
3-26	721-723	IL	_
3-27	723-724	-	_
3-28	724-725	2	_
3-29	725-726	,	_
3-30	727-729	IL	_
3-31	729-730	-	_
3-32	730-731	6	_
3-33	731-732	,	_
3-34	733-735	IL	_
3-35	735-736	-	_
3-36	736-737	8	_
3-37	738-741	and	_
3-38	742-744	IL	_
3-39	744-745	-	_
3-40	745-747	18	_
3-41	747-748	)	_
3-42	748-749	,	_
3-43	750-762	intelligence	_
3-44	763-771	quotient	_
3-45	771-772	,	_
3-46	773-779	memory	_
3-47	780-783	and	_
3-48	784-790	verbal	_
3-49	791-798	fluency	_
3-50	798-799	,	_
3-51	800-807	symptom	_
3-52	808-816	severity	_
3-53	817-820	and	_
3-54	821-829	cortical	_
3-55	830-835	brain	_
3-56	836-843	volumes	_
3-57	844-852	integral	_
3-58	853-855	to	_
3-59	856-864	language	_
3-60	865-866	(	_
3-61	866-870	that	_
3-62	871-873	is	_
3-63	873-874	,	_
3-64	875-882	Broca's	_
3-65	883-886	and	_
3-66	887-897	Wernicke's	_
3-67	898-903	areas	_
3-68	903-904	)	_
3-69	904-905	.	_

#Text=IL-1β mRNA levels were 28% increased in schizophrenia compared with controls (t(82)=2.64, P<0.01).
4-1	906-908	IL	_
4-2	908-909	-	_
4-3	909-911	1β	_
4-4	912-916	mRNA	_
4-5	917-923	levels	_
4-6	924-928	were	_
4-7	929-932	28%	_
4-8	933-942	increased	_
4-9	943-945	in	_
4-10	946-959	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
4-11	960-968	compared	_
4-12	969-973	with	_
4-13	974-982	controls	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
4-14	983-984	(	_
4-15	984-985	t	_
4-16	985-986	(	_
4-17	986-988	82	_
4-18	988-989	)	_
4-19	989-990	=	_
4-20	990-994	2.64	_
4-21	994-995	,	_
4-22	996-997	P	_
4-23	997-998	<	_
4-24	998-1002	0.01	_
4-25	1002-1003	)	_
4-26	1003-1004	.	_

#Text=Using a two-step clustering procedure, we identified a subgroup of people displaying relatively elevated cytokine mRNA levels (17/43 people with schizophrenia and 9/42 controls).
5-1	1005-1010	Using	_
5-2	1011-1012	a	_
5-3	1013-1021	two-step	_
5-4	1022-1032	clustering	_
5-5	1033-1042	procedure	_
5-6	1042-1043	,	_
5-7	1044-1046	we	_
5-8	1047-1057	identified	_
5-9	1058-1059	a	_
5-10	1060-1068	subgroup	_
5-11	1069-1071	of	_
5-12	1072-1078	people	_
5-13	1079-1089	displaying	_
5-14	1090-1100	relatively	_
5-15	1101-1109	elevated	_
5-16	1110-1118	cytokine	_
5-17	1119-1123	mRNA	_
5-18	1124-1130	levels	_
5-19	1131-1132	(	_
5-20	1132-1134	17	_
5-21	1134-1135	/	_
5-22	1135-1137	43	_
5-23	1138-1144	people	_
5-24	1145-1149	with	_
5-25	1150-1163	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
5-26	1164-1167	and	_
5-27	1168-1169	9	_
5-28	1169-1170	/	_
5-29	1170-1172	42	_
5-30	1173-1181	controls	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
5-31	1181-1182	)	_
5-32	1182-1183	.	_

#Text=Individuals with schizophrenia in the elevated cytokine subgroup performed significantly worse than the low-cytokine subgroup on verbal fluency (F(1,40)=15.7, P<0.001).
6-1	1184-1195	Individuals	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[4]
6-2	1196-1200	with	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[4]
6-3	1201-1214	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[4]
6-4	1215-1217	in	_
6-5	1218-1221	the	_
6-6	1222-1230	elevated	_
6-7	1231-1239	cytokine	_
6-8	1240-1248	subgroup	_
6-9	1249-1258	performed	_
6-10	1259-1272	significantly	_
6-11	1273-1278	worse	_
6-12	1279-1283	than	_
6-13	1284-1287	the	_
6-14	1288-1300	low-cytokine	_
6-15	1301-1309	subgroup	_
6-16	1310-1312	on	_
6-17	1313-1319	verbal	_
6-18	1320-1327	fluency	_
6-19	1328-1329	(	_
6-20	1329-1330	F	_
6-21	1330-1331	(	_
6-22	1331-1335	1,40	_
6-23	1335-1336	)	_
6-24	1336-1337	=	_
6-25	1337-1341	15.7	_
6-26	1341-1342	,	_
6-27	1343-1344	P	_
6-28	1344-1345	<	_
6-29	1345-1350	0.001	_
6-30	1350-1351	)	_
6-31	1351-1352	.	_

#Text=There was a 17% volume reduction of the left pars opercularis (POp) (Broca's area) in patients with elevated cytokines compared with patients with lower cytokines (F(1,29)=9.41, P=0.005).
7-1	1353-1358	There	_
7-2	1359-1362	was	_
7-3	1363-1364	a	_
7-4	1365-1368	17%	_
7-5	1369-1375	volume	_
7-6	1376-1385	reduction	_
7-7	1386-1388	of	_
7-8	1389-1392	the	_
7-9	1393-1397	left	_
7-10	1398-1402	pars	_
7-11	1403-1414	opercularis	_
7-12	1415-1416	(	_
7-13	1416-1419	POp	_
7-14	1419-1420	)	_
7-15	1421-1422	(	_
7-16	1422-1429	Broca's	_
7-17	1430-1434	area	_
7-18	1434-1435	)	_
7-19	1436-1438	in	_
7-20	1439-1447	patients	_
7-21	1448-1452	with	_
7-22	1453-1461	elevated	_
7-23	1462-1471	cytokines	_
7-24	1472-1480	compared	_
7-25	1481-1485	with	_
7-26	1486-1494	patients	_
7-27	1495-1499	with	_
7-28	1500-1505	lower	_
7-29	1506-1515	cytokines	_
7-30	1516-1517	(	_
7-31	1517-1518	F	_
7-32	1518-1519	(	_
7-33	1519-1523	1,29	_
7-34	1523-1524	)	_
7-35	1524-1525	=	_
7-36	1525-1529	9.41	_
7-37	1529-1530	,	_
7-38	1531-1532	P	_
7-39	1532-1533	=	_
7-40	1533-1538	0.005	_
7-41	1538-1539	)	_
7-42	1539-1540	.	_

#Text=Negative linear relationships between IL-1β mRNA levels and both verbal fluency and left POp volume were found in schizophrenia.
8-1	1541-1549	Negative	_
8-2	1550-1556	linear	_
8-3	1557-1570	relationships	_
8-4	1571-1578	between	_
8-5	1579-1581	IL	_
8-6	1581-1582	-	_
8-7	1582-1584	1β	_
8-8	1585-1589	mRNA	_
8-9	1590-1596	levels	_
8-10	1597-1600	and	_
8-11	1601-1605	both	_
8-12	1606-1612	verbal	_
8-13	1613-1620	fluency	_
8-14	1621-1624	and	_
8-15	1625-1629	left	_
8-16	1630-1633	POp	_
8-17	1634-1640	volume	_
8-18	1641-1645	were	_
8-19	1646-1651	found	_
8-20	1652-1654	in	_
8-21	1655-1668	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
8-22	1668-1669	.	_

#Text=This study is among the first to link blood biomarkers of inflammation with both cognitive deficits and brain volume reductions in people with schizophrenia, supporting that those with elevated cytokines represent a neurobiologically meaningful subgroup.
9-1	1670-1674	This	_
9-2	1675-1680	study	_
9-3	1681-1683	is	_
9-4	1684-1689	among	_
9-5	1690-1693	the	_
9-6	1694-1699	first	_
9-7	1700-1702	to	_
9-8	1703-1707	link	_
9-9	1708-1713	blood	_
9-10	1714-1724	biomarkers	_
9-11	1725-1727	of	_
9-12	1728-1740	inflammation	_
9-13	1741-1745	with	_
9-14	1746-1750	both	_
9-15	1751-1760	cognitive	_
9-16	1761-1769	deficits	_
9-17	1770-1773	and	_
9-18	1774-1779	brain	_
9-19	1780-1786	volume	_
9-20	1787-1797	reductions	_
9-21	1798-1800	in	_
9-22	1801-1807	people	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[5]
9-23	1808-1812	with	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[5]
9-24	1813-1826	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[5]
9-25	1826-1827	,	_
9-26	1828-1838	supporting	_
9-27	1839-1843	that	_
9-28	1844-1849	those	_
9-29	1850-1854	with	_
9-30	1855-1863	elevated	_
9-31	1864-1873	cytokines	_
9-32	1874-1883	represent	_
9-33	1884-1885	a	_
9-34	1886-1903	neurobiologically	_
9-35	1904-1914	meaningful	_
9-36	1915-1923	subgroup	_
9-37	1923-1924	.	_

#Text=These findings raise the possibility that targeted anti-inflammatory treatments may ameliorate cognitive and brain morphological abnormalities in some people with schizophrenia.
10-1	1925-1930	These	_
10-2	1931-1939	findings	_
10-3	1940-1945	raise	_
10-4	1946-1949	the	_
10-5	1950-1961	possibility	_
10-6	1962-1966	that	_
10-7	1967-1975	targeted	_
10-8	1976-1993	anti-inflammatory	_
10-9	1994-2004	treatments	_
10-10	2005-2008	may	_
10-11	2009-2019	ameliorate	_
10-12	2020-2029	cognitive	_
10-13	2030-2033	and	_
10-14	2034-2039	brain	_
10-15	2040-2053	morphological	_
10-16	2054-2067	abnormalities	_
10-17	2068-2070	in	_
10-18	2071-2075	some	_
10-19	2076-2082	people	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[6]
10-20	2083-2087	with	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[6]
10-21	2088-2101	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[6]
10-22	2101-2102	.	_

#Text=Introduction
#Text=Biological abnormalities reported in schizophrenia suggest multiple causative pathways, with no single biological etiology likely to be responsible for all cases.
11-1	2103-2115	Introduction	_
11-2	2116-2126	Biological	_
11-3	2127-2140	abnormalities	_
11-4	2141-2149	reported	_
11-5	2150-2152	in	_
11-6	2153-2166	schizophrenia	_
11-7	2167-2174	suggest	_
11-8	2175-2183	multiple	_
11-9	2184-2193	causative	_
11-10	2194-2202	pathways	_
11-11	2202-2203	,	_
11-12	2204-2208	with	_
11-13	2209-2211	no	_
11-14	2212-2218	single	_
11-15	2219-2229	biological	_
11-16	2230-2238	etiology	_
11-17	2239-2245	likely	_
11-18	2246-2248	to	_
11-19	2249-2251	be	_
11-20	2252-2263	responsible	_
11-21	2264-2267	for	_
11-22	2268-2271	all	_
11-23	2272-2277	cases	_
11-24	2277-2278	.	_

#Text=Improving interventions for schizophrenia, therefore, may depend on identifying subgroups of individuals characterized by particular biological abnormalities that can be targeted with specific treatments.
12-1	2279-2288	Improving	_
12-2	2289-2302	interventions	_
12-3	2303-2306	for	_
12-4	2307-2320	schizophrenia	_
12-5	2320-2321	,	_
12-6	2322-2331	therefore	_
12-7	2331-2332	,	_
12-8	2333-2336	may	_
12-9	2337-2343	depend	_
12-10	2344-2346	on	_
12-11	2347-2358	identifying	_
12-12	2359-2368	subgroups	_
12-13	2369-2371	of	_
12-14	2372-2383	individuals	_
12-15	2384-2397	characterized	_
12-16	2398-2400	by	_
12-17	2401-2411	particular	_
12-18	2412-2422	biological	_
12-19	2423-2436	abnormalities	_
12-20	2437-2441	that	_
12-21	2442-2445	can	_
12-22	2446-2448	be	_
12-23	2449-2457	targeted	_
12-24	2458-2462	with	_
12-25	2463-2471	specific	_
12-26	2472-2482	treatments	_
12-27	2482-2483	.	_

#Text=Plausible causative pathways may involve early (prenatal) activation of the immune system and/or abnormal immune responses contributing to the ongoing pathophysiology of schizophrenia, which are supported by epidemiological observations, animal models, post-mortem brain research and clinical studies.
13-1	2484-2493	Plausible	_
13-2	2494-2503	causative	_
13-3	2504-2512	pathways	_
13-4	2513-2516	may	_
13-5	2517-2524	involve	_
13-6	2525-2530	early	_
13-7	2531-2532	(	_
13-8	2532-2540	prenatal	_
13-9	2540-2541	)	_
13-10	2542-2552	activation	_
13-11	2553-2555	of	_
13-12	2556-2559	the	_
13-13	2560-2566	immune	_
13-14	2567-2573	system	_
13-15	2574-2577	and	_
13-16	2577-2578	/	_
13-17	2578-2580	or	_
13-18	2581-2589	abnormal	_
13-19	2590-2596	immune	_
13-20	2597-2606	responses	_
13-21	2607-2619	contributing	_
13-22	2620-2622	to	_
13-23	2623-2626	the	_
13-24	2627-2634	ongoing	_
13-25	2635-2650	pathophysiology	_
13-26	2651-2653	of	_
13-27	2654-2667	schizophrenia	_
13-28	2667-2668	,	_
13-29	2669-2674	which	_
13-30	2675-2678	are	_
13-31	2679-2688	supported	_
13-32	2689-2691	by	_
13-33	2692-2707	epidemiological	_
13-34	2708-2720	observations	_
13-35	2720-2721	,	_
13-36	2722-2728	animal	_
13-37	2729-2735	models	_
13-38	2735-2736	,	_
13-39	2737-2748	post-mortem	_
13-40	2749-2754	brain	_
13-41	2755-2763	research	_
13-42	2764-2767	and	_
13-43	2768-2776	clinical	_
13-44	2777-2784	studies	_
13-45	2784-2785	.	_

#Text=Group comparisons of peripheral circulating cytokines (signaling peptides of the immune system mediating the inflammation response) between individuals with schizophrenia and controls have consistently identified higher mean levels of interleukin (IL)-6, IL-1β, tumor necrosis factor and other cytokines in schizophrenia and even greater elevations during acute psychosis.
14-1	2786-2791	Group	_
14-2	2792-2803	comparisons	_
14-3	2804-2806	of	_
14-4	2807-2817	peripheral	_
14-5	2818-2829	circulating	_
14-6	2830-2839	cytokines	_
14-7	2840-2841	(	_
14-8	2841-2850	signaling	_
14-9	2851-2859	peptides	_
14-10	2860-2862	of	_
14-11	2863-2866	the	_
14-12	2867-2873	immune	_
14-13	2874-2880	system	_
14-14	2881-2890	mediating	_
14-15	2891-2894	the	_
14-16	2895-2907	inflammation	_
14-17	2908-2916	response	_
14-18	2916-2917	)	_
14-19	2918-2925	between	_
14-20	2926-2937	individuals	_
14-21	2938-2942	with	_
14-22	2943-2956	schizophrenia	_
14-23	2957-2960	and	_
14-24	2961-2969	controls	_
14-25	2970-2974	have	_
14-26	2975-2987	consistently	_
14-27	2988-2998	identified	_
14-28	2999-3005	higher	_
14-29	3006-3010	mean	_
14-30	3011-3017	levels	_
14-31	3018-3020	of	_
14-32	3021-3032	interleukin	_
14-33	3033-3034	(	_
14-34	3034-3036	IL	_
14-35	3036-3037	)	_
14-36	3037-3038	-	_
14-37	3038-3039	6	_
14-38	3039-3040	,	_
14-39	3041-3043	IL	_
14-40	3043-3044	-	_
14-41	3044-3046	1β	_
14-42	3046-3047	,	_
14-43	3048-3053	tumor	_
14-44	3054-3062	necrosis	_
14-45	3063-3069	factor	_
14-46	3070-3073	and	_
14-47	3074-3079	other	_
14-48	3080-3089	cytokines	_
14-49	3090-3092	in	_
14-50	3093-3106	schizophrenia	_
14-51	3107-3110	and	_
14-52	3111-3115	even	_
14-53	3116-3123	greater	_
14-54	3124-3134	elevations	_
14-55	3135-3141	during	_
14-56	3142-3147	acute	_
14-57	3148-3157	psychosis	_
14-58	3157-3158	.	_

#Text=We have recently provided evidence of central immune activation with cytokine messenger RNAs (mRNAs) for IL-6, IL-8 and IL-1β upregulated in brain tissue of ~40% of individuals who were chronically ill with schizophrenia.
15-1	3159-3161	We	_
15-2	3162-3166	have	_
15-3	3167-3175	recently	_
15-4	3176-3184	provided	_
15-5	3185-3193	evidence	_
15-6	3194-3196	of	_
15-7	3197-3204	central	_
15-8	3205-3211	immune	_
15-9	3212-3222	activation	_
15-10	3223-3227	with	_
15-11	3228-3236	cytokine	_
15-12	3237-3246	messenger	_
15-13	3247-3251	RNAs	_
15-14	3252-3253	(	_
15-15	3253-3258	mRNAs	_
15-16	3258-3259	)	_
15-17	3260-3263	for	_
15-18	3264-3266	IL	_
15-19	3266-3267	-	_
15-20	3267-3268	6	_
15-21	3268-3269	,	_
15-22	3270-3272	IL	_
15-23	3272-3273	-	_
15-24	3273-3274	8	_
15-25	3275-3278	and	_
15-26	3279-3281	IL	_
15-27	3281-3282	-	_
15-28	3282-3284	1β	_
15-29	3285-3296	upregulated	_
15-30	3297-3299	in	_
15-31	3300-3305	brain	_
15-32	3306-3312	tissue	_
15-33	3313-3315	of	_
15-34	3316-3317	~	_
15-35	3317-3320	40%	_
15-36	3321-3323	of	_
15-37	3324-3335	individuals	_
15-38	3336-3339	who	_
15-39	3340-3344	were	_
15-40	3345-3356	chronically	_
15-41	3357-3360	ill	_
15-42	3361-3365	with	_
15-43	3366-3379	schizophrenia	_
15-44	3379-3380	.	_

#Text=Demonstrating that a proportion of individuals with schizophrenia have abnormal cytokine profiles in blood, similar to what was previously described in post-mortem brain samples, would further support the relevance of inflammation to pathophysiology in a subgroup of those with the disease.
16-1	3381-3394	Demonstrating	_
16-2	3395-3399	that	_
16-3	3400-3401	a	_
16-4	3402-3412	proportion	_
16-5	3413-3415	of	_
16-6	3416-3427	individuals	_
16-7	3428-3432	with	_
16-8	3433-3446	schizophrenia	_
16-9	3447-3451	have	_
16-10	3452-3460	abnormal	_
16-11	3461-3469	cytokine	_
16-12	3470-3478	profiles	_
16-13	3479-3481	in	_
16-14	3482-3487	blood	_
16-15	3487-3488	,	_
16-16	3489-3496	similar	_
16-17	3497-3499	to	_
16-18	3500-3504	what	_
16-19	3505-3508	was	_
16-20	3509-3519	previously	_
16-21	3520-3529	described	_
16-22	3530-3532	in	_
16-23	3533-3544	post-mortem	_
16-24	3545-3550	brain	_
16-25	3551-3558	samples	_
16-26	3558-3559	,	_
16-27	3560-3565	would	_
16-28	3566-3573	further	_
16-29	3574-3581	support	_
16-30	3582-3585	the	_
16-31	3586-3595	relevance	_
16-32	3596-3598	of	_
16-33	3599-3611	inflammation	_
16-34	3612-3614	to	_
16-35	3615-3630	pathophysiology	_
16-36	3631-3633	in	_
16-37	3634-3635	a	_
16-38	3636-3644	subgroup	_
16-39	3645-3647	of	_
16-40	3648-3653	those	_
16-41	3654-3658	with	_
16-42	3659-3662	the	_
16-43	3663-3670	disease	_
16-44	3670-3671	.	_

#Text=As the characteristics of a distinct subgroup of people with schizophrenia with relatively elevated cytokine levels have yet to be fully described, other diseases may provide insight into the possible clinical presentation.
17-1	3672-3674	As	_
17-2	3675-3678	the	_
17-3	3679-3694	characteristics	_
17-4	3695-3697	of	_
17-5	3698-3699	a	_
17-6	3700-3708	distinct	_
17-7	3709-3717	subgroup	_
17-8	3718-3720	of	_
17-9	3721-3727	people	_
17-10	3728-3732	with	_
17-11	3733-3746	schizophrenia	_
17-12	3747-3751	with	_
17-13	3752-3762	relatively	_
17-14	3763-3771	elevated	_
17-15	3772-3780	cytokine	_
17-16	3781-3787	levels	_
17-17	3788-3792	have	_
17-18	3793-3796	yet	_
17-19	3797-3799	to	_
17-20	3800-3802	be	_
17-21	3803-3808	fully	_
17-22	3809-3818	described	_
17-23	3818-3819	,	_
17-24	3820-3825	other	_
17-25	3826-3834	diseases	_
17-26	3835-3838	may	_
17-27	3839-3846	provide	_
17-28	3847-3854	insight	_
17-29	3855-3859	into	_
17-30	3860-3863	the	_
17-31	3864-3872	possible	_
17-32	3873-3881	clinical	_
17-33	3882-3894	presentation	_
17-34	3894-3895	.	_

#Text=A subgroup of people with Alzheimer's disease display elevated markers of inflammation that have been linked to exaggerated cortical atrophy.
18-1	3896-3897	A	_
18-2	3898-3906	subgroup	_
18-3	3907-3909	of	_
18-4	3910-3916	people	_
18-5	3917-3921	with	_
18-6	3922-3933	Alzheimer's	_
18-7	3934-3941	disease	_
18-8	3942-3949	display	_
18-9	3950-3958	elevated	_
18-10	3959-3966	markers	_
18-11	3967-3969	of	_
18-12	3970-3982	inflammation	_
18-13	3983-3987	that	_
18-14	3988-3992	have	_
18-15	3993-3997	been	_
18-16	3998-4004	linked	_
18-17	4005-4007	to	_
18-18	4008-4019	exaggerated	_
18-19	4020-4028	cortical	_
18-20	4029-4036	atrophy	_
18-21	4036-4037	.	_

#Text=A strong association between higher circulating IL-8 levels and poor cognitive function, including verbal fluency measured by the Controlled Oral Word Association Test (COWAT), has also been observed in Alzheimer's disease; and in a separate study, targeted anti-inflammatory therapy with an inhibitor of tumor necrosis factor-alpha produced significant improvements in verbal fluency.
19-1	4038-4039	A	_
19-2	4040-4046	strong	_
19-3	4047-4058	association	_
19-4	4059-4066	between	_
19-5	4067-4073	higher	_
19-6	4074-4085	circulating	_
19-7	4086-4088	IL	_
19-8	4088-4089	-	_
19-9	4089-4090	8	_
19-10	4091-4097	levels	_
19-11	4098-4101	and	_
19-12	4102-4106	poor	_
19-13	4107-4116	cognitive	_
19-14	4117-4125	function	_
19-15	4125-4126	,	_
19-16	4127-4136	including	_
19-17	4137-4143	verbal	_
19-18	4144-4151	fluency	_
19-19	4152-4160	measured	_
19-20	4161-4163	by	_
19-21	4164-4167	the	_
19-22	4168-4178	Controlled	_
19-23	4179-4183	Oral	_
19-24	4184-4188	Word	_
19-25	4189-4200	Association	_
19-26	4201-4205	Test	_
19-27	4206-4207	(	_
19-28	4207-4212	COWAT	_
19-29	4212-4213	)	_
19-30	4213-4214	,	_
19-31	4215-4218	has	_
19-32	4219-4223	also	_
19-33	4224-4228	been	_
19-34	4229-4237	observed	_
19-35	4238-4240	in	_
19-36	4241-4252	Alzheimer's	_
19-37	4253-4260	disease	_
19-38	4260-4261	;	_
19-39	4262-4265	and	_
19-40	4266-4268	in	_
19-41	4269-4270	a	_
19-42	4271-4279	separate	_
19-43	4280-4285	study	_
19-44	4285-4286	,	_
19-45	4287-4295	targeted	_
19-46	4296-4313	anti-inflammatory	_
19-47	4314-4321	therapy	_
19-48	4322-4326	with	_
19-49	4327-4329	an	_
19-50	4330-4339	inhibitor	_
19-51	4340-4342	of	_
19-52	4343-4348	tumor	_
19-53	4349-4357	necrosis	_
19-54	4358-4370	factor-alpha	_
19-55	4371-4379	produced	_
19-56	4380-4391	significant	_
19-57	4392-4404	improvements	_
19-58	4405-4407	in	_
19-59	4408-4414	verbal	_
19-60	4415-4422	fluency	_
19-61	4422-4423	.	_

#Text=Similarly to Alzheimer's disease, individuals with schizophrenia, as a group, are known to show significantly poorer performance on many cognitive domains, including COWAT verbal fluency.
20-1	4424-4433	Similarly	_
20-2	4434-4436	to	_
20-3	4437-4448	Alzheimer's	_
20-4	4449-4456	disease	_
20-5	4456-4457	,	_
20-6	4458-4469	individuals	_
20-7	4470-4474	with	_
20-8	4475-4488	schizophrenia	_
20-9	4488-4489	,	_
20-10	4490-4492	as	_
20-11	4493-4494	a	_
20-12	4495-4500	group	_
20-13	4500-4501	,	_
20-14	4502-4505	are	_
20-15	4506-4511	known	_
20-16	4512-4514	to	_
20-17	4515-4519	show	_
20-18	4520-4533	significantly	_
20-19	4534-4540	poorer	_
20-20	4541-4552	performance	_
20-21	4553-4555	on	_
20-22	4556-4560	many	_
20-23	4561-4570	cognitive	_
20-24	4571-4578	domains	_
20-25	4578-4579	,	_
20-26	4580-4589	including	_
20-27	4590-4595	COWAT	_
20-28	4596-4602	verbal	_
20-29	4603-4610	fluency	_
20-30	4610-4611	.	_

#Text=Of particular interest with regards to impaired verbal fluency in schizophrenia are structural and functional changes in Broca's and Wernicke's areas, where magnetic resonance imaging (MRI) studies have found abnormal cortical folding and decreased volumes in schizophrenia compared with controls.
21-1	4612-4614	Of	_
21-2	4615-4625	particular	_
21-3	4626-4634	interest	_
21-4	4635-4639	with	_
21-5	4640-4647	regards	_
21-6	4648-4650	to	_
21-7	4651-4659	impaired	_
21-8	4660-4666	verbal	_
21-9	4667-4674	fluency	_
21-10	4675-4677	in	_
21-11	4678-4691	schizophrenia	_
21-12	4692-4695	are	_
21-13	4696-4706	structural	_
21-14	4707-4710	and	_
21-15	4711-4721	functional	_
21-16	4722-4729	changes	_
21-17	4730-4732	in	_
21-18	4733-4740	Broca's	_
21-19	4741-4744	and	_
21-20	4745-4755	Wernicke's	_
21-21	4756-4761	areas	_
21-22	4761-4762	,	_
21-23	4763-4768	where	_
21-24	4769-4777	magnetic	_
21-25	4778-4787	resonance	_
21-26	4788-4795	imaging	_
21-27	4796-4797	(	_
21-28	4797-4800	MRI	_
21-29	4800-4801	)	_
21-30	4802-4809	studies	_
21-31	4810-4814	have	_
21-32	4815-4820	found	_
21-33	4821-4829	abnormal	_
21-34	4830-4838	cortical	_
21-35	4839-4846	folding	_
21-36	4847-4850	and	_
21-37	4851-4860	decreased	_
21-38	4861-4868	volumes	_
21-39	4869-4871	in	_
21-40	4872-4885	schizophrenia	_
21-41	4886-4894	compared	_
21-42	4895-4899	with	_
21-43	4900-4908	controls	_
21-44	4908-4909	.	_

#Text=Whether these cortical abnormalities in schizophrenia are related to either verbal fluency deficits or peripheral immune alterations is unknown.
22-1	4910-4917	Whether	_
22-2	4918-4923	these	_
22-3	4924-4932	cortical	_
22-4	4933-4946	abnormalities	_
22-5	4947-4949	in	_
22-6	4950-4963	schizophrenia	_
22-7	4964-4967	are	_
22-8	4968-4975	related	_
22-9	4976-4978	to	_
22-10	4979-4985	either	_
22-11	4986-4992	verbal	_
22-12	4993-5000	fluency	_
22-13	5001-5009	deficits	_
22-14	5010-5012	or	_
22-15	5013-5023	peripheral	_
22-16	5024-5030	immune	_
22-17	5031-5042	alterations	_
22-18	5043-5045	is	_
22-19	5046-5053	unknown	_
22-20	5053-5054	.	_

#Text=Although in vivo techniques such as MRI have identified gross brain volumetric changes in schizophrenia, particularly increased size of the lateral ventricles and a decrease in cortical grey matter, these changes have not been definitively linked to any specific pathological process.
23-1	5055-5063	Although	_
23-2	5064-5066	in	_
23-3	5067-5071	vivo	_
23-4	5072-5082	techniques	_
23-5	5083-5087	such	_
23-6	5088-5090	as	_
23-7	5091-5094	MRI	_
23-8	5095-5099	have	_
23-9	5100-5110	identified	_
23-10	5111-5116	gross	_
23-11	5117-5122	brain	_
23-12	5123-5133	volumetric	_
23-13	5134-5141	changes	_
23-14	5142-5144	in	_
23-15	5145-5158	schizophrenia	_
23-16	5158-5159	,	_
23-17	5160-5172	particularly	_
23-18	5173-5182	increased	_
23-19	5183-5187	size	_
23-20	5188-5190	of	_
23-21	5191-5194	the	_
23-22	5195-5202	lateral	_
23-23	5203-5213	ventricles	_
23-24	5214-5217	and	_
23-25	5218-5219	a	_
23-26	5220-5228	decrease	_
23-27	5229-5231	in	_
23-28	5232-5240	cortical	_
23-29	5241-5245	grey	_
23-30	5246-5252	matter	_
23-31	5252-5253	,	_
23-32	5254-5259	these	_
23-33	5260-5267	changes	_
23-34	5268-5272	have	_
23-35	5273-5276	not	_
23-36	5277-5281	been	_
23-37	5282-5294	definitively	_
23-38	5295-5301	linked	_
23-39	5302-5304	to	_
23-40	5305-5308	any	_
23-41	5309-5317	specific	_
23-42	5318-5330	pathological	_
23-43	5331-5338	process	_
23-44	5338-5339	.	_

#Text=Identification of the processes underlying the observed volumetric changes is complicated by the lack of replicable histological changes in post-mortem brain from individuals with schizophrenia.
24-1	5340-5354	Identification	_
24-2	5355-5357	of	_
24-3	5358-5361	the	_
24-4	5362-5371	processes	_
24-5	5372-5382	underlying	_
24-6	5383-5386	the	_
24-7	5387-5395	observed	_
24-8	5396-5406	volumetric	_
24-9	5407-5414	changes	_
24-10	5415-5417	is	_
24-11	5418-5429	complicated	_
24-12	5430-5432	by	_
24-13	5433-5436	the	_
24-14	5437-5441	lack	_
24-15	5442-5444	of	_
24-16	5445-5455	replicable	_
24-17	5456-5468	histological	_
24-18	5469-5476	changes	_
24-19	5477-5479	in	_
24-20	5480-5491	post-mortem	_
24-21	5492-5497	brain	_
24-22	5498-5502	from	_
24-23	5503-5514	individuals	_
24-24	5515-5519	with	_
24-25	5520-5533	schizophrenia	_
24-26	5533-5534	.	_

#Text=However, we have previously shown that a group of individuals with schizophrenia who were characterized by high cytokine mRNAs in post-mortem brain tissue also displayed astrogliosis.
25-1	5535-5542	However	_
25-2	5542-5543	,	_
25-3	5544-5546	we	_
25-4	5547-5551	have	_
25-5	5552-5562	previously	_
25-6	5563-5568	shown	_
25-7	5569-5573	that	_
25-8	5574-5575	a	_
25-9	5576-5581	group	_
25-10	5582-5584	of	_
25-11	5585-5596	individuals	_
25-12	5597-5601	with	_
25-13	5602-5615	schizophrenia	_
25-14	5616-5619	who	_
25-15	5620-5624	were	_
25-16	5625-5638	characterized	_
25-17	5639-5641	by	_
25-18	5642-5646	high	_
25-19	5647-5655	cytokine	_
25-20	5656-5661	mRNAs	_
25-21	5662-5664	in	_
25-22	5665-5676	post-mortem	_
25-23	5677-5682	brain	_
25-24	5683-5689	tissue	_
25-25	5690-5694	also	_
25-26	5695-5704	displayed	_
25-27	5705-5717	astrogliosis	_
25-28	5717-5718	.	_

#Text=Further, several studies have linked structural volumetric changes to some cognitive deficits and symptomatic profiles; however, the relationship to peripheral cytokine elevation is not clear.
26-1	5719-5726	Further	_
26-2	5726-5727	,	_
26-3	5728-5735	several	_
26-4	5736-5743	studies	_
26-5	5744-5748	have	_
26-6	5749-5755	linked	_
26-7	5756-5766	structural	_
26-8	5767-5777	volumetric	_
26-9	5778-5785	changes	_
26-10	5786-5788	to	_
26-11	5789-5793	some	_
26-12	5794-5803	cognitive	_
26-13	5804-5812	deficits	_
26-14	5813-5816	and	_
26-15	5817-5828	symptomatic	_
26-16	5829-5837	profiles	_
26-17	5837-5838	;	_
26-18	5839-5846	however	_
26-19	5846-5847	,	_
26-20	5848-5851	the	_
26-21	5852-5864	relationship	_
26-22	5865-5867	to	_
26-23	5868-5878	peripheral	_
26-24	5879-5887	cytokine	_
26-25	5888-5897	elevation	_
26-26	5898-5900	is	_
26-27	5901-5904	not	_
26-28	5905-5910	clear	_
26-29	5910-5911	.	_

#Text=Thus, based on previous studies individually showing elevated cytokines, cognitive deficits and structural brain abnormalities in schizophrenia, we hypothesized that a higher proportion of people with schizophrenia will display elevated peripheral cytokine mRNA levels and those patients with elevated cytokines will also display cognitive deficits and volumetric brain abnormalities.
27-1	5912-5916	Thus	_
27-2	5916-5917	,	_
27-3	5918-5923	based	_
27-4	5924-5926	on	_
27-5	5927-5935	previous	_
27-6	5936-5943	studies	_
27-7	5944-5956	individually	_
27-8	5957-5964	showing	_
27-9	5965-5973	elevated	_
27-10	5974-5983	cytokines	_
27-11	5983-5984	,	_
27-12	5985-5994	cognitive	_
27-13	5995-6003	deficits	_
27-14	6004-6007	and	_
27-15	6008-6018	structural	_
27-16	6019-6024	brain	_
27-17	6025-6038	abnormalities	_
27-18	6039-6041	in	_
27-19	6042-6055	schizophrenia	_
27-20	6055-6056	,	_
27-21	6057-6059	we	_
27-22	6060-6072	hypothesized	_
27-23	6073-6077	that	_
27-24	6078-6079	a	_
27-25	6080-6086	higher	_
27-26	6087-6097	proportion	_
27-27	6098-6100	of	_
27-28	6101-6107	people	_
27-29	6108-6112	with	_
27-30	6113-6126	schizophrenia	_
27-31	6127-6131	will	_
27-32	6132-6139	display	_
27-33	6140-6148	elevated	_
27-34	6149-6159	peripheral	_
27-35	6160-6168	cytokine	_
27-36	6169-6173	mRNA	_
27-37	6174-6180	levels	_
27-38	6181-6184	and	_
27-39	6185-6190	those	_
27-40	6191-6199	patients	_
27-41	6200-6204	with	_
27-42	6205-6213	elevated	_
27-43	6214-6223	cytokines	_
27-44	6224-6228	will	_
27-45	6229-6233	also	_
27-46	6234-6241	display	_
27-47	6242-6251	cognitive	_
27-48	6252-6260	deficits	_
27-49	6261-6264	and	_
27-50	6265-6275	volumetric	_
27-51	6276-6281	brain	_
27-52	6282-6295	abnormalities	_
27-53	6295-6296	.	_

#Text=Cytokine mRNA assays were chosen on the basis of published findings, showing changes in specific cytokines in schizophrenia.
28-1	6297-6305	Cytokine	_
28-2	6306-6310	mRNA	_
28-3	6311-6317	assays	_
28-4	6318-6322	were	_
28-5	6323-6329	chosen	_
28-6	6330-6332	on	_
28-7	6333-6336	the	_
28-8	6337-6342	basis	_
28-9	6343-6345	of	_
28-10	6346-6355	published	_
28-11	6356-6364	findings	_
28-12	6364-6365	,	_
28-13	6366-6373	showing	_
28-14	6374-6381	changes	_
28-15	6382-6384	in	_
28-16	6385-6393	specific	_
28-17	6394-6403	cytokines	_
28-18	6404-6406	in	_
28-19	6407-6420	schizophrenia	_
28-20	6420-6421	.	_

#Text=Materials and methods
#Text=Participants
#Text=Forty-three people with a diagnosis of schizophrenia or schizoaffective disorder and 43 age-matched controls were recruited for this study (see Table 1).
29-1	6422-6431	Materials	http://www.case.edu/ProvCaRe/provcare#StudyMethod[7]
29-2	6432-6435	and	http://www.case.edu/ProvCaRe/provcare#StudyMethod[7]
29-3	6436-6443	methods	http://www.case.edu/ProvCaRe/provcare#StudyMethod[7]
29-4	6444-6456	Participants	_
29-5	6457-6468	Forty-three	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
29-6	6469-6475	people	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
29-7	6476-6480	with	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
29-8	6481-6482	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
29-9	6483-6492	diagnosis	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
29-10	6493-6495	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
29-11	6496-6509	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]|http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[9]
29-12	6510-6512	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
29-13	6513-6528	schizoaffective	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]|http://maven.renci.org/NeuroBridge/neurobridge#SchizoaffectiveDisorder[10]
29-14	6529-6537	disorder	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]|http://maven.renci.org/NeuroBridge/neurobridge#SchizoaffectiveDisorder[10]
29-15	6538-6541	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
29-16	6542-6544	43	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
29-17	6545-6556	age-matched	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
29-18	6557-6565	controls	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[11]
29-19	6566-6570	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
29-20	6571-6580	recruited	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
29-21	6581-6584	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
29-22	6585-6589	this	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
29-23	6590-6595	study	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
29-24	6596-6597	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
29-25	6597-6600	see	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
29-26	6601-6606	Table	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
29-27	6607-6608	1	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
29-28	6608-6609	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
29-29	6609-6610	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]

#Text=Patient recruitment was via either clinician or self/family referral following a nationally televised documentary.
30-1	6611-6618	Patient	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]
30-2	6619-6630	recruitment	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]
30-3	6631-6634	was	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]
30-4	6635-6638	via	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]
30-5	6639-6645	either	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]
30-6	6646-6655	clinician	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]
30-7	6656-6658	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]
30-8	6659-6663	self	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]
30-9	6663-6664	/	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]
30-10	6664-6670	family	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]
30-11	6671-6679	referral	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]
30-12	6680-6689	following	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]
30-13	6690-6691	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]
30-14	6692-6702	nationally	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]
30-15	6703-6712	televised	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]
30-16	6713-6724	documentary	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]
30-17	6724-6725	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]

#Text=All patients were living in the community and had been receiving antipsychotic medication for at least 1 year prior to entry in the study.
31-1	6726-6729	All	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]
31-2	6730-6738	patients	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]
31-3	6739-6743	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]
31-4	6744-6750	living	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]
31-5	6751-6753	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]
31-6	6754-6757	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]
31-7	6758-6767	community	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]
31-8	6768-6771	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]
31-9	6772-6775	had	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]
31-10	6776-6780	been	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]
31-11	6781-6790	receiving	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]
31-12	6791-6804	antipsychotic	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]
31-13	6805-6815	medication	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]
31-14	6816-6819	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]
31-15	6820-6822	at	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]
31-16	6823-6828	least	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]
31-17	6829-6830	1	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]
31-18	6831-6835	year	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]
31-19	6836-6841	prior	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]
31-20	6842-6844	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]
31-21	6845-6850	entry	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]
31-22	6851-6853	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]
31-23	6854-6857	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]
31-24	6858-6863	study	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]
31-25	6863-6864	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]

#Text=Patient symptom severity scores revealed that the patients displayed mild-to-moderate symptom severity (see Table 1).
32-1	6865-6872	Patient	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]
32-2	6873-6880	symptom	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]
32-3	6881-6889	severity	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]
32-4	6890-6896	scores	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]
32-5	6897-6905	revealed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]
32-6	6906-6910	that	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]
32-7	6911-6914	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]
32-8	6915-6923	patients	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]
32-9	6924-6933	displayed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]
32-10	6934-6950	mild-to-moderate	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]
32-11	6951-6958	symptom	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]
32-12	6959-6967	severity	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]
32-13	6968-6969	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]
32-14	6969-6972	see	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]
32-15	6973-6978	Table	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]
32-16	6979-6980	1	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]
32-17	6980-6981	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]
32-18	6981-6982	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]

#Text=Diagnostic status was determined by Structured Clinical Interview for DSM-IV-TR administered by a trained psychiatrist or psychologist and independently confirmed by another research psychiatrist.
33-1	6983-6993	Diagnostic	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
33-2	6994-7000	status	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
33-3	7001-7004	was	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
33-4	7005-7015	determined	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
33-5	7016-7018	by	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
33-6	7019-7029	Structured	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]|http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewfortheDiagnosticStatisticalManualofMentalDisorder[16]
33-7	7030-7038	Clinical	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]|http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewfortheDiagnosticStatisticalManualofMentalDisorder[16]
33-8	7039-7048	Interview	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]|http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewfortheDiagnosticStatisticalManualofMentalDisorder[16]
33-9	7049-7052	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]|http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewfortheDiagnosticStatisticalManualofMentalDisorder[16]
33-10	7053-7062	DSM-IV-TR	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]|http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewfortheDiagnosticStatisticalManualofMentalDisorder[16]
33-11	7063-7075	administered	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
33-12	7076-7078	by	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
33-13	7079-7080	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
33-14	7081-7088	trained	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
33-15	7089-7101	psychiatrist	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
33-16	7102-7104	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
33-17	7105-7117	psychologist	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
33-18	7118-7121	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
33-19	7122-7135	independently	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
33-20	7136-7145	confirmed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
33-21	7146-7148	by	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
33-22	7149-7156	another	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
33-23	7157-7165	research	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
33-24	7166-7178	psychiatrist	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
33-25	7178-7179	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]

#Text=Antipsychotic medication doses were obtained from the treating physician and converted to mean daily chlorpromazine equivalent dose.
34-1	7180-7193	Antipsychotic	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]|http://maven.renci.org/NeuroBridge/neurobridge#MedicationStatus[18]
34-2	7194-7204	medication	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]|http://maven.renci.org/NeuroBridge/neurobridge#MedicationStatus[18]
34-3	7205-7210	doses	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]|http://maven.renci.org/NeuroBridge/neurobridge#MedicationStatus[18]
34-4	7211-7215	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]
34-5	7216-7224	obtained	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]
34-6	7225-7229	from	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]
34-7	7230-7233	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]
34-8	7234-7242	treating	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]
34-9	7243-7252	physician	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]
34-10	7253-7256	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]
34-11	7257-7266	converted	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]
34-12	7267-7269	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]
34-13	7270-7274	mean	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]
34-14	7275-7280	daily	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]
34-15	7281-7295	chlorpromazine	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]
34-16	7296-7306	equivalent	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]
34-17	7307-7311	dose	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]
34-18	7311-7312	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]

#Text=Thirty-three patients (and no healthy controls) had their height and weight collected for body mass index (BMI) calculation.
35-1	7313-7325	Thirty-three	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
35-2	7326-7334	patients	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
35-3	7335-7336	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
35-4	7336-7339	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
35-5	7340-7342	no	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
35-6	7343-7350	healthy	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[20]
35-7	7351-7359	controls	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[20]
35-8	7359-7360	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
35-9	7361-7364	had	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
35-10	7365-7370	their	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
35-11	7371-7377	height	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
35-12	7378-7381	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
35-13	7382-7388	weight	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
35-14	7389-7398	collected	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
35-15	7399-7402	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
35-16	7403-7407	body	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
35-17	7408-7412	mass	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
35-18	7413-7418	index	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
35-19	7419-7420	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
35-20	7420-7423	BMI	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
35-21	7423-7424	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
35-22	7425-7436	calculation	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
35-23	7436-7437	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]

#Text=For further details and inclusion/exclusion criteria refer to Supplementary Methods.
36-1	7438-7441	For	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]
36-2	7442-7449	further	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]
36-3	7450-7457	details	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]
36-4	7458-7461	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]
36-5	7462-7471	inclusion	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]
36-6	7471-7472	/	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]
36-7	7472-7481	exclusion	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]
36-8	7482-7490	criteria	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]
36-9	7491-7496	refer	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]
36-10	7497-7499	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]
36-11	7500-7513	Supplementary	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]
36-12	7514-7521	Methods	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]
36-13	7521-7522	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]

#Text=Healthy controls were recruited through advertisements at the University of New South Wales and the local community.
37-1	7523-7530	Healthy	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[23]
37-2	7531-7539	controls	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[23]
37-3	7540-7544	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]
37-4	7545-7554	recruited	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]
37-5	7555-7562	through	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]
37-6	7563-7577	advertisements	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]
37-7	7578-7580	at	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]
37-8	7581-7584	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]
37-9	7585-7595	University	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]
37-10	7596-7598	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]
37-11	7599-7602	New	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]
37-12	7603-7608	South	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]
37-13	7609-7614	Wales	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]
37-14	7615-7618	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]
37-15	7619-7622	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]
37-16	7623-7628	local	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]
37-17	7629-7638	community	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]
37-18	7638-7639	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]

#Text=The procedures were explained and written informed consent was obtained from participants prior to participation in the study, which was approved by the South Eastern Sydney and Illawara Area Health Services (HREC 07/259) and the University of New South Wales Human Research Ethics Committees (HREC 07121 and HREC 09187).
38-1	7640-7643	The	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]
38-2	7644-7654	procedures	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]
38-3	7655-7659	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]
38-4	7660-7669	explained	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]
38-5	7670-7673	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]
38-6	7674-7681	written	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]
38-7	7682-7690	informed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]
38-8	7691-7698	consent	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]
38-9	7699-7702	was	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]
38-10	7703-7711	obtained	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]
38-11	7712-7716	from	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]
38-12	7717-7729	participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]
38-13	7730-7735	prior	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]
38-14	7736-7738	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]
38-15	7739-7752	participation	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]
38-16	7753-7755	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]
38-17	7756-7759	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]
38-18	7760-7765	study	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]
38-19	7765-7766	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]
38-20	7767-7772	which	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]
38-21	7773-7776	was	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]
38-22	7777-7785	approved	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]
38-23	7786-7788	by	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]
38-24	7789-7792	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]
38-25	7793-7798	South	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]
38-26	7799-7806	Eastern	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]
38-27	7807-7813	Sydney	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]
38-28	7814-7817	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]
38-29	7818-7826	Illawara	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]
38-30	7827-7831	Area	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]
38-31	7832-7838	Health	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]
38-32	7839-7847	Services	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]
38-33	7848-7849	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]
38-34	7849-7853	HREC	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]
38-35	7854-7856	07	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]
38-36	7856-7857	/	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]
38-37	7857-7860	259	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]
38-38	7860-7861	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]
38-39	7862-7865	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]
38-40	7866-7869	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]
38-41	7870-7880	University	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]
38-42	7881-7883	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]
38-43	7884-7887	New	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]
38-44	7888-7893	South	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]
38-45	7894-7899	Wales	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]
38-46	7900-7905	Human	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]
38-47	7906-7914	Research	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]
38-48	7915-7921	Ethics	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]
38-49	7922-7932	Committees	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]
38-50	7933-7934	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]
38-51	7934-7938	HREC	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]
38-52	7939-7944	07121	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]
38-53	7945-7948	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]
38-54	7949-7953	HREC	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]
38-55	7954-7959	09187	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]
38-56	7959-7960	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]
38-57	7960-7961	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]

#Text=Blood collection, RNA isolation and complementary DNA synthesis
#Text=Blood was collected from participants in 9 ml ACD-B yellow topped tubes (BD Biosciences, North Ryde, NSW, Australia) before being processed.
39-1	7962-7967	Blood	_
39-2	7968-7978	collection	_
39-3	7978-7979	,	_
39-4	7980-7983	RNA	_
39-5	7984-7993	isolation	_
39-6	7994-7997	and	_
39-7	7998-8011	complementary	_
39-8	8012-8015	DNA	_
39-9	8016-8025	synthesis	_
39-10	8026-8031	Blood	_
39-11	8032-8035	was	_
39-12	8036-8045	collected	_
39-13	8046-8050	from	_
39-14	8051-8063	participants	_
39-15	8064-8066	in	_
39-16	8067-8068	9	_
39-17	8069-8071	ml	_
39-18	8072-8077	ACD-B	_
39-19	8078-8084	yellow	_
39-20	8085-8091	topped	_
39-21	8092-8097	tubes	_
39-22	8098-8099	(	_
39-23	8099-8101	BD	_
39-24	8102-8113	Biosciences	_
39-25	8113-8114	,	_
39-26	8115-8120	North	_
39-27	8121-8125	Ryde	_
39-28	8125-8126	,	_
39-29	8127-8130	NSW	_
39-30	8130-8131	,	_
39-31	8132-8141	Australia	_
39-32	8141-8142	)	_
39-33	8143-8149	before	_
39-34	8150-8155	being	_
39-35	8156-8165	processed	_
39-36	8165-8166	.	_

#Text=RNA isolation was according to the TRIZOL method.
40-1	8167-8170	RNA	_
40-2	8171-8180	isolation	_
40-3	8181-8184	was	_
40-4	8185-8194	according	_
40-5	8195-8197	to	_
40-6	8198-8201	the	_
40-7	8202-8208	TRIZOL	_
40-8	8209-8215	method	_
40-9	8215-8216	.	_

#Text=Four micrograms of total RNA per sample was used in 50 μl reverse transcriptase reactions using the SuperScript III First-Strand Synthesis System to create complementary DNA (Invitrogen, Carlsbad, CA, USA).
41-1	8217-8221	Four	_
41-2	8222-8232	micrograms	_
41-3	8233-8235	of	_
41-4	8236-8241	total	_
41-5	8242-8245	RNA	_
41-6	8246-8249	per	_
41-7	8250-8256	sample	_
41-8	8257-8260	was	_
41-9	8261-8265	used	_
41-10	8266-8268	in	_
41-11	8269-8271	50	_
41-12	8272-8274	μl	_
41-13	8275-8282	reverse	_
41-14	8283-8296	transcriptase	_
41-15	8297-8306	reactions	_
41-16	8307-8312	using	_
41-17	8313-8316	the	_
41-18	8317-8328	SuperScript	_
41-19	8329-8332	III	_
41-20	8333-8345	First-Strand	_
41-21	8346-8355	Synthesis	_
41-22	8356-8362	System	_
41-23	8363-8365	to	_
41-24	8366-8372	create	_
41-25	8373-8386	complementary	_
41-26	8387-8390	DNA	_
41-27	8391-8392	(	_
41-28	8392-8402	Invitrogen	_
41-29	8402-8403	,	_
41-30	8404-8412	Carlsbad	_
41-31	8412-8413	,	_
41-32	8414-8416	CA	_
41-33	8416-8417	,	_
41-34	8418-8421	USA	_
41-35	8421-8422	)	_
41-36	8422-8423	.	_

#Text=Further details can be found in Supplementary Methods: blood collection, RNA isolation and complementary DNA synthesis.
42-1	8424-8431	Further	_
42-2	8432-8439	details	_
42-3	8440-8443	can	_
42-4	8444-8446	be	_
42-5	8447-8452	found	_
42-6	8453-8455	in	_
42-7	8456-8469	Supplementary	_
42-8	8470-8477	Methods	_
42-9	8477-8478	:	_
42-10	8479-8484	blood	_
42-11	8485-8495	collection	_
42-12	8495-8496	,	_
42-13	8497-8500	RNA	_
42-14	8501-8510	isolation	_
42-15	8511-8514	and	_
42-16	8515-8528	complementary	_
42-17	8529-8532	DNA	_
42-18	8533-8542	synthesis	_
42-19	8542-8543	.	_

#Text=Quantitative PCR
#Text=Transcript levels were measured by quantitative PCR using Applied Biosystems' Prism 7900HT (Foster City, CA, USA) sequence detection system.
43-1	8544-8556	Quantitative	_
43-2	8557-8560	PCR	_
43-3	8561-8571	Transcript	_
43-4	8572-8578	levels	_
43-5	8579-8583	were	_
43-6	8584-8592	measured	_
43-7	8593-8595	by	_
43-8	8596-8608	quantitative	_
43-9	8609-8612	PCR	_
43-10	8613-8618	using	_
43-11	8619-8626	Applied	_
43-12	8627-8637	Biosystems	_
43-13	8637-8638	'	_
43-14	8639-8644	Prism	_
43-15	8645-8651	7900HT	_
43-16	8652-8653	(	_
43-17	8653-8659	Foster	_
43-18	8660-8664	City	_
43-19	8664-8665	,	_
43-20	8666-8668	CA	_
43-21	8668-8669	,	_
43-22	8670-8673	USA	_
43-23	8673-8674	)	_
43-24	8675-8683	sequence	_
43-25	8684-8693	detection	_
43-26	8694-8700	system	_
43-27	8700-8701	.	_

#Text=Four housekeeping genes, TATA binding protein, ubiquitin C, beta-actin and cyclophilin A, with stable expression, were chosen for normalization through calculation of a geometric mean.
44-1	8702-8706	Four	_
44-2	8707-8719	housekeeping	_
44-3	8720-8725	genes	_
44-4	8725-8726	,	_
44-5	8727-8731	TATA	_
44-6	8732-8739	binding	_
44-7	8740-8747	protein	_
44-8	8747-8748	,	_
44-9	8749-8758	ubiquitin	_
44-10	8759-8760	C	_
44-11	8760-8761	,	_
44-12	8762-8772	beta-actin	_
44-13	8773-8776	and	_
44-14	8777-8788	cyclophilin	_
44-15	8789-8790	A	_
44-16	8790-8791	,	_
44-17	8792-8796	with	_
44-18	8797-8803	stable	_
44-19	8804-8814	expression	_
44-20	8814-8815	,	_
44-21	8816-8820	were	_
44-22	8821-8827	chosen	_
44-23	8828-8831	for	_
44-24	8832-8845	normalization	_
44-25	8846-8853	through	_
44-26	8854-8865	calculation	_
44-27	8866-8868	of	_
44-28	8869-8870	a	_
44-29	8871-8880	geometric	_
44-30	8881-8885	mean	_
44-31	8885-8886	.	_

#Text=Probe ID's and M-values (to test for stability of control mRNAs) are provided in Supplementary Methods.
45-1	8887-8892	Probe	_
45-2	8893-8897	ID's	_
45-3	8898-8901	and	_
45-4	8902-8910	M-values	_
45-5	8911-8912	(	_
45-6	8912-8914	to	_
45-7	8915-8919	test	_
45-8	8920-8923	for	_
45-9	8924-8933	stability	_
45-10	8934-8936	of	_
45-11	8937-8944	control	_
45-12	8945-8950	mRNAs	_
45-13	8950-8951	)	_
45-14	8952-8955	are	_
45-15	8956-8964	provided	_
45-16	8965-8967	in	_
45-17	8968-8981	Supplementary	_
45-18	8982-8989	Methods	_
45-19	8989-8990	.	_

#Text=Measured mRNAs were quantified using the following probes: IL1β (Hs01555410_m1), IL2 (Hs00174114_m1), IL-6 (Hs00174131_m1), IL-8 (HS00174103_m1) and IL-18 (Hs01038788_m1).
46-1	8991-8999	Measured	_
46-2	9000-9005	mRNAs	_
46-3	9006-9010	were	_
46-4	9011-9021	quantified	_
46-5	9022-9027	using	_
46-6	9028-9031	the	_
46-7	9032-9041	following	_
46-8	9042-9048	probes	_
46-9	9048-9049	:	_
46-10	9050-9054	IL1β	_
46-11	9055-9056	(	_
46-12	9056-9066	Hs01555410	_
46-13	9066-9067	_	_
46-14	9067-9069	m1	_
46-15	9069-9070	)	_
46-16	9070-9071	,	_
46-17	9072-9075	IL2	_
46-18	9076-9077	(	_
46-19	9077-9087	Hs00174114	_
46-20	9087-9088	_	_
46-21	9088-9090	m1	_
46-22	9090-9091	)	_
46-23	9091-9092	,	_
46-24	9093-9095	IL	_
46-25	9095-9096	-	_
46-26	9096-9097	6	_
46-27	9098-9099	(	_
46-28	9099-9109	Hs00174131	_
46-29	9109-9110	_	_
46-30	9110-9112	m1	_
46-31	9112-9113	)	_
46-32	9113-9114	,	_
46-33	9115-9117	IL	_
46-34	9117-9118	-	_
46-35	9118-9119	8	_
46-36	9120-9121	(	_
46-37	9121-9131	HS00174103	_
46-38	9131-9132	_	_
46-39	9132-9134	m1	_
46-40	9134-9135	)	_
46-41	9136-9139	and	_
46-42	9140-9142	IL	_
46-43	9142-9143	-	_
46-44	9143-9145	18	_
46-45	9146-9147	(	_
46-46	9147-9157	Hs01038788	_
46-47	9157-9158	_	_
46-48	9158-9160	m1	_
46-49	9160-9161	)	_
46-50	9161-9162	.	_

#Text=Cycling conditions and reaction amounts were as previously described.
47-1	9163-9170	Cycling	_
47-2	9171-9181	conditions	_
47-3	9182-9185	and	_
47-4	9186-9194	reaction	_
47-5	9195-9202	amounts	_
47-6	9203-9207	were	_
47-7	9208-9210	as	_
47-8	9211-9221	previously	_
47-9	9222-9231	described	_
47-10	9231-9232	.	_

#Text=One control individual did not amplify and was excluded from further analysis.
48-1	9233-9236	One	_
48-2	9237-9244	control	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
48-3	9245-9255	individual	_
48-4	9256-9259	did	_
48-5	9260-9263	not	_
48-6	9264-9271	amplify	_
48-7	9272-9275	and	_
48-8	9276-9279	was	_
48-9	9280-9288	excluded	_
48-10	9289-9293	from	_
48-11	9294-9301	further	_
48-12	9302-9310	analysis	_
48-13	9310-9311	.	_

#Text=Cognitive and symptom assessment
#Text=Cognitive function was assessed using the COWAT F-A-S letter test to assess verbal fluency, and Logical Memory I and II from the Wechsler Memory Scale-III to assess immediate and delayed declarative memory.
49-1	9312-9321	Cognitive	_
49-2	9322-9325	and	_
49-3	9326-9333	symptom	_
49-4	9334-9344	assessment	_
49-5	9345-9354	Cognitive	_
49-6	9355-9363	function	_
49-7	9364-9367	was	_
49-8	9368-9376	assessed	_
49-9	9377-9382	using	_
49-10	9383-9386	the	_
49-11	9387-9392	COWAT	http://www.case.edu/ProvCaRe/provcare#NeurocognitiveTest[25]
49-12	9393-9398	F-A-S	http://www.case.edu/ProvCaRe/provcare#NeurocognitiveTest[25]
49-13	9399-9405	letter	http://www.case.edu/ProvCaRe/provcare#NeurocognitiveTest[25]
49-14	9406-9410	test	http://www.case.edu/ProvCaRe/provcare#NeurocognitiveTest[25]
49-15	9411-9413	to	_
49-16	9414-9420	assess	_
49-17	9421-9427	verbal	_
49-18	9428-9435	fluency	_
49-19	9435-9436	,	_
49-20	9437-9440	and	_
49-21	9441-9448	Logical	_
49-22	9449-9455	Memory	_
49-23	9456-9457	I	_
49-24	9458-9461	and	_
49-25	9462-9464	II	_
49-26	9465-9469	from	_
49-27	9470-9473	the	_
49-28	9474-9482	Wechsler	http://www.case.edu/ProvCaRe/provcare#NeurocognitiveTest[26]
49-29	9483-9489	Memory	http://www.case.edu/ProvCaRe/provcare#NeurocognitiveTest[26]
49-30	9490-9499	Scale-III	http://www.case.edu/ProvCaRe/provcare#NeurocognitiveTest[26]
49-31	9500-9502	to	_
49-32	9503-9509	assess	_
49-33	9510-9519	immediate	_
49-34	9520-9523	and	_
49-35	9524-9531	delayed	_
49-36	9532-9543	declarative	_
49-37	9544-9550	memory	_
49-38	9550-9551	.	_

#Text=The Letter-Number Sequencing subtest from the Wechsler Adult Intelligence Scale–3rd edition was used to assess working memory; picture completion, Digit-Symbol Coding, similarities and arithmetic subtests from the Wechsler Adult Intelligence Scale–3rd edition were used as a current intelligence quotient estimate; and the Wechsler Test of Adult Reading was used to estimate premorbid intelligence quotient.
50-1	9552-9555	The	_
50-2	9556-9569	Letter-Number	http://www.case.edu/ProvCaRe/provcare#NeurocognitiveTest[27]
50-3	9570-9580	Sequencing	http://www.case.edu/ProvCaRe/provcare#NeurocognitiveTest[27]
50-4	9581-9588	subtest	http://www.case.edu/ProvCaRe/provcare#NeurocognitiveTest[27]
50-5	9589-9593	from	http://www.case.edu/ProvCaRe/provcare#NeurocognitiveTest[27]
50-6	9594-9597	the	http://www.case.edu/ProvCaRe/provcare#NeurocognitiveTest[27]
50-7	9598-9606	Wechsler	http://www.case.edu/ProvCaRe/provcare#NeurocognitiveTest[27]
50-8	9607-9612	Adult	http://www.case.edu/ProvCaRe/provcare#NeurocognitiveTest[27]
50-9	9613-9625	Intelligence	http://www.case.edu/ProvCaRe/provcare#NeurocognitiveTest[27]
50-10	9626-9631	Scale	http://www.case.edu/ProvCaRe/provcare#NeurocognitiveTest[27]
50-11	9631-9632	–	http://www.case.edu/ProvCaRe/provcare#NeurocognitiveTest[27]
50-12	9632-9635	3rd	http://www.case.edu/ProvCaRe/provcare#NeurocognitiveTest[27]
50-13	9636-9643	edition	http://www.case.edu/ProvCaRe/provcare#NeurocognitiveTest[27]
50-14	9644-9647	was	_
50-15	9648-9652	used	_
50-16	9653-9655	to	_
50-17	9656-9662	assess	_
50-18	9663-9670	working	_
50-19	9671-9677	memory	_
50-20	9677-9678	;	_
50-21	9679-9686	picture	_
50-22	9687-9697	completion	_
50-23	9697-9698	,	_
50-24	9699-9711	Digit-Symbol	_
50-25	9712-9718	Coding	_
50-26	9718-9719	,	_
50-27	9720-9732	similarities	_
50-28	9733-9736	and	_
50-29	9737-9747	arithmetic	_
50-30	9748-9756	subtests	_
50-31	9757-9761	from	_
50-32	9762-9765	the	_
50-33	9766-9774	Wechsler	http://www.case.edu/ProvCaRe/provcare#NeurocognitiveTest[28]
50-34	9775-9780	Adult	http://www.case.edu/ProvCaRe/provcare#NeurocognitiveTest[28]
50-35	9781-9793	Intelligence	http://www.case.edu/ProvCaRe/provcare#NeurocognitiveTest[28]
50-36	9794-9799	Scale	http://www.case.edu/ProvCaRe/provcare#NeurocognitiveTest[28]
50-37	9799-9800	–	http://www.case.edu/ProvCaRe/provcare#NeurocognitiveTest[28]
50-38	9800-9803	3rd	http://www.case.edu/ProvCaRe/provcare#NeurocognitiveTest[28]
50-39	9804-9811	edition	http://www.case.edu/ProvCaRe/provcare#NeurocognitiveTest[28]
50-40	9812-9816	were	_
50-41	9817-9821	used	_
50-42	9822-9824	as	_
50-43	9825-9826	a	_
50-44	9827-9834	current	_
50-45	9835-9847	intelligence	_
50-46	9848-9856	quotient	_
50-47	9857-9865	estimate	_
50-48	9865-9866	;	_
50-49	9867-9870	and	_
50-50	9871-9874	the	_
50-51	9875-9883	Wechsler	http://www.case.edu/ProvCaRe/provcare#NeurocognitiveTest[29]
50-52	9884-9888	Test	http://www.case.edu/ProvCaRe/provcare#NeurocognitiveTest[29]
50-53	9889-9891	of	http://www.case.edu/ProvCaRe/provcare#NeurocognitiveTest[29]
50-54	9892-9897	Adult	http://www.case.edu/ProvCaRe/provcare#NeurocognitiveTest[29]
50-55	9898-9905	Reading	http://www.case.edu/ProvCaRe/provcare#NeurocognitiveTest[29]
50-56	9906-9909	was	_
50-57	9910-9914	used	_
50-58	9915-9917	to	_
50-59	9918-9926	estimate	_
50-60	9927-9936	premorbid	_
50-61	9937-9949	intelligence	_
50-62	9950-9958	quotient	_
50-63	9958-9959	.	_

#Text=The Positive and Negative Syndrome Scale was administered to all patients to obtain measures of positive, negative, general psychopathology and total symptom severity.
51-1	9960-9963	The	_
51-2	9964-9972	Positive	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale[30]
51-3	9973-9976	and	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale[30]
51-4	9977-9985	Negative	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale[30]
51-5	9986-9994	Syndrome	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale[30]
51-6	9995-10000	Scale	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale[30]
51-7	10001-10004	was	_
51-8	10005-10017	administered	_
51-9	10018-10020	to	_
51-10	10021-10024	all	_
51-11	10025-10033	patients	_
51-12	10034-10036	to	_
51-13	10037-10043	obtain	_
51-14	10044-10052	measures	_
51-15	10053-10055	of	_
51-16	10056-10064	positive	_
51-17	10064-10065	,	_
51-18	10066-10074	negative	_
51-19	10074-10075	,	_
51-20	10076-10083	general	_
51-21	10084-10099	psychopathology	_
51-22	10100-10103	and	_
51-23	10104-10109	total	_
51-24	10110-10117	symptom	_
51-25	10118-10126	severity	_
51-26	10126-10127	.	_

#Text=All assessments were made by psychologists or psychometricians trained in administration and scoring of the assessments.
52-1	10128-10131	All	_
52-2	10132-10143	assessments	_
52-3	10144-10148	were	_
52-4	10149-10153	made	_
52-5	10154-10156	by	_
52-6	10157-10170	psychologists	_
52-7	10171-10173	or	_
52-8	10174-10190	psychometricians	_
52-9	10191-10198	trained	_
52-10	10199-10201	in	_
52-11	10202-10216	administration	_
52-12	10217-10220	and	_
52-13	10221-10228	scoring	_
52-14	10229-10231	of	_
52-15	10232-10235	the	_
52-16	10236-10247	assessments	_
52-17	10247-10248	.	_

#Text=For further details pertaining to cognitive test scoring refer to Supplementary Methods: cognitive assessment.
53-1	10249-10252	For	_
53-2	10253-10260	further	_
53-3	10261-10268	details	_
53-4	10269-10279	pertaining	_
53-5	10280-10282	to	_
53-6	10283-10292	cognitive	_
53-7	10293-10297	test	_
53-8	10298-10305	scoring	_
53-9	10306-10311	refer	_
53-10	10312-10314	to	_
53-11	10315-10328	Supplementary	_
53-12	10329-10336	Methods	_
53-13	10336-10337	:	_
53-14	10338-10347	cognitive	_
53-15	10348-10358	assessment	_
53-16	10358-10359	.	_

#Text=Structural brain imaging
#Text=Participants were scanned using a 3.0 T Philips Achieva MRI scanner with an 8 channel, bird-cage type, head coil (Neuroscience Research Australia, Randwick, NSW, Australia).
54-1	10360-10370	Structural	http://maven.renci.org/NeuroBridge/neurobridge#StructuralImaging[31]
54-2	10371-10376	brain	http://maven.renci.org/NeuroBridge/neurobridge#StructuralImaging[31]
54-3	10377-10384	imaging	http://maven.renci.org/NeuroBridge/neurobridge#StructuralImaging[31]
54-4	10385-10397	Participants	_
54-5	10398-10402	were	_
54-6	10403-10410	scanned	_
54-7	10411-10416	using	_
54-8	10417-10418	a	_
54-9	10419-10422	3.0	http://www.case.edu/ProvCaRe/provcare#MagneticResonanceImagingInstrument[32]
54-10	10423-10424	T	http://www.case.edu/ProvCaRe/provcare#MagneticResonanceImagingInstrument[32]
54-11	10425-10432	Philips	http://www.case.edu/ProvCaRe/provcare#MagneticResonanceImagingInstrument[32]
54-12	10433-10440	Achieva	http://www.case.edu/ProvCaRe/provcare#MagneticResonanceImagingInstrument[32]
54-13	10441-10444	MRI	http://www.case.edu/ProvCaRe/provcare#MagneticResonanceImagingInstrument[32]
54-14	10445-10452	scanner	http://www.case.edu/ProvCaRe/provcare#MagneticResonanceImagingInstrument[32]
54-15	10453-10457	with	_
54-16	10458-10460	an	_
54-17	10461-10462	8	_
54-18	10463-10470	channel	_
54-19	10470-10471	,	_
54-20	10472-10481	bird-cage	_
54-21	10482-10486	type	_
54-22	10486-10487	,	_
54-23	10488-10492	head	_
54-24	10493-10497	coil	_
54-25	10498-10499	(	_
54-26	10499-10511	Neuroscience	_
54-27	10512-10520	Research	_
54-28	10521-10530	Australia	_
54-29	10530-10531	,	_
54-30	10532-10540	Randwick	_
54-31	10540-10541	,	_
54-32	10542-10545	NSW	_
54-33	10545-10546	,	_
54-34	10547-10556	Australia	_
54-35	10556-10557	)	_
54-36	10557-10558	.	_

#Text=A T1-weighted high-resolution anatomical scan was obtained with the following parameters: 180 slices, thickness 1mm, no gap, repetition time: 5.4ms, echo time: 2.4ms, field of view: 256mm.
55-1	10559-10560	A	_
55-2	10561-10563	T1	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[33]
55-3	10563-10564	-	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[33]
55-4	10564-10572	weighted	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[33]
55-5	10573-10588	high-resolution	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[33]
55-6	10589-10599	anatomical	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[33]
55-7	10600-10604	scan	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[33]
55-8	10605-10608	was	_
55-9	10609-10617	obtained	_
55-10	10618-10622	with	_
55-11	10623-10626	the	_
55-12	10627-10636	following	_
55-13	10637-10647	parameters	_
55-14	10647-10648	:	_
55-15	10649-10652	180	_
55-16	10653-10659	slices	_
55-17	10659-10660	,	_
55-18	10661-10670	thickness	_
55-19	10671-10674	1mm	_
55-20	10674-10675	,	_
55-21	10676-10678	no	_
55-22	10679-10682	gap	_
55-23	10682-10683	,	_
55-24	10684-10694	repetition	_
55-25	10695-10699	time	_
55-26	10699-10700	:	_
55-27	10701-10706	5.4ms	_
55-28	10706-10707	,	_
55-29	10708-10712	echo	_
55-30	10713-10717	time	_
55-31	10717-10718	:	_
55-32	10719-10724	2.4ms	_
55-33	10724-10725	,	_
55-34	10726-10731	field	_
55-35	10732-10734	of	_
55-36	10735-10739	view	_
55-37	10739-10740	:	_
55-38	10741-10746	256mm	_
55-39	10746-10747	.	_

#Text=Eight of the 43 participants with schizophrenia elected not to undergo the scanning procedure.
56-1	10748-10753	Eight	_
56-2	10754-10756	of	_
56-3	10757-10760	the	_
56-4	10761-10763	43	_
56-5	10764-10776	participants	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[34]
56-6	10777-10781	with	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[34]
56-7	10782-10795	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[34]
56-8	10796-10803	elected	_
56-9	10804-10807	not	_
56-10	10808-10810	to	_
56-11	10811-10818	undergo	_
56-12	10819-10822	the	_
56-13	10823-10831	scanning	_
56-14	10832-10841	procedure	_
56-15	10841-10842	.	_

#Text=Two patients were excluded owing to abnormal MRI findings (that is, developmental asymmetry of the lateral ventricles and partial agenesis of the posterior portions of the corpus callosum).
57-1	10843-10846	Two	_
57-2	10847-10855	patients	_
57-3	10856-10860	were	_
57-4	10861-10869	excluded	_
57-5	10870-10875	owing	_
57-6	10876-10878	to	_
57-7	10879-10887	abnormal	_
57-8	10888-10891	MRI	_
57-9	10892-10900	findings	_
57-10	10901-10902	(	_
57-11	10902-10906	that	_
57-12	10907-10909	is	_
57-13	10909-10910	,	_
57-14	10911-10924	developmental	_
57-15	10925-10934	asymmetry	_
57-16	10935-10937	of	_
57-17	10938-10941	the	_
57-18	10942-10949	lateral	_
57-19	10950-10960	ventricles	_
57-20	10961-10964	and	_
57-21	10965-10972	partial	_
57-22	10973-10981	agenesis	_
57-23	10982-10984	of	_
57-24	10985-10988	the	_
57-25	10989-10998	posterior	_
57-26	10999-11007	portions	_
57-27	11008-11010	of	_
57-28	11011-11014	the	_
57-29	11015-11021	corpus	_
57-30	11022-11030	callosum	_
57-31	11030-11031	)	_
57-32	11031-11032	.	_

#Text=Imaging data from one control subject was not included because their mRNA sample was not amplified by quantitative PCR.
58-1	11033-11040	Imaging	_
58-2	11041-11045	data	_
58-3	11046-11050	from	_
58-4	11051-11054	one	_
58-5	11055-11062	control	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
58-6	11063-11070	subject	_
58-7	11071-11074	was	_
58-8	11075-11078	not	_
58-9	11079-11087	included	_
58-10	11088-11095	because	_
58-11	11096-11101	their	_
58-12	11102-11106	mRNA	_
58-13	11107-11113	sample	_
58-14	11114-11117	was	_
58-15	11118-11121	not	_
58-16	11122-11131	amplified	_
58-17	11132-11134	by	_
58-18	11135-11147	quantitative	_
58-19	11148-11151	PCR	_
58-20	11151-11152	.	_

#Text=This resulted in imaging and cytokine data being available from a subset of people (total of 75), including 33 people with schizophrenia (15 with elevated and 18 with low cytokine levels) and 42 healthy controls (9 with elevated and 33 with low cytokine levels).
59-1	11153-11157	This	_
59-2	11158-11166	resulted	_
59-3	11167-11169	in	_
59-4	11170-11177	imaging	_
59-5	11178-11181	and	_
59-6	11182-11190	cytokine	_
59-7	11191-11195	data	_
59-8	11196-11201	being	_
59-9	11202-11211	available	_
59-10	11212-11216	from	_
59-11	11217-11218	a	_
59-12	11219-11225	subset	_
59-13	11226-11228	of	_
59-14	11229-11235	people	_
59-15	11236-11237	(	_
59-16	11237-11242	total	_
59-17	11243-11245	of	_
59-18	11246-11248	75	_
59-19	11248-11249	)	_
59-20	11249-11250	,	_
59-21	11251-11260	including	_
59-22	11261-11263	33	_
59-23	11264-11270	people	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[35]
59-24	11271-11275	with	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[35]
59-25	11276-11289	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[35]
59-26	11290-11291	(	_
59-27	11291-11293	15	_
59-28	11294-11298	with	_
59-29	11299-11307	elevated	_
59-30	11308-11311	and	_
59-31	11312-11314	18	_
59-32	11315-11319	with	_
59-33	11320-11323	low	_
59-34	11324-11332	cytokine	_
59-35	11333-11339	levels	_
59-36	11339-11340	)	_
59-37	11341-11344	and	_
59-38	11345-11347	42	_
59-39	11348-11355	healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[36]
59-40	11356-11364	controls	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[36]
59-41	11365-11366	(	_
59-42	11366-11367	9	_
59-43	11368-11372	with	_
59-44	11373-11381	elevated	_
59-45	11382-11385	and	_
59-46	11386-11388	33	_
59-47	11389-11393	with	_
59-48	11394-11397	low	_
59-49	11398-11406	cytokine	_
59-50	11407-11413	levels	_
59-51	11413-11414	)	_
59-52	11414-11415	.	_

#Text=MRI image processing was performed on a Mac OSX 10.8 workstation using FreeSurfer v5.1.0 (Desikan Atlas) to calculate volumes for specific brain regions of interest.
60-1	11416-11419	MRI	_
60-2	11420-11425	image	_
60-3	11426-11436	processing	_
60-4	11437-11440	was	_
60-5	11441-11450	performed	_
60-6	11451-11453	on	_
60-7	11454-11455	a	_
60-8	11456-11459	Mac	_
60-9	11460-11463	OSX	_
60-10	11464-11468	10.8	_
60-11	11469-11480	workstation	_
60-12	11481-11486	using	_
60-13	11487-11497	FreeSurfer	_
60-14	11498-11504	v5.1.0	_
60-15	11505-11506	(	_
60-16	11506-11513	Desikan	_
60-17	11514-11519	Atlas	_
60-18	11519-11520	)	_
60-19	11521-11523	to	_
60-20	11524-11533	calculate	_
60-21	11534-11541	volumes	_
60-22	11542-11545	for	_
60-23	11546-11554	specific	_
60-24	11555-11560	brain	_
60-25	11561-11568	regions	_
60-26	11569-11571	of	_
60-27	11572-11580	interest	_
60-28	11580-11581	.	_

#Text=For further details on processing refer to Supplementary Methods: MRI.
61-1	11582-11585	For	_
61-2	11586-11593	further	_
61-3	11594-11601	details	_
61-4	11602-11604	on	_
61-5	11605-11615	processing	_
61-6	11616-11621	refer	_
61-7	11622-11624	to	_
61-8	11625-11638	Supplementary	_
61-9	11639-11646	Methods	_
61-10	11646-11647	:	_
61-11	11648-11651	MRI	_
61-12	11651-11652	.	_

#Text=Statistical analyses
#Text=Statistical tests were performed using SPSS (version 21, OSX, IBM, Armonk, NY, USA).
62-1	11653-11664	Statistical	_
62-2	11665-11673	analyses	_
62-3	11674-11685	Statistical	_
62-4	11686-11691	tests	_
62-5	11692-11696	were	_
62-6	11697-11706	performed	_
62-7	11707-11712	using	_
62-8	11713-11717	SPSS	_
62-9	11718-11719	(	_
62-10	11719-11726	version	_
62-11	11727-11729	21	_
62-12	11729-11730	,	_
62-13	11731-11734	OSX	_
62-14	11734-11735	,	_
62-15	11736-11739	IBM	_
62-16	11739-11740	,	_
62-17	11741-11747	Armonk	_
62-18	11747-11748	,	_
62-19	11749-11751	NY	_
62-20	11751-11752	,	_
62-21	11753-11756	USA	_
62-22	11756-11757	)	_
62-23	11757-11758	.	_

#Text=All quantitative PCR measures were normally distributed either before (IL-8) or after log10 transformation (IL-1β, IL-2, IL-6 and IL-18) with no outliers identified using the Grubb's test.
63-1	11759-11762	All	_
63-2	11763-11775	quantitative	_
63-3	11776-11779	PCR	_
63-4	11780-11788	measures	_
63-5	11789-11793	were	_
63-6	11794-11802	normally	_
63-7	11803-11814	distributed	_
63-8	11815-11821	either	_
63-9	11822-11828	before	_
63-10	11829-11830	(	_
63-11	11830-11832	IL	_
63-12	11832-11833	-	_
63-13	11833-11834	8	_
63-14	11834-11835	)	_
63-15	11836-11838	or	_
63-16	11839-11844	after	_
63-17	11845-11850	log10	_
63-18	11851-11865	transformation	_
63-19	11866-11867	(	_
63-20	11867-11869	IL	_
63-21	11869-11870	-	_
63-22	11870-11872	1β	_
63-23	11872-11873	,	_
63-24	11874-11876	IL	_
63-25	11876-11877	-	_
63-26	11877-11878	2	_
63-27	11878-11879	,	_
63-28	11880-11882	IL	_
63-29	11882-11883	-	_
63-30	11883-11884	6	_
63-31	11885-11888	and	_
63-32	11889-11891	IL	_
63-33	11891-11892	-	_
63-34	11892-11894	18	_
63-35	11894-11895	)	_
63-36	11896-11900	with	_
63-37	11901-11903	no	_
63-38	11904-11912	outliers	_
63-39	11913-11923	identified	_
63-40	11924-11929	using	_
63-41	11930-11933	the	_
63-42	11934-11941	Grubb's	_
63-43	11942-11946	test	_
63-44	11946-11947	.	_

#Text=Forward stepwise regressions using age, education and RIN as independent variables were performed to assess relationships of these potentially confounding variables to cytokine mRNA measures.
64-1	11948-11955	Forward	_
64-2	11956-11964	stepwise	_
64-3	11965-11976	regressions	_
64-4	11977-11982	using	_
64-5	11983-11986	age	_
64-6	11986-11987	,	_
64-7	11988-11997	education	_
64-8	11998-12001	and	_
64-9	12002-12005	RIN	_
64-10	12006-12008	as	_
64-11	12009-12020	independent	_
64-12	12021-12030	variables	_
64-13	12031-12035	were	_
64-14	12036-12045	performed	_
64-15	12046-12048	to	_
64-16	12049-12055	assess	_
64-17	12056-12069	relationships	_
64-18	12070-12072	of	_
64-19	12073-12078	these	_
64-20	12079-12090	potentially	_
64-21	12091-12102	confounding	_
64-22	12103-12112	variables	_
64-23	12113-12115	to	_
64-24	12116-12124	cytokine	_
64-25	12125-12129	mRNA	_
64-26	12130-12138	measures	_
64-27	12138-12139	.	_

#Text=Student's t-tests or analysis of variances (ANCOVAs) were performed on each mRNA measurement to identify diagnostic differences between groups.
65-1	12140-12149	Student's	_
65-2	12150-12157	t-tests	_
65-3	12158-12160	or	_
65-4	12161-12169	analysis	_
65-5	12170-12172	of	_
65-6	12173-12182	variances	_
65-7	12183-12184	(	_
65-8	12184-12191	ANCOVAs	_
65-9	12191-12192	)	_
65-10	12193-12197	were	_
65-11	12198-12207	performed	_
65-12	12208-12210	on	_
65-13	12211-12215	each	_
65-14	12216-12220	mRNA	_
65-15	12221-12232	measurement	_
65-16	12233-12235	to	_
65-17	12236-12244	identify	_
65-18	12245-12255	diagnostic	_
65-19	12256-12267	differences	_
65-20	12268-12275	between	_
65-21	12276-12282	groups	_
65-22	12282-12283	.	_

#Text=The elevated cytokine subgroup was defined using a recursive two-step cluster analysis as performed previously on the entire case/control cohort, with missing values (average 3.8 measurements/cytokine) replaced by the expectation maximization algorithm.
66-1	12284-12287	The	_
66-2	12288-12296	elevated	_
66-3	12297-12305	cytokine	_
66-4	12306-12314	subgroup	_
66-5	12315-12318	was	_
66-6	12319-12326	defined	_
66-7	12327-12332	using	_
66-8	12333-12334	a	_
66-9	12335-12344	recursive	_
66-10	12345-12353	two-step	_
66-11	12354-12361	cluster	_
66-12	12362-12370	analysis	_
66-13	12371-12373	as	_
66-14	12374-12383	performed	_
66-15	12384-12394	previously	_
66-16	12395-12397	on	_
66-17	12398-12401	the	_
66-18	12402-12408	entire	_
66-19	12409-12413	case	_
66-20	12413-12414	/	_
66-21	12414-12421	control	_
66-22	12422-12428	cohort	_
66-23	12428-12429	,	_
66-24	12430-12434	with	_
66-25	12435-12442	missing	_
66-26	12443-12449	values	_
66-27	12450-12451	(	_
66-28	12451-12458	average	_
66-29	12459-12462	3.8	_
66-30	12463-12475	measurements	_
66-31	12475-12476	/	_
66-32	12476-12484	cytokine	_
66-33	12484-12485	)	_
66-34	12486-12494	replaced	_
66-35	12495-12497	by	_
66-36	12498-12501	the	_
66-37	12502-12513	expectation	_
66-38	12514-12526	maximization	_
66-39	12527-12536	algorithm	_
66-40	12536-12537	.	_

#Text=The optimal clustering model was determined by obtaining the greatest silhouette measure of cohesion and separation (see Supplementary Methods: statistical analysis for additional details of the clustering analysis).
67-1	12538-12541	The	_
67-2	12542-12549	optimal	_
67-3	12550-12560	clustering	_
67-4	12561-12566	model	_
67-5	12567-12570	was	_
67-6	12571-12581	determined	_
67-7	12582-12584	by	_
67-8	12585-12594	obtaining	_
67-9	12595-12598	the	_
67-10	12599-12607	greatest	_
67-11	12608-12618	silhouette	_
67-12	12619-12626	measure	_
67-13	12627-12629	of	_
67-14	12630-12638	cohesion	_
67-15	12639-12642	and	_
67-16	12643-12653	separation	_
67-17	12654-12655	(	_
67-18	12655-12658	see	_
67-19	12659-12672	Supplementary	_
67-20	12673-12680	Methods	_
67-21	12680-12681	:	_
67-22	12682-12693	statistical	_
67-23	12694-12702	analysis	_
67-24	12703-12706	for	_
67-25	12707-12717	additional	_
67-26	12718-12725	details	_
67-27	12726-12728	of	_
67-28	12729-12732	the	_
67-29	12733-12743	clustering	_
67-30	12744-12752	analysis	_
67-31	12752-12753	)	_
67-32	12753-12754	.	_

#Text=Demographics difference between the clusters were tested using t-tests or χ2-tests for continuous and categorical variables, respectively.
68-1	12755-12767	Demographics	_
68-2	12768-12778	difference	_
68-3	12779-12786	between	_
68-4	12787-12790	the	_
68-5	12791-12799	clusters	_
68-6	12800-12804	were	_
68-7	12805-12811	tested	_
68-8	12812-12817	using	_
68-9	12818-12825	t-tests	_
68-10	12826-12828	or	_
68-11	12829-12831	χ2	_
68-12	12831-12832	-	_
68-13	12832-12837	tests	_
68-14	12838-12841	for	_
68-15	12842-12852	continuous	_
68-16	12853-12856	and	_
68-17	12857-12868	categorical	_
68-18	12869-12878	variables	_
68-19	12878-12879	,	_
68-20	12880-12892	respectively	_
68-21	12892-12893	.	_

#Text=Cognitive scores were converted into z-scores and used in two-way ANCOVAs, with diagnosis and cytokine group as independent variables and premorbid intelligence quotient estimate (Wechsler Test of Adult Reading) included as a covariate.
69-1	12894-12903	Cognitive	_
69-2	12904-12910	scores	_
69-3	12911-12915	were	_
69-4	12916-12925	converted	_
69-5	12926-12930	into	_
69-6	12931-12939	z-scores	_
69-7	12940-12943	and	_
69-8	12944-12948	used	_
69-9	12949-12951	in	_
69-10	12952-12959	two-way	_
69-11	12960-12967	ANCOVAs	_
69-12	12967-12968	,	_
69-13	12969-12973	with	_
69-14	12974-12983	diagnosis	_
69-15	12984-12987	and	_
69-16	12988-12996	cytokine	_
69-17	12997-13002	group	_
69-18	13003-13005	as	_
69-19	13006-13017	independent	_
69-20	13018-13027	variables	_
69-21	13028-13031	and	_
69-22	13032-13041	premorbid	_
69-23	13042-13054	intelligence	_
69-24	13055-13063	quotient	_
69-25	13064-13072	estimate	_
69-26	13073-13074	(	_
69-27	13074-13082	Wechsler	_
69-28	13083-13087	Test	_
69-29	13088-13090	of	_
69-30	13091-13096	Adult	_
69-31	13097-13104	Reading	_
69-32	13104-13105	)	_
69-33	13106-13114	included	_
69-34	13115-13117	as	_
69-35	13118-13119	a	_
69-36	13120-13129	covariate	_
69-37	13129-13130	.	_

#Text=Specific brain regions of interest were chosen based on the outcome of the cognitive analyses, to target anatomical regions underlying cognitive domains that had demonstrated impairment linked to cytokine levels.
70-1	13131-13139	Specific	_
70-2	13140-13145	brain	_
70-3	13146-13153	regions	_
70-4	13154-13156	of	_
70-5	13157-13165	interest	_
70-6	13166-13170	were	_
70-7	13171-13177	chosen	_
70-8	13178-13183	based	_
70-9	13184-13186	on	_
70-10	13187-13190	the	_
70-11	13191-13198	outcome	_
70-12	13199-13201	of	_
70-13	13202-13205	the	_
70-14	13206-13215	cognitive	_
70-15	13216-13224	analyses	_
70-16	13224-13225	,	_
70-17	13226-13228	to	_
70-18	13229-13235	target	_
70-19	13236-13246	anatomical	_
70-20	13247-13254	regions	_
70-21	13255-13265	underlying	_
70-22	13266-13275	cognitive	_
70-23	13276-13283	domains	_
70-24	13284-13288	that	_
70-25	13289-13292	had	_
70-26	13293-13305	demonstrated	_
70-27	13306-13316	impairment	_
70-28	13317-13323	linked	_
70-29	13324-13326	to	_
70-30	13327-13335	cytokine	_
70-31	13336-13342	levels	_
70-32	13342-13343	.	_

#Text=Specifically, Broca's area, left pars opercularis (POp) and pars triangularis, and Wernicke's area, supramarginal gyrus (SMG), and their right hemisphere analogs were chosen for analysis based on the presence of a language deficit in the elevated cytokine patient group, as described in the Results section.
71-1	13344-13356	Specifically	_
71-2	13356-13357	,	_
71-3	13358-13365	Broca's	_
71-4	13366-13370	area	_
71-5	13370-13371	,	_
71-6	13372-13376	left	_
71-7	13377-13381	pars	_
71-8	13382-13393	opercularis	_
71-9	13394-13395	(	_
71-10	13395-13398	POp	_
71-11	13398-13399	)	_
71-12	13400-13403	and	_
71-13	13404-13408	pars	_
71-14	13409-13421	triangularis	_
71-15	13421-13422	,	_
71-16	13423-13426	and	_
71-17	13427-13437	Wernicke's	_
71-18	13438-13442	area	_
71-19	13442-13443	,	_
71-20	13444-13457	supramarginal	_
71-21	13458-13463	gyrus	_
71-22	13464-13465	(	_
71-23	13465-13468	SMG	_
71-24	13468-13469	)	_
71-25	13469-13470	,	_
71-26	13471-13474	and	_
71-27	13475-13480	their	_
71-28	13481-13486	right	_
71-29	13487-13497	hemisphere	_
71-30	13498-13505	analogs	_
71-31	13506-13510	were	_
71-32	13511-13517	chosen	_
71-33	13518-13521	for	_
71-34	13522-13530	analysis	_
71-35	13531-13536	based	_
71-36	13537-13539	on	_
71-37	13540-13543	the	_
71-38	13544-13552	presence	_
71-39	13553-13555	of	_
71-40	13556-13557	a	_
71-41	13558-13566	language	_
71-42	13567-13574	deficit	_
71-43	13575-13577	in	_
71-44	13578-13581	the	_
71-45	13582-13590	elevated	_
71-46	13591-13599	cytokine	_
71-47	13600-13607	patient	_
71-48	13608-13613	group	_
71-49	13613-13614	,	_
71-50	13615-13617	as	_
71-51	13618-13627	described	_
71-52	13628-13630	in	_
71-53	13631-13634	the	_
71-54	13635-13642	Results	_
71-55	13643-13650	section	_
71-56	13650-13651	.	_

#Text=These structures were assessed using two-way ANCOVAs with brain structure as the dependent variable, diagnosis and elevated/low-cytokine subgroup as independent variables and sex and age as covariates.
72-1	13652-13657	These	_
72-2	13658-13668	structures	_
72-3	13669-13673	were	_
72-4	13674-13682	assessed	_
72-5	13683-13688	using	_
72-6	13689-13696	two-way	_
72-7	13697-13704	ANCOVAs	_
72-8	13705-13709	with	_
72-9	13710-13715	brain	_
72-10	13716-13725	structure	_
72-11	13726-13728	as	_
72-12	13729-13732	the	_
72-13	13733-13742	dependent	_
72-14	13743-13751	variable	_
72-15	13751-13752	,	_
72-16	13753-13762	diagnosis	_
72-17	13763-13766	and	_
72-18	13767-13775	elevated	_
72-19	13775-13776	/	_
72-20	13776-13788	low-cytokine	_
72-21	13789-13797	subgroup	_
72-22	13798-13800	as	_
72-23	13801-13812	independent	_
72-24	13813-13822	variables	_
72-25	13823-13826	and	_
72-26	13827-13830	sex	_
72-27	13831-13834	and	_
72-28	13835-13838	age	_
72-29	13839-13841	as	_
72-30	13842-13852	covariates	_
72-31	13852-13853	.	_

#Text=Linear regression using IL-1β expression levels as the independent variable were performed to assess the strength of the relationships among cytokine expression, COWAT score (covaried for Wechsler Test of Adult Reading) and left hemisphere opercularis volume.
73-1	13854-13860	Linear	_
73-2	13861-13871	regression	_
73-3	13872-13877	using	_
73-4	13878-13880	IL	_
73-5	13880-13881	-	_
73-6	13881-13883	1β	_
73-7	13884-13894	expression	_
73-8	13895-13901	levels	_
73-9	13902-13904	as	_
73-10	13905-13908	the	_
73-11	13909-13920	independent	_
73-12	13921-13929	variable	_
73-13	13930-13934	were	_
73-14	13935-13944	performed	_
73-15	13945-13947	to	_
73-16	13948-13954	assess	_
73-17	13955-13958	the	_
73-18	13959-13967	strength	_
73-19	13968-13970	of	_
73-20	13971-13974	the	_
73-21	13975-13988	relationships	_
73-22	13989-13994	among	_
73-23	13995-14003	cytokine	_
73-24	14004-14014	expression	_
73-25	14014-14015	,	_
73-26	14016-14021	COWAT	_
73-27	14022-14027	score	_
73-28	14028-14029	(	_
73-29	14029-14037	covaried	_
73-30	14038-14041	for	_
73-31	14042-14050	Wechsler	_
73-32	14051-14055	Test	_
73-33	14056-14058	of	_
73-34	14059-14064	Adult	_
73-35	14065-14072	Reading	_
73-36	14072-14073	)	_
73-37	14074-14077	and	_
73-38	14078-14082	left	_
73-39	14083-14093	hemisphere	_
73-40	14094-14105	opercularis	_
73-41	14106-14112	volume	_
73-42	14112-14113	.	_

#Text=A Hochberg-Bonferroni correction for multiple comparisons of both cognitive and imaging results was used on combined ANCOVA results on a post hoc basis.
74-1	14114-14115	A	_
74-2	14116-14135	Hochberg-Bonferroni	_
74-3	14136-14146	correction	_
74-4	14147-14150	for	_
74-5	14151-14159	multiple	_
74-6	14160-14171	comparisons	_
74-7	14172-14174	of	_
74-8	14175-14179	both	_
74-9	14180-14189	cognitive	_
74-10	14190-14193	and	_
74-11	14194-14201	imaging	_
74-12	14202-14209	results	_
74-13	14210-14213	was	_
74-14	14214-14218	used	_
74-15	14219-14221	on	_
74-16	14222-14230	combined	_
74-17	14231-14237	ANCOVA	_
74-18	14238-14245	results	_
74-19	14246-14248	on	_
74-20	14249-14250	a	_
74-21	14251-14255	post	_
74-22	14256-14259	hoc	_
74-23	14260-14265	basis	_
74-24	14265-14266	.	_

#Text=To assess the main effect of elevated/low-cytokine subgroup within the diagnostic group of schizophrenia and to control for potential confounds of antipsychotic exposure, a planned ANCOVA between elevated and low-cytokine patient groups was performed with mean daily chlorpromazine equivalent dose as a covariate.
75-1	14267-14269	To	_
75-2	14270-14276	assess	_
75-3	14277-14280	the	_
75-4	14281-14285	main	_
75-5	14286-14292	effect	_
75-6	14293-14295	of	_
75-7	14296-14304	elevated	_
75-8	14304-14305	/	_
75-9	14305-14317	low-cytokine	_
75-10	14318-14326	subgroup	_
75-11	14327-14333	within	_
75-12	14334-14337	the	_
75-13	14338-14348	diagnostic	_
75-14	14349-14354	group	_
75-15	14355-14357	of	_
75-16	14358-14371	schizophrenia	_
75-17	14372-14375	and	_
75-18	14376-14378	to	_
75-19	14379-14386	control	_
75-20	14387-14390	for	_
75-21	14391-14400	potential	_
75-22	14401-14410	confounds	_
75-23	14411-14413	of	_
75-24	14414-14427	antipsychotic	_
75-25	14428-14436	exposure	_
75-26	14436-14437	,	_
75-27	14438-14439	a	_
75-28	14440-14447	planned	_
75-29	14448-14454	ANCOVA	_
75-30	14455-14462	between	_
75-31	14463-14471	elevated	_
75-32	14472-14475	and	_
75-33	14476-14488	low-cytokine	_
75-34	14489-14496	patient	_
75-35	14497-14503	groups	_
75-36	14504-14507	was	_
75-37	14508-14517	performed	_
75-38	14518-14522	with	_
75-39	14523-14527	mean	_
75-40	14528-14533	daily	_
75-41	14534-14548	chlorpromazine	_
75-42	14549-14559	equivalent	_
75-43	14560-14564	dose	_
75-44	14565-14567	as	_
75-45	14568-14569	a	_
75-46	14570-14579	covariate	_
75-47	14579-14580	.	_

#Text=Results
#Text=Elevated IL-1β cytokine mRNA in individuals with schizophrenia
#Text=Peripheral IL-1β mRNA was increased by 28.4% in individuals with schizophrenia (t(82)=2.64, P<0.01, Figure 1).
76-1	14581-14588	Results	_
76-2	14589-14597	Elevated	_
76-3	14598-14600	IL	_
76-4	14600-14601	-	_
76-5	14601-14603	1β	_
76-6	14604-14612	cytokine	_
76-7	14613-14617	mRNA	_
76-8	14618-14620	in	_
76-9	14621-14632	individuals	_
76-10	14633-14637	with	_
76-11	14638-14651	schizophrenia	_
76-12	14652-14662	Peripheral	_
76-13	14663-14665	IL	_
76-14	14665-14666	-	_
76-15	14666-14668	1β	_
76-16	14669-14673	mRNA	_
76-17	14674-14677	was	_
76-18	14678-14687	increased	_
76-19	14688-14690	by	_
76-20	14691-14696	28.4%	_
76-21	14697-14699	in	_
76-22	14700-14711	individuals	_
76-23	14712-14716	with	_
76-24	14717-14730	schizophrenia	_
76-25	14731-14732	(	_
76-26	14732-14733	t	_
76-27	14733-14734	(	_
76-28	14734-14736	82	_
76-29	14736-14737	)	_
76-30	14737-14738	=	_
76-31	14738-14742	2.64	_
76-32	14742-14743	,	_
76-33	14744-14745	P	_
76-34	14745-14746	<	_
76-35	14746-14750	0.01	_
76-36	14750-14751	,	_
76-37	14752-14758	Figure	_
76-38	14759-14760	1	_
76-39	14760-14761	)	_
76-40	14761-14762	.	_

#Text=The majority of the remaining cytokines were also increased in schizophrenia but differences did not reach statistical significance: IL-8: 9.20% t(82)=0.87, P=0.39, IL-18: 11.5% t(83)=1.29, P=0.20, IL-6: 8.78%, t(83)=1.06, P=0.29.
77-1	14763-14766	The	_
77-2	14767-14775	majority	_
77-3	14776-14778	of	_
77-4	14779-14782	the	_
77-5	14783-14792	remaining	_
77-6	14793-14802	cytokines	_
77-7	14803-14807	were	_
77-8	14808-14812	also	_
77-9	14813-14822	increased	_
77-10	14823-14825	in	_
77-11	14826-14839	schizophrenia	_
77-12	14840-14843	but	_
77-13	14844-14855	differences	_
77-14	14856-14859	did	_
77-15	14860-14863	not	_
77-16	14864-14869	reach	_
77-17	14870-14881	statistical	_
77-18	14882-14894	significance	_
77-19	14894-14895	:	_
77-20	14896-14898	IL	_
77-21	14898-14899	-	_
77-22	14899-14900	8	_
77-23	14900-14901	:	_
77-24	14902-14907	9.20%	_
77-25	14908-14909	t	_
77-26	14909-14910	(	_
77-27	14910-14912	82	_
77-28	14912-14913	)	_
77-29	14913-14914	=	_
77-30	14914-14918	0.87	_
77-31	14918-14919	,	_
77-32	14920-14921	P	_
77-33	14921-14922	=	_
77-34	14922-14926	0.39	_
77-35	14926-14927	,	_
77-36	14928-14930	IL	_
77-37	14930-14931	-	_
77-38	14931-14933	18	_
77-39	14933-14934	:	_
77-40	14935-14940	11.5%	_
77-41	14941-14942	t	_
77-42	14942-14943	(	_
77-43	14943-14945	83	_
77-44	14945-14946	)	_
77-45	14946-14947	=	_
77-46	14947-14951	1.29	_
77-47	14951-14952	,	_
77-48	14953-14954	P	_
77-49	14954-14955	=	_
77-50	14955-14959	0.20	_
77-51	14959-14960	,	_
77-52	14961-14963	IL	_
77-53	14963-14964	-	_
77-54	14964-14965	6	_
77-55	14965-14966	:	_
77-56	14967-14972	8.78%	_
77-57	14972-14973	,	_
77-58	14974-14975	t	_
77-59	14975-14976	(	_
77-60	14976-14978	83	_
77-61	14978-14979	)	_
77-62	14979-14980	=	_
77-63	14980-14984	1.06	_
77-64	14984-14985	,	_
77-65	14986-14987	P	_
77-66	14987-14988	=	_
77-67	14988-14992	0.29	_
77-68	14992-14993	.	_

#Text=We found that the median (as shown in Figure 1) IL2 mRNA value was higher in schizophrenia; however, the mean was actually 18.2%, higher in controls (t(82)=−0.20, P=0.84).
78-1	14994-14996	We	_
78-2	14997-15002	found	_
78-3	15003-15007	that	_
78-4	15008-15011	the	_
78-5	15012-15018	median	_
78-6	15019-15020	(	_
78-7	15020-15022	as	_
78-8	15023-15028	shown	_
78-9	15029-15031	in	_
78-10	15032-15038	Figure	_
78-11	15039-15040	1	_
78-12	15040-15041	)	_
78-13	15042-15045	IL2	_
78-14	15046-15050	mRNA	_
78-15	15051-15056	value	_
78-16	15057-15060	was	_
78-17	15061-15067	higher	_
78-18	15068-15070	in	_
78-19	15071-15084	schizophrenia	_
78-20	15084-15085	;	_
78-21	15086-15093	however	_
78-22	15093-15094	,	_
78-23	15095-15098	the	_
78-24	15099-15103	mean	_
78-25	15104-15107	was	_
78-26	15108-15116	actually	_
78-27	15117-15122	18.2%	_
78-28	15122-15123	,	_
78-29	15124-15130	higher	_
78-30	15131-15133	in	_
78-31	15134-15142	controls	_
78-32	15143-15144	(	_
78-33	15144-15145	t	_
78-34	15145-15146	(	_
78-35	15146-15148	82	_
78-36	15148-15149	)	_
78-37	15149-15150	=	_
78-38	15150-15151	−	_
78-39	15151-15155	0.20	_
78-40	15155-15156	,	_
78-41	15157-15158	P	_
78-42	15158-15159	=	_
78-43	15159-15163	0.84	_
78-44	15163-15164	)	_
78-45	15164-15165	.	_

#Text=The cytokine mRNA measurements did not significantly differ between sexes, except for IL-1β, (t(82)=-2.57, P<0.01), which was 28% higher in women.
79-1	15166-15169	The	_
79-2	15170-15178	cytokine	_
79-3	15179-15183	mRNA	_
79-4	15184-15196	measurements	_
79-5	15197-15200	did	_
79-6	15201-15204	not	_
79-7	15205-15218	significantly	_
79-8	15219-15225	differ	_
79-9	15226-15233	between	_
79-10	15234-15239	sexes	_
79-11	15239-15240	,	_
79-12	15241-15247	except	_
79-13	15248-15251	for	_
79-14	15252-15254	IL	_
79-15	15254-15255	-	_
79-16	15255-15257	1β	_
79-17	15257-15258	,	_
79-18	15259-15260	(	_
79-19	15260-15261	t	_
79-20	15261-15262	(	_
79-21	15262-15264	82	_
79-22	15264-15265	)	_
79-23	15265-15266	=	_
79-24	15266-15267	-	_
79-25	15267-15271	2.57	_
79-26	15271-15272	,	_
79-27	15273-15274	P	_
79-28	15274-15275	<	_
79-29	15275-15279	0.01	_
79-30	15279-15280	)	_
79-31	15280-15281	,	_
79-32	15282-15287	which	_
79-33	15288-15291	was	_
79-34	15292-15295	28%	_
79-35	15296-15302	higher	_
79-36	15303-15305	in	_
79-37	15306-15311	women	_
79-38	15311-15312	.	_

#Text=IL-1β remained significantly different between diagnostic groups when sex was included in a two-way ANOVA (diagnosis: F(1,80)=8.83, P<0.01, sex: F(1,80)=8.79, P<0.01, interaction: F(1,80)=0.33, P=0.57).
80-1	15313-15315	IL	_
80-2	15315-15316	-	_
80-3	15316-15318	1β	_
80-4	15319-15327	remained	_
80-5	15328-15341	significantly	_
80-6	15342-15351	different	_
80-7	15352-15359	between	_
80-8	15360-15370	diagnostic	_
80-9	15371-15377	groups	_
80-10	15378-15382	when	_
80-11	15383-15386	sex	_
80-12	15387-15390	was	_
80-13	15391-15399	included	_
80-14	15400-15402	in	_
80-15	15403-15404	a	_
80-16	15405-15412	two-way	_
80-17	15413-15418	ANOVA	_
80-18	15419-15420	(	_
80-19	15420-15429	diagnosis	_
80-20	15429-15430	:	_
80-21	15431-15432	F	_
80-22	15432-15433	(	_
80-23	15433-15437	1,80	_
80-24	15437-15438	)	_
80-25	15438-15439	=	_
80-26	15439-15443	8.83	_
80-27	15443-15444	,	_
80-28	15445-15446	P	_
80-29	15446-15447	<	_
80-30	15447-15451	0.01	_
80-31	15451-15452	,	_
80-32	15453-15456	sex	_
80-33	15456-15457	:	_
80-34	15458-15459	F	_
80-35	15459-15460	(	_
80-36	15460-15464	1,80	_
80-37	15464-15465	)	_
80-38	15465-15466	=	_
80-39	15466-15470	8.79	_
80-40	15470-15471	,	_
80-41	15472-15473	P	_
80-42	15473-15474	<	_
80-43	15474-15478	0.01	_
80-44	15478-15479	,	_
80-45	15480-15491	interaction	_
80-46	15491-15492	:	_
80-47	15493-15494	F	_
80-48	15494-15495	(	_
80-49	15495-15499	1,80	_
80-50	15499-15500	)	_
80-51	15500-15501	=	_
80-52	15501-15505	0.33	_
80-53	15505-15506	,	_
80-54	15507-15508	P	_
80-55	15508-15509	=	_
80-56	15509-15513	0.57	_
80-57	15513-15514	)	_
80-58	15514-15515	.	_

#Text=Identification of cytokine subgroups by mRNA levels
#Text=A two-step cluster analysis on the blood cytokine mRNA expression data (IL-1β, IL-2, IL-6, IL-8 and IL-18) from all participants identified two distinct subgroups characterized by IL-1β, IL-18, IL-8 and IL-2 mRNA levels, whereas IL-6 did not significantly contribute.
81-1	15516-15530	Identification	_
81-2	15531-15533	of	_
81-3	15534-15542	cytokine	_
81-4	15543-15552	subgroups	_
81-5	15553-15555	by	_
81-6	15556-15560	mRNA	_
81-7	15561-15567	levels	_
81-8	15568-15569	A	_
81-9	15570-15578	two-step	_
81-10	15579-15586	cluster	_
81-11	15587-15595	analysis	_
81-12	15596-15598	on	_
81-13	15599-15602	the	_
81-14	15603-15608	blood	_
81-15	15609-15617	cytokine	_
81-16	15618-15622	mRNA	_
81-17	15623-15633	expression	_
81-18	15634-15638	data	_
81-19	15639-15640	(	_
81-20	15640-15642	IL	_
81-21	15642-15643	-	_
81-22	15643-15645	1β	_
81-23	15645-15646	,	_
81-24	15647-15649	IL	_
81-25	15649-15650	-	_
81-26	15650-15651	2	_
81-27	15651-15652	,	_
81-28	15653-15655	IL	_
81-29	15655-15656	-	_
81-30	15656-15657	6	_
81-31	15657-15658	,	_
81-32	15659-15661	IL	_
81-33	15661-15662	-	_
81-34	15662-15663	8	_
81-35	15664-15667	and	_
81-36	15668-15670	IL	_
81-37	15670-15671	-	_
81-38	15671-15673	18	_
81-39	15673-15674	)	_
81-40	15675-15679	from	_
81-41	15680-15683	all	_
81-42	15684-15696	participants	_
81-43	15697-15707	identified	_
81-44	15708-15711	two	_
81-45	15712-15720	distinct	_
81-46	15721-15730	subgroups	_
81-47	15731-15744	characterized	_
81-48	15745-15747	by	_
81-49	15748-15750	IL	_
81-50	15750-15751	-	_
81-51	15751-15753	1β	_
81-52	15753-15754	,	_
81-53	15755-15757	IL	_
81-54	15757-15758	-	_
81-55	15758-15760	18	_
81-56	15760-15761	,	_
81-57	15762-15764	IL	_
81-58	15764-15765	-	_
81-59	15765-15766	8	_
81-60	15767-15770	and	_
81-61	15771-15773	IL	_
81-62	15773-15774	-	_
81-63	15774-15775	2	_
81-64	15776-15780	mRNA	_
81-65	15781-15787	levels	_
81-66	15787-15788	,	_
81-67	15789-15796	whereas	_
81-68	15797-15799	IL	_
81-69	15799-15800	-	_
81-70	15800-15801	6	_
81-71	15802-15805	did	_
81-72	15806-15809	not	_
81-73	15810-15823	significantly	_
81-74	15824-15834	contribute	_
81-75	15834-15835	.	_

#Text=Thus, we labeled the groups ‘elevated cytokine' referring to a pattern of relatively higher cytokine mRNA levels (total n=26; 17 patients and 9 controls) and ‘low cytokine' for those with a pattern of relatively decreased cytokine mRNA levels (total n=59; 26 patients and 33 controls) defined in a similar manner to our previous work (see Figure 2a).
82-1	15836-15840	Thus	_
82-2	15840-15841	,	_
82-3	15842-15844	we	_
82-4	15845-15852	labeled	_
82-5	15853-15856	the	_
82-6	15857-15863	groups	_
82-7	15864-15865	‘	_
82-8	15865-15873	elevated	_
82-9	15874-15882	cytokine	_
82-10	15882-15883	'	_
82-11	15884-15893	referring	_
82-12	15894-15896	to	_
82-13	15897-15898	a	_
82-14	15899-15906	pattern	_
82-15	15907-15909	of	_
82-16	15910-15920	relatively	_
82-17	15921-15927	higher	_
82-18	15928-15936	cytokine	_
82-19	15937-15941	mRNA	_
82-20	15942-15948	levels	_
82-21	15949-15950	(	_
82-22	15950-15955	total	_
82-23	15956-15957	n	_
82-24	15957-15958	=	_
82-25	15958-15960	26	_
82-26	15960-15961	;	_
82-27	15962-15964	17	_
82-28	15965-15973	patients	_
82-29	15974-15977	and	_
82-30	15978-15979	9	_
82-31	15980-15988	controls	_
82-32	15988-15989	)	_
82-33	15990-15993	and	_
82-34	15994-15995	‘	_
82-35	15995-15998	low	_
82-36	15999-16007	cytokine	_
82-37	16007-16008	'	_
82-38	16009-16012	for	_
82-39	16013-16018	those	_
82-40	16019-16023	with	_
82-41	16024-16025	a	_
82-42	16026-16033	pattern	_
82-43	16034-16036	of	_
82-44	16037-16047	relatively	_
82-45	16048-16057	decreased	_
82-46	16058-16066	cytokine	_
82-47	16067-16071	mRNA	_
82-48	16072-16078	levels	_
82-49	16079-16080	(	_
82-50	16080-16085	total	_
82-51	16086-16087	n	_
82-52	16087-16088	=	_
82-53	16088-16090	59	_
82-54	16090-16091	;	_
82-55	16092-16094	26	_
82-56	16095-16103	patients	_
82-57	16104-16107	and	_
82-58	16108-16110	33	_
82-59	16111-16119	controls	_
82-60	16119-16120	)	_
82-61	16121-16128	defined	_
82-62	16129-16131	in	_
82-63	16132-16133	a	_
82-64	16134-16141	similar	_
82-65	16142-16148	manner	_
82-66	16149-16151	to	_
82-67	16152-16155	our	_
82-68	16156-16164	previous	_
82-69	16165-16169	work	_
82-70	16170-16171	(	_
82-71	16171-16174	see	_
82-72	16175-16181	Figure	_
82-73	16182-16184	2a	_
82-74	16184-16185	)	_
82-75	16185-16186	.	_

#Text=There was a trend towards more individuals with schizophrenia (n=17) than controls (n=9) being classified into the relatively elevated cytokine group, whereas controls were more likely in the low-cytokine group (CON: n=33, SCZ: n=26, χ2=3.28, P=0.07) (Figure 2b).
83-1	16187-16192	There	_
83-2	16193-16196	was	_
83-3	16197-16198	a	_
83-4	16199-16204	trend	_
83-5	16205-16212	towards	_
83-6	16213-16217	more	_
83-7	16218-16229	individuals	_
83-8	16230-16234	with	_
83-9	16235-16248	schizophrenia	_
83-10	16249-16250	(	_
83-11	16250-16251	n	_
83-12	16251-16252	=	_
83-13	16252-16254	17	_
83-14	16254-16255	)	_
83-15	16256-16260	than	_
83-16	16261-16269	controls	_
83-17	16270-16271	(	_
83-18	16271-16272	n	_
83-19	16272-16273	=	_
83-20	16273-16274	9	_
83-21	16274-16275	)	_
83-22	16276-16281	being	_
83-23	16282-16292	classified	_
83-24	16293-16297	into	_
83-25	16298-16301	the	_
83-26	16302-16312	relatively	_
83-27	16313-16321	elevated	_
83-28	16322-16330	cytokine	_
83-29	16331-16336	group	_
83-30	16336-16337	,	_
83-31	16338-16345	whereas	_
83-32	16346-16354	controls	_
83-33	16355-16359	were	_
83-34	16360-16364	more	_
83-35	16365-16371	likely	_
83-36	16372-16374	in	_
83-37	16375-16378	the	_
83-38	16379-16391	low-cytokine	_
83-39	16392-16397	group	_
83-40	16398-16399	(	_
83-41	16399-16402	CON	_
83-42	16402-16403	:	_
83-43	16404-16405	n	_
83-44	16405-16406	=	_
83-45	16406-16408	33	_
83-46	16408-16409	,	_
83-47	16410-16413	SCZ	_
83-48	16413-16414	:	_
83-49	16415-16416	n	_
83-50	16416-16417	=	_
83-51	16417-16419	26	_
83-52	16419-16420	,	_
83-53	16421-16423	χ2	_
83-54	16423-16424	=	_
83-55	16424-16428	3.28	_
83-56	16428-16429	,	_
83-57	16430-16431	P	_
83-58	16431-16432	=	_
83-59	16432-16436	0.07	_
83-60	16436-16437	)	_
83-61	16438-16439	(	_
83-62	16439-16445	Figure	_
83-63	16446-16448	2b	_
83-64	16448-16449	)	_
83-65	16449-16450	.	_

#Text=Relationship of cytokine group to demographic factors
#Text=There were no significant differences between elevated and low-cytokine groups on the basis of age, gender, handedness (non-parametric test), BMI, illness duration, age of onset, chlorpromazine equivalent dose, all Positive and Negative Syndrome Scale scores and RNA integrity number (for details refer to Supplementary Table 1).
84-1	16451-16463	Relationship	_
84-2	16464-16466	of	_
84-3	16467-16475	cytokine	_
84-4	16476-16481	group	_
84-5	16482-16484	to	_
84-6	16485-16496	demographic	_
84-7	16497-16504	factors	_
84-8	16505-16510	There	_
84-9	16511-16515	were	_
84-10	16516-16518	no	_
84-11	16519-16530	significant	_
84-12	16531-16542	differences	_
84-13	16543-16550	between	_
84-14	16551-16559	elevated	_
84-15	16560-16563	and	_
84-16	16564-16576	low-cytokine	_
84-17	16577-16583	groups	_
84-18	16584-16586	on	_
84-19	16587-16590	the	_
84-20	16591-16596	basis	_
84-21	16597-16599	of	_
84-22	16600-16603	age	_
84-23	16603-16604	,	_
84-24	16605-16611	gender	_
84-25	16611-16612	,	_
84-26	16613-16623	handedness	_
84-27	16624-16625	(	_
84-28	16625-16639	non-parametric	_
84-29	16640-16644	test	_
84-30	16644-16645	)	_
84-31	16645-16646	,	_
84-32	16647-16650	BMI	_
84-33	16650-16651	,	_
84-34	16652-16659	illness	_
84-35	16660-16668	duration	_
84-36	16668-16669	,	_
84-37	16670-16673	age	_
84-38	16674-16676	of	_
84-39	16677-16682	onset	_
84-40	16682-16683	,	_
84-41	16684-16698	chlorpromazine	_
84-42	16699-16709	equivalent	_
84-43	16710-16714	dose	_
84-44	16714-16715	,	_
84-45	16716-16719	all	_
84-46	16720-16728	Positive	_
84-47	16729-16732	and	_
84-48	16733-16741	Negative	_
84-49	16742-16750	Syndrome	_
84-50	16751-16756	Scale	_
84-51	16757-16763	scores	_
84-52	16764-16767	and	_
84-53	16768-16771	RNA	_
84-54	16772-16781	integrity	_
84-55	16782-16788	number	_
84-56	16789-16790	(	_
84-57	16790-16793	for	_
84-58	16794-16801	details	_
84-59	16802-16807	refer	_
84-60	16808-16810	to	_
84-61	16811-16824	Supplementary	_
84-62	16825-16830	Table	_
84-63	16831-16832	1	_
84-64	16832-16833	)	_
84-65	16833-16834	.	_

#Text=Education duration was longer in controls than in people with schizophrenia (Table 1), but not between elevated and low-cytokine groups.
85-1	16835-16844	Education	_
85-2	16845-16853	duration	_
85-3	16854-16857	was	_
85-4	16858-16864	longer	_
85-5	16865-16867	in	_
85-6	16868-16876	controls	_
85-7	16877-16881	than	_
85-8	16882-16884	in	_
85-9	16885-16891	people	_
85-10	16892-16896	with	_
85-11	16897-16910	schizophrenia	_
85-12	16911-16912	(	_
85-13	16912-16917	Table	_
85-14	16918-16919	1	_
85-15	16919-16920	)	_
85-16	16920-16921	,	_
85-17	16922-16925	but	_
85-18	16926-16929	not	_
85-19	16930-16937	between	_
85-20	16938-16946	elevated	_
85-21	16947-16950	and	_
85-22	16951-16963	low-cytokine	_
85-23	16964-16970	groups	_
85-24	16970-16971	.	_

#Text=Smoking status, where available, was not different between cytokine groups with schizophrenia (results not shown).
86-1	16972-16979	Smoking	_
86-2	16980-16986	status	_
86-3	16986-16987	,	_
86-4	16988-16993	where	_
86-5	16994-17003	available	_
86-6	17003-17004	,	_
86-7	17005-17008	was	_
86-8	17009-17012	not	_
86-9	17013-17022	different	_
86-10	17023-17030	between	_
86-11	17031-17039	cytokine	_
86-12	17040-17046	groups	_
86-13	17047-17051	with	_
86-14	17052-17065	schizophrenia	_
86-15	17066-17067	(	_
86-16	17067-17074	results	_
86-17	17075-17078	not	_
86-18	17079-17084	shown	_
86-19	17084-17085	)	_
86-20	17085-17086	.	_

#Text=There were no significant correlations between individual cytokine mRNA expression levels and age, RIN or BMI for all subjects (results not shown).
87-1	17087-17092	There	_
87-2	17093-17097	were	_
87-3	17098-17100	no	_
87-4	17101-17112	significant	_
87-5	17113-17125	correlations	_
87-6	17126-17133	between	_
87-7	17134-17144	individual	_
87-8	17145-17153	cytokine	_
87-9	17154-17158	mRNA	_
87-10	17159-17169	expression	_
87-11	17170-17176	levels	_
87-12	17177-17180	and	_
87-13	17181-17184	age	_
87-14	17184-17185	,	_
87-15	17186-17189	RIN	_
87-16	17190-17192	or	_
87-17	17193-17196	BMI	_
87-18	17197-17200	for	_
87-19	17201-17204	all	_
87-20	17205-17213	subjects	_
87-21	17214-17215	(	_
87-22	17215-17222	results	_
87-23	17223-17226	not	_
87-24	17227-17232	shown	_
87-25	17232-17233	)	_
87-26	17233-17234	.	_

#Text=When examining correlations in diagnostic groups separately, two significant correlations were detected.
88-1	17235-17239	When	_
88-2	17240-17249	examining	_
88-3	17250-17262	correlations	_
88-4	17263-17265	in	_
88-5	17266-17276	diagnostic	_
88-6	17277-17283	groups	_
88-7	17284-17294	separately	_
88-8	17294-17295	,	_
88-9	17296-17299	two	_
88-10	17300-17311	significant	_
88-11	17312-17324	correlations	_
88-12	17325-17329	were	_
88-13	17330-17338	detected	_
88-14	17338-17339	.	_

#Text=We found a significant positive correlation between BMI and IL-2 levels (r=0.436, P=0.032) and between age and IL-8 levels (r=0.409, P=0.018) in the schizophrenia group.
89-1	17340-17342	We	_
89-2	17343-17348	found	_
89-3	17349-17350	a	_
89-4	17351-17362	significant	_
89-5	17363-17371	positive	_
89-6	17372-17383	correlation	_
89-7	17384-17391	between	_
89-8	17392-17395	BMI	_
89-9	17396-17399	and	_
89-10	17400-17402	IL	_
89-11	17402-17403	-	_
89-12	17403-17404	2	_
89-13	17405-17411	levels	_
89-14	17412-17413	(	_
89-15	17413-17414	r	_
89-16	17414-17415	=	_
89-17	17415-17420	0.436	_
89-18	17420-17421	,	_
89-19	17422-17423	P	_
89-20	17423-17424	=	_
89-21	17424-17429	0.032	_
89-22	17429-17430	)	_
89-23	17431-17434	and	_
89-24	17435-17442	between	_
89-25	17443-17446	age	_
89-26	17447-17450	and	_
89-27	17451-17453	IL	_
89-28	17453-17454	-	_
89-29	17454-17455	8	_
89-30	17456-17462	levels	_
89-31	17463-17464	(	_
89-32	17464-17465	r	_
89-33	17465-17466	=	_
89-34	17466-17471	0.409	_
89-35	17471-17472	,	_
89-36	17473-17474	P	_
89-37	17474-17475	=	_
89-38	17475-17480	0.018	_
89-39	17480-17481	)	_
89-40	17482-17484	in	_
89-41	17485-17488	the	_
89-42	17489-17502	schizophrenia	_
89-43	17503-17508	group	_
89-44	17508-17509	.	_

#Text=Mean daily chlorpromazine equivalent dose did not correlate significantly with individual cytokine mRNA levels (all rho's between –0.286 and 0.159; all p's between 0.07 and 0.895).
90-1	17510-17514	Mean	_
90-2	17515-17520	daily	_
90-3	17521-17535	chlorpromazine	_
90-4	17536-17546	equivalent	_
90-5	17547-17551	dose	_
90-6	17552-17555	did	_
90-7	17556-17559	not	_
90-8	17560-17569	correlate	_
90-9	17570-17583	significantly	_
90-10	17584-17588	with	_
90-11	17589-17599	individual	_
90-12	17600-17608	cytokine	_
90-13	17609-17613	mRNA	_
90-14	17614-17620	levels	_
90-15	17621-17622	(	_
90-16	17622-17625	all	_
90-17	17626-17631	rho's	_
90-18	17632-17639	between	_
90-19	17640-17641	–	_
90-20	17641-17646	0.286	_
90-21	17647-17650	and	_
90-22	17651-17656	0.159	_
90-23	17656-17657	;	_
90-24	17658-17661	all	_
90-25	17662-17665	p's	_
90-26	17666-17673	between	_
90-27	17674-17678	0.07	_
90-28	17679-17682	and	_
90-29	17683-17688	0.895	_
90-30	17688-17689	)	_
90-31	17689-17690	.	_

#Text=Across all patients with schizophrenia, there were no strong, statistically significant correlations between IL-1β mRNA levels and Positive and Negative Syndrome Scale positive, negative, general and total scores (all rho's between –0.22 and –0.13; all p's between 0.15 and 0.42).
91-1	17691-17697	Across	_
91-2	17698-17701	all	_
91-3	17702-17710	patients	_
91-4	17711-17715	with	_
91-5	17716-17729	schizophrenia	_
91-6	17729-17730	,	_
91-7	17731-17736	there	_
91-8	17737-17741	were	_
91-9	17742-17744	no	_
91-10	17745-17751	strong	_
91-11	17751-17752	,	_
91-12	17753-17766	statistically	_
91-13	17767-17778	significant	_
91-14	17779-17791	correlations	_
91-15	17792-17799	between	_
91-16	17800-17802	IL	_
91-17	17802-17803	-	_
91-18	17803-17805	1β	_
91-19	17806-17810	mRNA	_
91-20	17811-17817	levels	_
91-21	17818-17821	and	_
91-22	17822-17830	Positive	_
91-23	17831-17834	and	_
91-24	17835-17843	Negative	_
91-25	17844-17852	Syndrome	_
91-26	17853-17858	Scale	_
91-27	17859-17867	positive	_
91-28	17867-17868	,	_
91-29	17869-17877	negative	_
91-30	17877-17878	,	_
91-31	17879-17886	general	_
91-32	17887-17890	and	_
91-33	17891-17896	total	_
91-34	17897-17903	scores	_
91-35	17904-17905	(	_
91-36	17905-17908	all	_
91-37	17909-17914	rho's	_
91-38	17915-17922	between	_
91-39	17923-17924	–	_
91-40	17924-17928	0.22	_
91-41	17929-17932	and	_
91-42	17933-17934	–	_
91-43	17934-17938	0.13	_
91-44	17938-17939	;	_
91-45	17940-17943	all	_
91-46	17944-17947	p's	_
91-47	17948-17955	between	_
91-48	17956-17960	0.15	_
91-49	17961-17964	and	_
91-50	17965-17969	0.42	_
91-51	17969-17970	)	_
91-52	17970-17971	.	_

#Text=Decreased verbal fluency (COWAT) in schizophrenia patients with elevated cytokines
#Text=Performance on all cognitive tests was significantly lower in schizophrenia relative to controls (see Figure 3, Supplementary Table 2) with the exception of the COWAT letter fluency (which showed a trend at P=0.06) and the Wechsler Adult Intelligence Scale–3rd edition similarities subtest.
92-1	17972-17981	Decreased	_
92-2	17982-17988	verbal	_
92-3	17989-17996	fluency	_
92-4	17997-17998	(	_
92-5	17998-18003	COWAT	_
92-6	18003-18004	)	_
92-7	18005-18007	in	_
92-8	18008-18021	schizophrenia	_
92-9	18022-18030	patients	_
92-10	18031-18035	with	_
92-11	18036-18044	elevated	_
92-12	18045-18054	cytokines	_
92-13	18055-18066	Performance	_
92-14	18067-18069	on	_
92-15	18070-18073	all	_
92-16	18074-18083	cognitive	_
92-17	18084-18089	tests	_
92-18	18090-18093	was	_
92-19	18094-18107	significantly	_
92-20	18108-18113	lower	_
92-21	18114-18116	in	_
92-22	18117-18130	schizophrenia	_
92-23	18131-18139	relative	_
92-24	18140-18142	to	_
92-25	18143-18151	controls	_
92-26	18152-18153	(	_
92-27	18153-18156	see	_
92-28	18157-18163	Figure	_
92-29	18164-18165	3	_
92-30	18165-18166	,	_
92-31	18167-18180	Supplementary	_
92-32	18181-18186	Table	_
92-33	18187-18188	2	_
92-34	18188-18189	)	_
92-35	18190-18194	with	_
92-36	18195-18198	the	_
92-37	18199-18208	exception	_
92-38	18209-18211	of	_
92-39	18212-18215	the	_
92-40	18216-18221	COWAT	_
92-41	18222-18228	letter	_
92-42	18229-18236	fluency	_
92-43	18237-18238	(	_
92-44	18238-18243	which	_
92-45	18244-18250	showed	_
92-46	18251-18252	a	_
92-47	18253-18258	trend	_
92-48	18259-18261	at	_
92-49	18262-18263	P	_
92-50	18263-18264	=	_
92-51	18264-18268	0.06	_
92-52	18268-18269	)	_
92-53	18270-18273	and	_
92-54	18274-18277	the	_
92-55	18278-18286	Wechsler	_
92-56	18287-18292	Adult	_
92-57	18293-18305	Intelligence	_
92-58	18306-18311	Scale	_
92-59	18311-18312	–	_
92-60	18312-18315	3rd	_
92-61	18316-18323	edition	_
92-62	18324-18336	similarities	_
92-63	18337-18344	subtest	_
92-64	18344-18345	.	_

#Text=There were no significant main effects of cytokine group on cognitive variables, but importantly, there was a significant interaction between diagnosis and cytokine group for COWAT letter fluency (Supplementary Table 2).
93-1	18346-18351	There	_
93-2	18352-18356	were	_
93-3	18357-18359	no	_
93-4	18360-18371	significant	_
93-5	18372-18376	main	_
93-6	18377-18384	effects	_
93-7	18385-18387	of	_
93-8	18388-18396	cytokine	_
93-9	18397-18402	group	_
93-10	18403-18405	on	_
93-11	18406-18415	cognitive	_
93-12	18416-18425	variables	_
93-13	18425-18426	,	_
93-14	18427-18430	but	_
93-15	18431-18442	importantly	_
93-16	18442-18443	,	_
93-17	18444-18449	there	_
93-18	18450-18453	was	_
93-19	18454-18455	a	_
93-20	18456-18467	significant	_
93-21	18468-18479	interaction	_
93-22	18480-18487	between	_
93-23	18488-18497	diagnosis	_
93-24	18498-18501	and	_
93-25	18502-18510	cytokine	_
93-26	18511-18516	group	_
93-27	18517-18520	for	_
93-28	18521-18526	COWAT	_
93-29	18527-18533	letter	_
93-30	18534-18541	fluency	_
93-31	18542-18543	(	_
93-32	18543-18556	Supplementary	_
93-33	18557-18562	Table	_
93-34	18563-18564	2	_
93-35	18564-18565	)	_
93-36	18565-18566	.	_

#Text=When examining subgroup difference within the diagnosis of schizophrenia, COWAT letter fluency was decreased by 20% in individuals with schizophrenia who also displayed elevated cytokines compared with individuals with schizophrenia who did not display elevated cytokines (F(1,40)=15.7, P=0.001, see Figure 3).
94-1	18567-18571	When	_
94-2	18572-18581	examining	_
94-3	18582-18590	subgroup	_
94-4	18591-18601	difference	_
94-5	18602-18608	within	_
94-6	18609-18612	the	_
94-7	18613-18622	diagnosis	_
94-8	18623-18625	of	_
94-9	18626-18639	schizophrenia	_
94-10	18639-18640	,	_
94-11	18641-18646	COWAT	_
94-12	18647-18653	letter	_
94-13	18654-18661	fluency	_
94-14	18662-18665	was	_
94-15	18666-18675	decreased	_
94-16	18676-18678	by	_
94-17	18679-18682	20%	_
94-18	18683-18685	in	_
94-19	18686-18697	individuals	_
94-20	18698-18702	with	_
94-21	18703-18716	schizophrenia	_
94-22	18717-18720	who	_
94-23	18721-18725	also	_
94-24	18726-18735	displayed	_
94-25	18736-18744	elevated	_
94-26	18745-18754	cytokines	_
94-27	18755-18763	compared	_
94-28	18764-18768	with	_
94-29	18769-18780	individuals	_
94-30	18781-18785	with	_
94-31	18786-18799	schizophrenia	_
94-32	18800-18803	who	_
94-33	18804-18807	did	_
94-34	18808-18811	not	_
94-35	18812-18819	display	_
94-36	18820-18828	elevated	_
94-37	18829-18838	cytokines	_
94-38	18839-18840	(	_
94-39	18840-18841	F	_
94-40	18841-18842	(	_
94-41	18842-18846	1,40	_
94-42	18846-18847	)	_
94-43	18847-18848	=	_
94-44	18848-18852	15.7	_
94-45	18852-18853	,	_
94-46	18854-18855	P	_
94-47	18855-18856	=	_
94-48	18856-18861	0.001	_
94-49	18861-18862	,	_
94-50	18863-18866	see	_
94-51	18867-18873	Figure	_
94-52	18874-18875	3	_
94-53	18875-18876	)	_
94-54	18876-18877	.	_

#Text=An interaction was also found for Wechsler Memory Scale-III Logical Memory II, which, however, did not survive correction for multiple comparisons.
95-1	18878-18880	An	_
95-2	18881-18892	interaction	_
95-3	18893-18896	was	_
95-4	18897-18901	also	_
95-5	18902-18907	found	_
95-6	18908-18911	for	_
95-7	18912-18920	Wechsler	_
95-8	18921-18927	Memory	_
95-9	18928-18937	Scale-III	_
95-10	18938-18945	Logical	_
95-11	18946-18952	Memory	_
95-12	18953-18955	II	_
95-13	18955-18956	,	_
95-14	18957-18962	which	_
95-15	18962-18963	,	_
95-16	18964-18971	however	_
95-17	18971-18972	,	_
95-18	18973-18976	did	_
95-19	18977-18980	not	_
95-20	18981-18988	survive	_
95-21	18989-18999	correction	_
95-22	19000-19003	for	_
95-23	19004-19012	multiple	_
95-24	19013-19024	comparisons	_
95-25	19024-19025	.	_

#Text=Language related brain volumes in people with schizophrenia displaying elevated cytokines
#Text=Based on the interaction between diagnosis and cytokine group in relation to verbal fluency, Broca's area, POp and pars triangularis, and Wernicke's area, SMG, along with their right hemisphere analogs were selected as regions of interest.
96-1	19026-19034	Language	_
96-2	19035-19042	related	_
96-3	19043-19048	brain	_
96-4	19049-19056	volumes	_
96-5	19057-19059	in	_
96-6	19060-19066	people	_
96-7	19067-19071	with	_
96-8	19072-19085	schizophrenia	_
96-9	19086-19096	displaying	_
96-10	19097-19105	elevated	_
96-11	19106-19115	cytokines	_
96-12	19116-19121	Based	_
96-13	19122-19124	on	_
96-14	19125-19128	the	_
96-15	19129-19140	interaction	_
96-16	19141-19148	between	_
96-17	19149-19158	diagnosis	_
96-18	19159-19162	and	_
96-19	19163-19171	cytokine	_
96-20	19172-19177	group	_
96-21	19178-19180	in	_
96-22	19181-19189	relation	_
96-23	19190-19192	to	_
96-24	19193-19199	verbal	_
96-25	19200-19207	fluency	_
96-26	19207-19208	,	_
96-27	19209-19216	Broca's	_
96-28	19217-19221	area	_
96-29	19221-19222	,	_
96-30	19223-19226	POp	_
96-31	19227-19230	and	_
96-32	19231-19235	pars	_
96-33	19236-19248	triangularis	_
96-34	19248-19249	,	_
96-35	19250-19253	and	_
96-36	19254-19264	Wernicke's	_
96-37	19265-19269	area	_
96-38	19269-19270	,	_
96-39	19271-19274	SMG	_
96-40	19274-19275	,	_
96-41	19276-19281	along	_
96-42	19282-19286	with	_
96-43	19287-19292	their	_
96-44	19293-19298	right	_
96-45	19299-19309	hemisphere	_
96-46	19310-19317	analogs	_
96-47	19318-19322	were	_
96-48	19323-19331	selected	_
96-49	19332-19334	as	_
96-50	19335-19342	regions	_
96-51	19343-19345	of	_
96-52	19346-19354	interest	_
96-53	19354-19355	.	_

#Text=Broca's area volume (left POp, see Supplementary Figure 1) was significantly different between schizophrenia and control groups and this region also showed a significant difference between the schizophrenia elevated and low-cytokine groups (diagnosis: F(1,69)=7.10, P<0.01, cytokine group: F(1,69), 4.17, P<0.05, Figure 4a, Supplementary Table 3).
97-1	19356-19363	Broca's	_
97-2	19364-19368	area	_
97-3	19369-19375	volume	_
97-4	19376-19377	(	_
97-5	19377-19381	left	_
97-6	19382-19385	POp	_
97-7	19385-19386	,	_
97-8	19387-19390	see	_
97-9	19391-19404	Supplementary	_
97-10	19405-19411	Figure	_
97-11	19412-19413	1	_
97-12	19413-19414	)	_
97-13	19415-19418	was	_
97-14	19419-19432	significantly	_
97-15	19433-19442	different	_
97-16	19443-19450	between	_
97-17	19451-19464	schizophrenia	_
97-18	19465-19468	and	_
97-19	19469-19476	control	_
97-20	19477-19483	groups	_
97-21	19484-19487	and	_
97-22	19488-19492	this	_
97-23	19493-19499	region	_
97-24	19500-19504	also	_
97-25	19505-19511	showed	_
97-26	19512-19513	a	_
97-27	19514-19525	significant	_
97-28	19526-19536	difference	_
97-29	19537-19544	between	_
97-30	19545-19548	the	_
97-31	19549-19562	schizophrenia	_
97-32	19563-19571	elevated	_
97-33	19572-19575	and	_
97-34	19576-19588	low-cytokine	_
97-35	19589-19595	groups	_
97-36	19596-19597	(	_
97-37	19597-19606	diagnosis	_
97-38	19606-19607	:	_
97-39	19608-19609	F	_
97-40	19609-19610	(	_
97-41	19610-19614	1,69	_
97-42	19614-19615	)	_
97-43	19615-19616	=	_
97-44	19616-19620	7.10	_
97-45	19620-19621	,	_
97-46	19622-19623	P	_
97-47	19623-19624	<	_
97-48	19624-19628	0.01	_
97-49	19628-19629	,	_
97-50	19630-19638	cytokine	_
97-51	19639-19644	group	_
97-52	19644-19645	:	_
97-53	19646-19647	F	_
97-54	19647-19648	(	_
97-55	19648-19652	1,69	_
97-56	19652-19653	)	_
97-57	19653-19654	,	_
97-58	19655-19659	4.17	_
97-59	19659-19660	,	_
97-60	19661-19662	P	_
97-61	19662-19663	<	_
97-62	19663-19667	0.05	_
97-63	19667-19668	,	_
97-64	19669-19675	Figure	_
97-65	19676-19678	4a	_
97-66	19678-19679	,	_
97-67	19680-19693	Supplementary	_
97-68	19694-19699	Table	_
97-69	19700-19701	3	_
97-70	19701-19702	)	_
97-71	19702-19703	.	_

#Text=Within the group of people with schizophrenia, the volume of the left POp was decreased by 17% in the high cytokine group compared with the low-cytokine patient group (F(1,29)=9.40, P=0.005, Figure 4a).
98-1	19704-19710	Within	_
98-2	19711-19714	the	_
98-3	19715-19720	group	_
98-4	19721-19723	of	_
98-5	19724-19730	people	_
98-6	19731-19735	with	_
98-7	19736-19749	schizophrenia	_
98-8	19749-19750	,	_
98-9	19751-19754	the	_
98-10	19755-19761	volume	_
98-11	19762-19764	of	_
98-12	19765-19768	the	_
98-13	19769-19773	left	_
98-14	19774-19777	POp	_
98-15	19778-19781	was	_
98-16	19782-19791	decreased	_
98-17	19792-19794	by	_
98-18	19795-19798	17%	_
98-19	19799-19801	in	_
98-20	19802-19805	the	_
98-21	19806-19810	high	_
98-22	19811-19819	cytokine	_
98-23	19820-19825	group	_
98-24	19826-19834	compared	_
98-25	19835-19839	with	_
98-26	19840-19843	the	_
98-27	19844-19856	low-cytokine	_
98-28	19857-19864	patient	_
98-29	19865-19870	group	_
98-30	19871-19872	(	_
98-31	19872-19873	F	_
98-32	19873-19874	(	_
98-33	19874-19878	1,29	_
98-34	19878-19879	)	_
98-35	19879-19880	=	_
98-36	19880-19884	9.40	_
98-37	19884-19885	,	_
98-38	19886-19887	P	_
98-39	19887-19888	=	_
98-40	19888-19893	0.005	_
98-41	19893-19894	,	_
98-42	19895-19901	Figure	_
98-43	19902-19904	4a	_
98-44	19904-19905	)	_
98-45	19905-19906	.	_

#Text=The volume of Broca's area was decreased by 20% in the subgroup of individuals with schizophrenia and elevated cytokines compared with the combined mean volume of elevated and low-cytokine controls.
99-1	19907-19910	The	_
99-2	19911-19917	volume	_
99-3	19918-19920	of	_
99-4	19921-19928	Broca's	_
99-5	19929-19933	area	_
99-6	19934-19937	was	_
99-7	19938-19947	decreased	_
99-8	19948-19950	by	_
99-9	19951-19954	20%	_
99-10	19955-19957	in	_
99-11	19958-19961	the	_
99-12	19962-19970	subgroup	_
99-13	19971-19973	of	_
99-14	19974-19985	individuals	_
99-15	19986-19990	with	_
99-16	19991-20004	schizophrenia	_
99-17	20005-20008	and	_
99-18	20009-20017	elevated	_
99-19	20018-20027	cytokines	_
99-20	20028-20036	compared	_
99-21	20037-20041	with	_
99-22	20042-20045	the	_
99-23	20046-20054	combined	_
99-24	20055-20059	mean	_
99-25	20060-20066	volume	_
99-26	20067-20069	of	_
99-27	20070-20078	elevated	_
99-28	20079-20082	and	_
99-29	20083-20095	low-cytokine	_
99-30	20096-20104	controls	_
99-31	20104-20105	.	_

#Text=There were no significant differences observed in the left or right pars triangularis, right Pop or the left SMG.
100-1	20106-20111	There	_
100-2	20112-20116	were	_
100-3	20117-20119	no	_
100-4	20120-20131	significant	_
100-5	20132-20143	differences	_
100-6	20144-20152	observed	_
100-7	20153-20155	in	_
100-8	20156-20159	the	_
100-9	20160-20164	left	_
100-10	20165-20167	or	_
100-11	20168-20173	right	_
100-12	20174-20178	pars	_
100-13	20179-20191	triangularis	_
100-14	20191-20192	,	_
100-15	20193-20198	right	_
100-16	20199-20202	Pop	_
100-17	20203-20205	or	_
100-18	20206-20209	the	_
100-19	20210-20214	left	_
100-20	20215-20218	SMG	_
100-21	20218-20219	.	_

#Text=Although there were no main effects of diagnosis or cytokine group on the right SMG, there was a significant interaction between diagnosis and cytokine group (F(1,69)=5.03, P<0.05).
101-1	20220-20228	Although	_
101-2	20229-20234	there	_
101-3	20235-20239	were	_
101-4	20240-20242	no	_
101-5	20243-20247	main	_
101-6	20248-20255	effects	_
101-7	20256-20258	of	_
101-8	20259-20268	diagnosis	_
101-9	20269-20271	or	_
101-10	20272-20280	cytokine	_
101-11	20281-20286	group	_
101-12	20287-20289	on	_
101-13	20290-20293	the	_
101-14	20294-20299	right	_
101-15	20300-20303	SMG	_
101-16	20303-20304	,	_
101-17	20305-20310	there	_
101-18	20311-20314	was	_
101-19	20315-20316	a	_
101-20	20317-20328	significant	_
101-21	20329-20340	interaction	_
101-22	20341-20348	between	_
101-23	20349-20358	diagnosis	_
101-24	20359-20362	and	_
101-25	20363-20371	cytokine	_
101-26	20372-20377	group	_
101-27	20378-20379	(	_
101-28	20379-20380	F	_
101-29	20380-20381	(	_
101-30	20381-20385	1,69	_
101-31	20385-20386	)	_
101-32	20386-20387	=	_
101-33	20387-20391	5.03	_
101-34	20391-20392	,	_
101-35	20393-20394	P	_
101-36	20394-20395	<	_
101-37	20395-20399	0.05	_
101-38	20399-20400	)	_
101-39	20400-20401	.	_

#Text=Post hoc tests showed that in patients with schizophrenia, higher cytokines were associated with a 15% smaller right SMG volume (F(1,29)=6.53, P=0.02, Figure 4a), whereas there was no effect of cytokine grouping in controls.
102-1	20402-20406	Post	_
102-2	20407-20410	hoc	_
102-3	20411-20416	tests	_
102-4	20417-20423	showed	_
102-5	20424-20428	that	_
102-6	20429-20431	in	_
102-7	20432-20440	patients	_
102-8	20441-20445	with	_
102-9	20446-20459	schizophrenia	_
102-10	20459-20460	,	_
102-11	20461-20467	higher	_
102-12	20468-20477	cytokines	_
102-13	20478-20482	were	_
102-14	20483-20493	associated	_
102-15	20494-20498	with	_
102-16	20499-20500	a	_
102-17	20501-20504	15%	_
102-18	20505-20512	smaller	_
102-19	20513-20518	right	_
102-20	20519-20522	SMG	_
102-21	20523-20529	volume	_
102-22	20530-20531	(	_
102-23	20531-20532	F	_
102-24	20532-20533	(	_
102-25	20533-20537	1,29	_
102-26	20537-20538	)	_
102-27	20538-20539	=	_
102-28	20539-20543	6.53	_
102-29	20543-20544	,	_
102-30	20545-20546	P	_
102-31	20546-20547	=	_
102-32	20547-20551	0.02	_
102-33	20551-20552	,	_
102-34	20553-20559	Figure	_
102-35	20560-20562	4a	_
102-36	20562-20563	)	_
102-37	20563-20564	,	_
102-38	20565-20572	whereas	_
102-39	20573-20578	there	_
102-40	20579-20582	was	_
102-41	20583-20585	no	_
102-42	20586-20592	effect	_
102-43	20593-20595	of	_
102-44	20596-20604	cytokine	_
102-45	20605-20613	grouping	_
102-46	20614-20616	in	_
102-47	20617-20625	controls	_
102-48	20625-20626	.	_

#Text=For additional MRI results, refer to Supplementary Tables 3 and 4.
103-1	20627-20630	For	_
103-2	20631-20641	additional	_
103-3	20642-20645	MRI	_
103-4	20646-20653	results	_
103-5	20653-20654	,	_
103-6	20655-20660	refer	_
103-7	20661-20663	to	_
103-8	20664-20677	Supplementary	_
103-9	20678-20684	Tables	_
103-10	20685-20686	3	_
103-11	20687-20690	and	_
103-12	20691-20692	4	_
103-13	20692-20693	.	_

#Text=Relationships between peripheral IL-1β mRNA, verbal fluency scores and left POp/right SMG volumes in people with schizophrenia
#Text=Elevated IL-1β mRNA significantly predicted poorer COWAT verbal fluency score in individuals with schizophrenia, (Wechsler Test of Adult Reading β=0.48, IL-1β, β=−0.38, F(2,38)=13.3, P<0.0001, Figure 4b).
104-1	20694-20707	Relationships	_
104-2	20708-20715	between	_
104-3	20716-20726	peripheral	_
104-4	20727-20729	IL	_
104-5	20729-20730	-	_
104-6	20730-20732	1β	_
104-7	20733-20737	mRNA	_
104-8	20737-20738	,	_
104-9	20739-20745	verbal	_
104-10	20746-20753	fluency	_
104-11	20754-20760	scores	_
104-12	20761-20764	and	_
104-13	20765-20769	left	_
104-14	20770-20773	POp	_
104-15	20773-20774	/	_
104-16	20774-20779	right	_
104-17	20780-20783	SMG	_
104-18	20784-20791	volumes	_
104-19	20792-20794	in	_
104-20	20795-20801	people	_
104-21	20802-20806	with	_
104-22	20807-20820	schizophrenia	_
104-23	20821-20829	Elevated	_
104-24	20830-20832	IL	_
104-25	20832-20833	-	_
104-26	20833-20835	1β	_
104-27	20836-20840	mRNA	_
104-28	20841-20854	significantly	_
104-29	20855-20864	predicted	_
104-30	20865-20871	poorer	_
104-31	20872-20877	COWAT	_
104-32	20878-20884	verbal	_
104-33	20885-20892	fluency	_
104-34	20893-20898	score	_
104-35	20899-20901	in	_
104-36	20902-20913	individuals	_
104-37	20914-20918	with	_
104-38	20919-20932	schizophrenia	_
104-39	20932-20933	,	_
104-40	20934-20935	(	_
104-41	20935-20943	Wechsler	_
104-42	20944-20948	Test	_
104-43	20949-20951	of	_
104-44	20952-20957	Adult	_
104-45	20958-20965	Reading	_
104-46	20966-20967	β	_
104-47	20967-20968	=	_
104-48	20968-20972	0.48	_
104-49	20972-20973	,	_
104-50	20974-20976	IL	_
104-51	20976-20977	-	_
104-52	20977-20979	1β	_
104-53	20979-20980	,	_
104-54	20981-20982	β	_
104-55	20982-20983	=	_
104-56	20983-20984	−	_
104-57	20984-20988	0.38	_
104-58	20988-20989	,	_
104-59	20990-20991	F	_
104-60	20991-20992	(	_
104-61	20992-20996	2,38	_
104-62	20996-20997	)	_
104-63	20997-20998	=	_
104-64	20998-21002	13.3	_
104-65	21002-21003	,	_
104-66	21004-21005	P	_
104-67	21005-21006	<	_
104-68	21006-21012	0.0001	_
104-69	21012-21013	,	_
104-70	21014-21020	Figure	_
104-71	21021-21023	4b	_
104-72	21023-21024	)	_
104-73	21024-21025	.	_

#Text=Also, elevated blood IL-1β mRNA was the only significant cytokine predictor of decreased volume in Broca's area (left Pop, IL-1β, β=−0.47, F(1,30)=8.43, P<0.01, Figure 4c), and the right SMG (IL-1β, β=−0.43, F(1,30)=6.95, P=0.01), in individuals with schizophrenia.
105-1	21026-21030	Also	_
105-2	21030-21031	,	_
105-3	21032-21040	elevated	_
105-4	21041-21046	blood	_
105-5	21047-21049	IL	_
105-6	21049-21050	-	_
105-7	21050-21052	1β	_
105-8	21053-21057	mRNA	_
105-9	21058-21061	was	_
105-10	21062-21065	the	_
105-11	21066-21070	only	_
105-12	21071-21082	significant	_
105-13	21083-21091	cytokine	_
105-14	21092-21101	predictor	_
105-15	21102-21104	of	_
105-16	21105-21114	decreased	_
105-17	21115-21121	volume	_
105-18	21122-21124	in	_
105-19	21125-21132	Broca's	_
105-20	21133-21137	area	_
105-21	21138-21139	(	_
105-22	21139-21143	left	_
105-23	21144-21147	Pop	_
105-24	21147-21148	,	_
105-25	21149-21151	IL	_
105-26	21151-21152	-	_
105-27	21152-21154	1β	_
105-28	21154-21155	,	_
105-29	21156-21157	β	_
105-30	21157-21158	=	_
105-31	21158-21159	−	_
105-32	21159-21163	0.47	_
105-33	21163-21164	,	_
105-34	21165-21166	F	_
105-35	21166-21167	(	_
105-36	21167-21171	1,30	_
105-37	21171-21172	)	_
105-38	21172-21173	=	_
105-39	21173-21177	8.43	_
105-40	21177-21178	,	_
105-41	21179-21180	P	_
105-42	21180-21181	<	_
105-43	21181-21185	0.01	_
105-44	21185-21186	,	_
105-45	21187-21193	Figure	_
105-46	21194-21196	4c	_
105-47	21196-21197	)	_
105-48	21197-21198	,	_
105-49	21199-21202	and	_
105-50	21203-21206	the	_
105-51	21207-21212	right	_
105-52	21213-21216	SMG	_
105-53	21217-21218	(	_
105-54	21218-21220	IL	_
105-55	21220-21221	-	_
105-56	21221-21223	1β	_
105-57	21223-21224	,	_
105-58	21225-21226	β	_
105-59	21226-21227	=	_
105-60	21227-21228	−	_
105-61	21228-21232	0.43	_
105-62	21232-21233	,	_
105-63	21234-21235	F	_
105-64	21235-21236	(	_
105-65	21236-21240	1,30	_
105-66	21240-21241	)	_
105-67	21241-21242	=	_
105-68	21242-21246	6.95	_
105-69	21246-21247	,	_
105-70	21248-21249	P	_
105-71	21249-21250	=	_
105-72	21250-21254	0.01	_
105-73	21254-21255	)	_
105-74	21255-21256	,	_
105-75	21257-21259	in	_
105-76	21260-21271	individuals	_
105-77	21272-21276	with	_
105-78	21277-21290	schizophrenia	_
105-79	21290-21291	.	_

#Text=No significant relationships were found through regression analysis between cytokines, cognitive scores and brain volumes in healthy controls (results not shown).
106-1	21292-21294	No	_
106-2	21295-21306	significant	_
106-3	21307-21320	relationships	_
106-4	21321-21325	were	_
106-5	21326-21331	found	_
106-6	21332-21339	through	_
106-7	21340-21350	regression	_
106-8	21351-21359	analysis	_
106-9	21360-21367	between	_
106-10	21368-21377	cytokines	_
106-11	21377-21378	,	_
106-12	21379-21388	cognitive	_
106-13	21389-21395	scores	_
106-14	21396-21399	and	_
106-15	21400-21405	brain	_
106-16	21406-21413	volumes	_
106-17	21414-21416	in	_
106-18	21417-21424	healthy	_
106-19	21425-21433	controls	_
106-20	21434-21435	(	_
106-21	21435-21442	results	_
106-22	21443-21446	not	_
106-23	21447-21452	shown	_
106-24	21452-21453	)	_
106-25	21453-21454	.	_

#Text=Discussion
#Text=Our study found evidence for a biological subgroup of people with schizophrenia who display elevated peripheral cytokine mRNA levels, poor verbal fluency and decreased Broca's area brain volumes.
107-1	21455-21465	Discussion	_
107-2	21466-21469	Our	_
107-3	21470-21475	study	_
107-4	21476-21481	found	_
107-5	21482-21490	evidence	_
107-6	21491-21494	for	_
107-7	21495-21496	a	_
107-8	21497-21507	biological	_
107-9	21508-21516	subgroup	_
107-10	21517-21519	of	_
107-11	21520-21526	people	_
107-12	21527-21531	with	_
107-13	21532-21545	schizophrenia	_
107-14	21546-21549	who	_
107-15	21550-21557	display	_
107-16	21558-21566	elevated	_
107-17	21567-21577	peripheral	_
107-18	21578-21586	cytokine	_
107-19	21587-21591	mRNA	_
107-20	21592-21598	levels	_
107-21	21598-21599	,	_
107-22	21600-21604	poor	_
107-23	21605-21611	verbal	_
107-24	21612-21619	fluency	_
107-25	21620-21623	and	_
107-26	21624-21633	decreased	_
107-27	21634-21641	Broca's	_
107-28	21642-21646	area	_
107-29	21647-21652	brain	_
107-30	21653-21660	volumes	_
107-31	21660-21661	.	_

#Text=Our finding that ~40% of individuals in a community clinical sample had a pattern of relatively elevated cytokine expression in peripheral blood is consistent with our previous post-mortem brain tissue observations, in which we found that ~40% had elevated cytokines in the prefrontal cortex.
108-1	21662-21665	Our	_
108-2	21666-21673	finding	_
108-3	21674-21678	that	_
108-4	21679-21680	~	_
108-5	21680-21683	40%	_
108-6	21684-21686	of	_
108-7	21687-21698	individuals	_
108-8	21699-21701	in	_
108-9	21702-21703	a	_
108-10	21704-21713	community	_
108-11	21714-21722	clinical	_
108-12	21723-21729	sample	_
108-13	21730-21733	had	_
108-14	21734-21735	a	_
108-15	21736-21743	pattern	_
108-16	21744-21746	of	_
108-17	21747-21757	relatively	_
108-18	21758-21766	elevated	_
108-19	21767-21775	cytokine	_
108-20	21776-21786	expression	_
108-21	21787-21789	in	_
108-22	21790-21800	peripheral	_
108-23	21801-21806	blood	_
108-24	21807-21809	is	_
108-25	21810-21820	consistent	_
108-26	21821-21825	with	_
108-27	21826-21829	our	_
108-28	21830-21838	previous	_
108-29	21839-21850	post-mortem	_
108-30	21851-21856	brain	_
108-31	21857-21863	tissue	_
108-32	21864-21876	observations	_
108-33	21876-21877	,	_
108-34	21878-21880	in	_
108-35	21881-21886	which	_
108-36	21887-21889	we	_
108-37	21890-21895	found	_
108-38	21896-21900	that	_
108-39	21901-21902	~	_
108-40	21902-21905	40%	_
108-41	21906-21909	had	_
108-42	21910-21918	elevated	_
108-43	21919-21928	cytokines	_
108-44	21929-21931	in	_
108-45	21932-21935	the	_
108-46	21936-21946	prefrontal	_
108-47	21947-21953	cortex	_
108-48	21953-21954	.	_

#Text=Peripheral cytokine changes appear to be related to brain dysfunction given that the elevated cytokine subgroup with schizophrenia showed worse verbal fluency and a more pronounced volumetric reduction of Broca's area.
109-1	21955-21965	Peripheral	_
109-2	21966-21974	cytokine	_
109-3	21975-21982	changes	_
109-4	21983-21989	appear	_
109-5	21990-21992	to	_
109-6	21993-21995	be	_
109-7	21996-22003	related	_
109-8	22004-22006	to	_
109-9	22007-22012	brain	_
109-10	22013-22024	dysfunction	_
109-11	22025-22030	given	_
109-12	22031-22035	that	_
109-13	22036-22039	the	_
109-14	22040-22048	elevated	_
109-15	22049-22057	cytokine	_
109-16	22058-22066	subgroup	_
109-17	22067-22071	with	_
109-18	22072-22085	schizophrenia	_
109-19	22086-22092	showed	_
109-20	22093-22098	worse	_
109-21	22099-22105	verbal	_
109-22	22106-22113	fluency	_
109-23	22114-22117	and	_
109-24	22118-22119	a	_
109-25	22120-22124	more	_
109-26	22125-22135	pronounced	_
109-27	22136-22146	volumetric	_
109-28	22147-22156	reduction	_
109-29	22157-22159	of	_
109-30	22160-22167	Broca's	_
109-31	22168-22172	area	_
109-32	22172-22173	.	_

#Text=Our results suggest that there may be a meaningful biotype of patients with schizophrenia and increased cytokines who can be identified using easily accessible markers; however, as our study is a proof of concept, independent replication in larger samples will be required.
110-1	22174-22177	Our	_
110-2	22178-22185	results	_
110-3	22186-22193	suggest	_
110-4	22194-22198	that	_
110-5	22199-22204	there	_
110-6	22205-22208	may	_
110-7	22209-22211	be	_
110-8	22212-22213	a	_
110-9	22214-22224	meaningful	_
110-10	22225-22232	biotype	_
110-11	22233-22235	of	_
110-12	22236-22244	patients	_
110-13	22245-22249	with	_
110-14	22250-22263	schizophrenia	_
110-15	22264-22267	and	_
110-16	22268-22277	increased	_
110-17	22278-22287	cytokines	_
110-18	22288-22291	who	_
110-19	22292-22295	can	_
110-20	22296-22298	be	_
110-21	22299-22309	identified	_
110-22	22310-22315	using	_
110-23	22316-22322	easily	_
110-24	22323-22333	accessible	_
110-25	22334-22341	markers	_
110-26	22341-22342	;	_
110-27	22343-22350	however	_
110-28	22350-22351	,	_
110-29	22352-22354	as	_
110-30	22355-22358	our	_
110-31	22359-22364	study	_
110-32	22365-22367	is	_
110-33	22368-22369	a	_
110-34	22370-22375	proof	_
110-35	22376-22378	of	_
110-36	22379-22386	concept	_
110-37	22386-22387	,	_
110-38	22388-22399	independent	_
110-39	22400-22411	replication	_
110-40	22412-22414	in	_
110-41	22415-22421	larger	_
110-42	22422-22429	samples	_
110-43	22430-22434	will	_
110-44	22435-22437	be	_
110-45	22438-22446	required	_
110-46	22446-22447	.	_

#Text=Out of all of the cytokine mRNAs that we measured peripherally, only IL-1β was significantly elevated in schizophrenia.
111-1	22448-22451	Out	_
111-2	22452-22454	of	_
111-3	22455-22458	all	_
111-4	22459-22461	of	_
111-5	22462-22465	the	_
111-6	22466-22474	cytokine	_
111-7	22475-22480	mRNAs	_
111-8	22481-22485	that	_
111-9	22486-22488	we	_
111-10	22489-22497	measured	_
111-11	22498-22510	peripherally	_
111-12	22510-22511	,	_
111-13	22512-22516	only	_
111-14	22517-22519	IL	_
111-15	22519-22520	-	_
111-16	22520-22522	1β	_
111-17	22523-22526	was	_
111-18	22527-22540	significantly	_
111-19	22541-22549	elevated	_
111-20	22550-22552	in	_
111-21	22553-22566	schizophrenia	_
111-22	22566-22567	.	_

#Text=IL-1β is a powerful classical proinflammatory cytokine, which has been described as a master regulator of other immune cells and immune processes.
112-1	22568-22570	IL	_
112-2	22570-22571	-	_
112-3	22571-22573	1β	_
112-4	22574-22576	is	_
112-5	22577-22578	a	_
112-6	22579-22587	powerful	_
112-7	22588-22597	classical	_
112-8	22598-22613	proinflammatory	_
112-9	22614-22622	cytokine	_
112-10	22622-22623	,	_
112-11	22624-22629	which	_
112-12	22630-22633	has	_
112-13	22634-22638	been	_
112-14	22639-22648	described	_
112-15	22649-22651	as	_
112-16	22652-22653	a	_
112-17	22654-22660	master	_
112-18	22661-22670	regulator	_
112-19	22671-22673	of	_
112-20	22674-22679	other	_
112-21	22680-22686	immune	_
112-22	22687-22692	cells	_
112-23	22693-22696	and	_
112-24	22697-22703	immune	_
112-25	22704-22713	processes	_
112-26	22713-22714	.	_

#Text=Our cluster analysis concurs with this in that individuals with elevated IL-1β tend to also have elevations in other cytokines forming a fingerprint, or a pattern.
113-1	22715-22718	Our	_
113-2	22719-22726	cluster	_
113-3	22727-22735	analysis	_
113-4	22736-22743	concurs	_
113-5	22744-22748	with	_
113-6	22749-22753	this	_
113-7	22754-22756	in	_
113-8	22757-22761	that	_
113-9	22762-22773	individuals	_
113-10	22774-22778	with	_
113-11	22779-22787	elevated	_
113-12	22788-22790	IL	_
113-13	22790-22791	-	_
113-14	22791-22793	1β	_
113-15	22794-22798	tend	_
113-16	22799-22801	to	_
113-17	22802-22806	also	_
113-18	22807-22811	have	_
113-19	22812-22822	elevations	_
113-20	22823-22825	in	_
113-21	22826-22831	other	_
113-22	22832-22841	cytokines	_
113-23	22842-22849	forming	_
113-24	22850-22851	a	_
113-25	22852-22863	fingerprint	_
113-26	22863-22864	,	_
113-27	22865-22867	or	_
113-28	22868-22869	a	_
113-29	22870-22877	pattern	_
113-30	22877-22878	.	_

#Text=The possibility that patients with schizophrenia are abnormally sensitive to immune activation mediated by IL-1β is supported by our findings of robust correlations between elevated IL-1β mRNA levels, lower verbal fluency scores and reduced Broca's area volumes.
114-1	22879-22882	The	_
114-2	22883-22894	possibility	_
114-3	22895-22899	that	_
114-4	22900-22908	patients	_
114-5	22909-22913	with	_
114-6	22914-22927	schizophrenia	_
114-7	22928-22931	are	_
114-8	22932-22942	abnormally	_
114-9	22943-22952	sensitive	_
114-10	22953-22955	to	_
114-11	22956-22962	immune	_
114-12	22963-22973	activation	_
114-13	22974-22982	mediated	_
114-14	22983-22985	by	_
114-15	22986-22988	IL	_
114-16	22988-22989	-	_
114-17	22989-22991	1β	_
114-18	22992-22994	is	_
114-19	22995-23004	supported	_
114-20	23005-23007	by	_
114-21	23008-23011	our	_
114-22	23012-23020	findings	_
114-23	23021-23023	of	_
114-24	23024-23030	robust	_
114-25	23031-23043	correlations	_
114-26	23044-23051	between	_
114-27	23052-23060	elevated	_
114-28	23061-23063	IL	_
114-29	23063-23064	-	_
114-30	23064-23066	1β	_
114-31	23067-23071	mRNA	_
114-32	23072-23078	levels	_
114-33	23078-23079	,	_
114-34	23080-23085	lower	_
114-35	23086-23092	verbal	_
114-36	23093-23100	fluency	_
114-37	23101-23107	scores	_
114-38	23108-23111	and	_
114-39	23112-23119	reduced	_
114-40	23120-23127	Broca's	_
114-41	23128-23132	area	_
114-42	23133-23140	volumes	_
114-43	23140-23141	.	_

#Text=There are several potential confounding factors common to case–control studies of schizophrenia that are relevant to the present study.
115-1	23142-23147	There	_
115-2	23148-23151	are	_
115-3	23152-23159	several	_
115-4	23160-23169	potential	_
115-5	23170-23181	confounding	_
115-6	23182-23189	factors	_
115-7	23190-23196	common	_
115-8	23197-23199	to	_
115-9	23200-23212	case–control	_
115-10	23213-23220	studies	_
115-11	23221-23223	of	_
115-12	23224-23237	schizophrenia	_
115-13	23238-23242	that	_
115-14	23243-23246	are	_
115-15	23247-23255	relevant	_
115-16	23256-23258	to	_
115-17	23259-23262	the	_
115-18	23263-23270	present	_
115-19	23271-23276	study	_
115-20	23276-23277	.	_

#Text=It is possible that the correlations of IL-1β mRNA with cognitive function and brain volume are not directly related in a causal manner, but are both changed as a consequence of other factors.
116-1	23278-23280	It	_
116-2	23281-23283	is	_
116-3	23284-23292	possible	_
116-4	23293-23297	that	_
116-5	23298-23301	the	_
116-6	23302-23314	correlations	_
116-7	23315-23317	of	_
116-8	23318-23320	IL	_
116-9	23320-23321	-	_
116-10	23321-23323	1β	_
116-11	23324-23328	mRNA	_
116-12	23329-23333	with	_
116-13	23334-23343	cognitive	_
116-14	23344-23352	function	_
116-15	23353-23356	and	_
116-16	23357-23362	brain	_
116-17	23363-23369	volume	_
116-18	23370-23373	are	_
116-19	23374-23377	not	_
116-20	23378-23386	directly	_
116-21	23387-23394	related	_
116-22	23395-23397	in	_
116-23	23398-23399	a	_
116-24	23400-23406	causal	_
116-25	23407-23413	manner	_
116-26	23413-23414	,	_
116-27	23415-23418	but	_
116-28	23419-23422	are	_
116-29	23423-23427	both	_
116-30	23428-23435	changed	_
116-31	23436-23438	as	_
116-32	23439-23440	a	_
116-33	23441-23452	consequence	_
116-34	23453-23455	of	_
116-35	23456-23461	other	_
116-36	23462-23469	factors	_
116-37	23469-23470	.	_

#Text=We will discuss each of these factors and their possible relevance to our findings separately.
117-1	23471-23473	We	_
117-2	23474-23478	will	_
117-3	23479-23486	discuss	_
117-4	23487-23491	each	_
117-5	23492-23494	of	_
117-6	23495-23500	these	_
117-7	23501-23508	factors	_
117-8	23509-23512	and	_
117-9	23513-23518	their	_
117-10	23519-23527	possible	_
117-11	23528-23537	relevance	_
117-12	23538-23540	to	_
117-13	23541-23544	our	_
117-14	23545-23553	findings	_
117-15	23554-23564	separately	_
117-16	23564-23565	.	_

#Text=One important potential confound is that all of the individuals with schizophrenia in our study were receiving antipsychotics.
118-1	23566-23569	One	_
118-2	23570-23579	important	_
118-3	23580-23589	potential	_
118-4	23590-23598	confound	_
118-5	23599-23601	is	_
118-6	23602-23606	that	_
118-7	23607-23610	all	_
118-8	23611-23613	of	_
118-9	23614-23617	the	_
118-10	23618-23629	individuals	_
118-11	23630-23634	with	_
118-12	23635-23648	schizophrenia	_
118-13	23649-23651	in	_
118-14	23652-23655	our	_
118-15	23656-23661	study	_
118-16	23662-23666	were	_
118-17	23667-23676	receiving	_
118-18	23677-23691	antipsychotics	_
118-19	23691-23692	.	_

#Text=It is not entirely clear whether antipsychotics would be expected to increase or decrease cytokine levels.
119-1	23693-23695	It	_
119-2	23696-23698	is	_
119-3	23699-23702	not	_
119-4	23703-23711	entirely	_
119-5	23712-23717	clear	_
119-6	23718-23725	whether	_
119-7	23726-23740	antipsychotics	_
119-8	23741-23746	would	_
119-9	23747-23749	be	_
119-10	23750-23758	expected	_
119-11	23759-23761	to	_
119-12	23762-23770	increase	_
119-13	23771-23773	or	_
119-14	23774-23782	decrease	_
119-15	23783-23791	cytokine	_
119-16	23792-23798	levels	_
119-17	23798-23799	.	_

#Text=A recent meta-analysis of cytokine measures in patients with schizophrenia on and off antipsychotics suggested that antipsychotics may result in both increases and decreases in peripheral cytokine levels.
120-1	23800-23801	A	_
120-2	23802-23808	recent	_
120-3	23809-23822	meta-analysis	_
120-4	23823-23825	of	_
120-5	23826-23834	cytokine	_
120-6	23835-23843	measures	_
120-7	23844-23846	in	_
120-8	23847-23855	patients	_
120-9	23856-23860	with	_
120-10	23861-23874	schizophrenia	_
120-11	23875-23877	on	_
120-12	23878-23881	and	_
120-13	23882-23885	off	_
120-14	23886-23900	antipsychotics	_
120-15	23901-23910	suggested	_
120-16	23911-23915	that	_
120-17	23916-23930	antipsychotics	_
120-18	23931-23934	may	_
120-19	23935-23941	result	_
120-20	23942-23944	in	_
120-21	23945-23949	both	_
120-22	23950-23959	increases	_
120-23	23960-23963	and	_
120-24	23964-23973	decreases	_
120-25	23974-23976	in	_
120-26	23977-23987	peripheral	_
120-27	23988-23996	cytokine	_
120-28	23997-24003	levels	_
120-29	24003-24004	.	_

#Text=Of particular interest for our study is that two proinflammatory cytokines, both IL-1β and IL-6, showed reductions following antipsychotic treatment.
121-1	24005-24007	Of	_
121-2	24008-24018	particular	_
121-3	24019-24027	interest	_
121-4	24028-24031	for	_
121-5	24032-24035	our	_
121-6	24036-24041	study	_
121-7	24042-24044	is	_
121-8	24045-24049	that	_
121-9	24050-24053	two	_
121-10	24054-24069	proinflammatory	_
121-11	24070-24079	cytokines	_
121-12	24079-24080	,	_
121-13	24081-24085	both	_
121-14	24086-24088	IL	_
121-15	24088-24089	-	_
121-16	24089-24091	1β	_
121-17	24092-24095	and	_
121-18	24096-24098	IL	_
121-19	24098-24099	-	_
121-20	24099-24100	6	_
121-21	24100-24101	,	_
121-22	24102-24108	showed	_
121-23	24109-24119	reductions	_
121-24	24120-24129	following	_
121-25	24130-24143	antipsychotic	_
121-26	24144-24153	treatment	_
121-27	24153-24154	.	_

#Text=As exposure to antipsychotics could be suppressing cytokines, an even larger proportion of patients may display an inflammatory profile without antipsychotics; thus, exposure to antipsychotics is not a likely explanation of our findings of more people with schizophrenia in the elevated cytokine group.
122-1	24155-24157	As	_
122-2	24158-24166	exposure	_
122-3	24167-24169	to	_
122-4	24170-24184	antipsychotics	_
122-5	24185-24190	could	_
122-6	24191-24193	be	_
122-7	24194-24205	suppressing	_
122-8	24206-24215	cytokines	_
122-9	24215-24216	,	_
122-10	24217-24219	an	_
122-11	24220-24224	even	_
122-12	24225-24231	larger	_
122-13	24232-24242	proportion	_
122-14	24243-24245	of	_
122-15	24246-24254	patients	_
122-16	24255-24258	may	_
122-17	24259-24266	display	_
122-18	24267-24269	an	_
122-19	24270-24282	inflammatory	_
122-20	24283-24290	profile	_
122-21	24291-24298	without	_
122-22	24299-24313	antipsychotics	_
122-23	24313-24314	;	_
122-24	24315-24319	thus	_
122-25	24319-24320	,	_
122-26	24321-24329	exposure	_
122-27	24330-24332	to	_
122-28	24333-24347	antipsychotics	_
122-29	24348-24350	is	_
122-30	24351-24354	not	_
122-31	24355-24356	a	_
122-32	24357-24363	likely	_
122-33	24364-24375	explanation	_
122-34	24376-24378	of	_
122-35	24379-24382	our	_
122-36	24383-24391	findings	_
122-37	24392-24394	of	_
122-38	24395-24399	more	_
122-39	24400-24406	people	_
122-40	24407-24411	with	_
122-41	24412-24425	schizophrenia	_
122-42	24426-24428	in	_
122-43	24429-24432	the	_
122-44	24433-24441	elevated	_
122-45	24442-24450	cytokine	_
122-46	24451-24456	group	_
122-47	24456-24457	.	_

#Text=We found no relationship between antipsychotic dose and peripheral cytokine mRNA levels or cognitive measures, suggesting that antipsychotic exposure did not mediate the relationship between peripheral cytokines and cognitive function.
123-1	24458-24460	We	_
123-2	24461-24466	found	_
123-3	24467-24469	no	_
123-4	24470-24482	relationship	_
123-5	24483-24490	between	_
123-6	24491-24504	antipsychotic	_
123-7	24505-24509	dose	_
123-8	24510-24513	and	_
123-9	24514-24524	peripheral	_
123-10	24525-24533	cytokine	_
123-11	24534-24538	mRNA	_
123-12	24539-24545	levels	_
123-13	24546-24548	or	_
123-14	24549-24558	cognitive	_
123-15	24559-24567	measures	_
123-16	24567-24568	,	_
123-17	24569-24579	suggesting	_
123-18	24580-24584	that	_
123-19	24585-24598	antipsychotic	_
123-20	24599-24607	exposure	_
123-21	24608-24611	did	_
123-22	24612-24615	not	_
123-23	24616-24623	mediate	_
123-24	24624-24627	the	_
123-25	24628-24640	relationship	_
123-26	24641-24648	between	_
123-27	24649-24659	peripheral	_
123-28	24660-24669	cytokines	_
123-29	24670-24673	and	_
123-30	24674-24683	cognitive	_
123-31	24684-24692	function	_
123-32	24692-24693	.	_

#Text=It is also possible that second-generation antipsychotics specifically impact leukocyte mRNA levels.
124-1	24694-24696	It	_
124-2	24697-24699	is	_
124-3	24700-24704	also	_
124-4	24705-24713	possible	_
124-5	24714-24718	that	_
124-6	24719-24736	second-generation	_
124-7	24737-24751	antipsychotics	_
124-8	24752-24764	specifically	_
124-9	24765-24771	impact	_
124-10	24772-24781	leukocyte	_
124-11	24782-24786	mRNA	_
124-12	24787-24793	levels	_
124-13	24793-24794	.	_

#Text=As all but two patients were receiving second-generation antipsychotics, we were unable to examine whether there was a difference between the effects of first and second-generation antipsychotics.
125-1	24795-24797	As	_
125-2	24798-24801	all	_
125-3	24802-24805	but	_
125-4	24806-24809	two	_
125-5	24810-24818	patients	_
125-6	24819-24823	were	_
125-7	24824-24833	receiving	_
125-8	24834-24851	second-generation	_
125-9	24852-24866	antipsychotics	_
125-10	24866-24867	,	_
125-11	24868-24870	we	_
125-12	24871-24875	were	_
125-13	24876-24882	unable	_
125-14	24883-24885	to	_
125-15	24886-24893	examine	_
125-16	24894-24901	whether	_
125-17	24902-24907	there	_
125-18	24908-24911	was	_
125-19	24912-24913	a	_
125-20	24914-24924	difference	_
125-21	24925-24932	between	_
125-22	24933-24936	the	_
125-23	24937-24944	effects	_
125-24	24945-24947	of	_
125-25	24948-24953	first	_
125-26	24954-24957	and	_
125-27	24958-24975	second-generation	_
125-28	24976-24990	antipsychotics	_
125-29	24990-24991	.	_

#Text=Further supporting the likelihood that cytokine changes may be present in schizophrenia independent of antipsychotic exposure, a recent study demonstrated both greater cortical volume loss and increased peripheral proinflammatory cytokines during the prodrome, before these individuals were diagnosed with schizophrenia (some of whom were not receiving antipsychotics).
126-1	24992-24999	Further	_
126-2	25000-25010	supporting	_
126-3	25011-25014	the	_
126-4	25015-25025	likelihood	_
126-5	25026-25030	that	_
126-6	25031-25039	cytokine	_
126-7	25040-25047	changes	_
126-8	25048-25051	may	_
126-9	25052-25054	be	_
126-10	25055-25062	present	_
126-11	25063-25065	in	_
126-12	25066-25079	schizophrenia	_
126-13	25080-25091	independent	_
126-14	25092-25094	of	_
126-15	25095-25108	antipsychotic	_
126-16	25109-25117	exposure	_
126-17	25117-25118	,	_
126-18	25119-25120	a	_
126-19	25121-25127	recent	_
126-20	25128-25133	study	_
126-21	25134-25146	demonstrated	_
126-22	25147-25151	both	_
126-23	25152-25159	greater	_
126-24	25160-25168	cortical	_
126-25	25169-25175	volume	_
126-26	25176-25180	loss	_
126-27	25181-25184	and	_
126-28	25185-25194	increased	_
126-29	25195-25205	peripheral	_
126-30	25206-25221	proinflammatory	_
126-31	25222-25231	cytokines	_
126-32	25232-25238	during	_
126-33	25239-25242	the	_
126-34	25243-25251	prodrome	_
126-35	25251-25252	,	_
126-36	25253-25259	before	_
126-37	25260-25265	these	_
126-38	25266-25277	individuals	_
126-39	25278-25282	were	_
126-40	25283-25292	diagnosed	_
126-41	25293-25297	with	_
126-42	25298-25311	schizophrenia	_
126-43	25312-25313	(	_
126-44	25313-25317	some	_
126-45	25318-25320	of	_
126-46	25321-25325	whom	_
126-47	25326-25330	were	_
126-48	25331-25334	not	_
126-49	25335-25344	receiving	_
126-50	25345-25359	antipsychotics	_
126-51	25359-25360	)	_
126-52	25360-25361	.	_

#Text=Antipsychotics can also induce weight gain, and fat cells can produce elevations in blood cytokines such as IL-6 and tumor necrosis factor, which could result in the gene expression changes in white blood cells that were found in our study.
127-1	25362-25376	Antipsychotics	_
127-2	25377-25380	can	_
127-3	25381-25385	also	_
127-4	25386-25392	induce	_
127-5	25393-25399	weight	_
127-6	25400-25404	gain	_
127-7	25404-25405	,	_
127-8	25406-25409	and	_
127-9	25410-25413	fat	_
127-10	25414-25419	cells	_
127-11	25420-25423	can	_
127-12	25424-25431	produce	_
127-13	25432-25442	elevations	_
127-14	25443-25445	in	_
127-15	25446-25451	blood	_
127-16	25452-25461	cytokines	_
127-17	25462-25466	such	_
127-18	25467-25469	as	_
127-19	25470-25472	IL	_
127-20	25472-25473	-	_
127-21	25473-25474	6	_
127-22	25475-25478	and	_
127-23	25479-25484	tumor	_
127-24	25485-25493	necrosis	_
127-25	25494-25500	factor	_
127-26	25500-25501	,	_
127-27	25502-25507	which	_
127-28	25508-25513	could	_
127-29	25514-25520	result	_
127-30	25521-25523	in	_
127-31	25524-25527	the	_
127-32	25528-25532	gene	_
127-33	25533-25543	expression	_
127-34	25544-25551	changes	_
127-35	25552-25554	in	_
127-36	25555-25560	white	_
127-37	25561-25566	blood	_
127-38	25567-25572	cells	_
127-39	25573-25577	that	_
127-40	25578-25582	were	_
127-41	25583-25588	found	_
127-42	25589-25591	in	_
127-43	25592-25595	our	_
127-44	25596-25601	study	_
127-45	25601-25602	.	_

#Text=However, in our study, the patients with schizophrenia in the elevated cytokine group, as compared with the low-cytokine group, did not have significantly greater BMI measures.
128-1	25603-25610	However	_
128-2	25610-25611	,	_
128-3	25612-25614	in	_
128-4	25615-25618	our	_
128-5	25619-25624	study	_
128-6	25624-25625	,	_
128-7	25626-25629	the	_
128-8	25630-25638	patients	_
128-9	25639-25643	with	_
128-10	25644-25657	schizophrenia	_
128-11	25658-25660	in	_
128-12	25661-25664	the	_
128-13	25665-25673	elevated	_
128-14	25674-25682	cytokine	_
128-15	25683-25688	group	_
128-16	25688-25689	,	_
128-17	25690-25692	as	_
128-18	25693-25701	compared	_
128-19	25702-25706	with	_
128-20	25707-25710	the	_
128-21	25711-25723	low-cytokine	_
128-22	25724-25729	group	_
128-23	25729-25730	,	_
128-24	25731-25734	did	_
128-25	25735-25738	not	_
128-26	25739-25743	have	_
128-27	25744-25757	significantly	_
128-28	25758-25765	greater	_
128-29	25766-25769	BMI	_
128-30	25770-25778	measures	_
128-31	25778-25779	.	_

#Text=In addition, by measuring peripheral mRNA levels of cytokines, we capture the transcripts exclusively from leukocyte cells, which are less likely to be confounded by the adipocyte cytokine secretion than total serum or plasma protein measurements.
129-1	25780-25782	In	_
129-2	25783-25791	addition	_
129-3	25791-25792	,	_
129-4	25793-25795	by	_
129-5	25796-25805	measuring	_
129-6	25806-25816	peripheral	_
129-7	25817-25821	mRNA	_
129-8	25822-25828	levels	_
129-9	25829-25831	of	_
129-10	25832-25841	cytokines	_
129-11	25841-25842	,	_
129-12	25843-25845	we	_
129-13	25846-25853	capture	_
129-14	25854-25857	the	_
129-15	25858-25869	transcripts	_
129-16	25870-25881	exclusively	_
129-17	25882-25886	from	_
129-18	25887-25896	leukocyte	_
129-19	25897-25902	cells	_
129-20	25902-25903	,	_
129-21	25904-25909	which	_
129-22	25910-25913	are	_
129-23	25914-25918	less	_
129-24	25919-25925	likely	_
129-25	25926-25928	to	_
129-26	25929-25931	be	_
129-27	25932-25942	confounded	_
129-28	25943-25945	by	_
129-29	25946-25949	the	_
129-30	25950-25959	adipocyte	_
129-31	25960-25968	cytokine	_
129-32	25969-25978	secretion	_
129-33	25979-25983	than	_
129-34	25984-25989	total	_
129-35	25990-25995	serum	_
129-36	25996-25998	or	_
129-37	25999-26005	plasma	_
129-38	26006-26013	protein	_
129-39	26014-26026	measurements	_
129-40	26026-26027	.	_

#Text=Owing to close leukocyte/central nervous system communication, particularly during inflammation states, the leukocyte mRNA may therefore be more representative of central nervous system immune status.
130-1	26028-26033	Owing	_
130-2	26034-26036	to	_
130-3	26037-26042	close	_
130-4	26043-26052	leukocyte	_
130-5	26052-26053	/	_
130-6	26053-26060	central	_
130-7	26061-26068	nervous	_
130-8	26069-26075	system	_
130-9	26076-26089	communication	_
130-10	26089-26090	,	_
130-11	26091-26103	particularly	_
130-12	26104-26110	during	_
130-13	26111-26123	inflammation	_
130-14	26124-26130	states	_
130-15	26130-26131	,	_
130-16	26132-26135	the	_
130-17	26136-26145	leukocyte	_
130-18	26146-26150	mRNA	_
130-19	26151-26154	may	_
130-20	26155-26164	therefore	_
130-21	26165-26167	be	_
130-22	26168-26172	more	_
130-23	26173-26187	representative	_
130-24	26188-26190	of	_
130-25	26191-26198	central	_
130-26	26199-26206	nervous	_
130-27	26207-26213	system	_
130-28	26214-26220	immune	_
130-29	26221-26227	status	_
130-30	26227-26228	.	_

#Text=Other potential confounds include the presence of an unrelated inflammatory condition and the age of the subject.
131-1	26229-26234	Other	_
131-2	26235-26244	potential	_
131-3	26245-26254	confounds	_
131-4	26255-26262	include	_
131-5	26263-26266	the	_
131-6	26267-26275	presence	_
131-7	26276-26278	of	_
131-8	26279-26281	an	_
131-9	26282-26291	unrelated	_
131-10	26292-26304	inflammatory	_
131-11	26305-26314	condition	_
131-12	26315-26318	and	_
131-13	26319-26322	the	_
131-14	26323-26326	age	_
131-15	26327-26329	of	_
131-16	26330-26333	the	_
131-17	26334-26341	subject	_
131-18	26341-26342	.	_

#Text=Our participants did not have any obvious medical conditions that would induce peripheral cytokine expression.
132-1	26343-26346	Our	_
132-2	26347-26359	participants	_
132-3	26360-26363	did	_
132-4	26364-26367	not	_
132-5	26368-26372	have	_
132-6	26373-26376	any	_
132-7	26377-26384	obvious	_
132-8	26385-26392	medical	_
132-9	26393-26403	conditions	_
132-10	26404-26408	that	_
132-11	26409-26414	would	_
132-12	26415-26421	induce	_
132-13	26422-26432	peripheral	_
132-14	26433-26441	cytokine	_
132-15	26442-26452	expression	_
132-16	26452-26453	.	_

#Text=The individuals with schizophrenia in the elevated versus low-cytokine group were on average 4 years older.
133-1	26454-26457	The	_
133-2	26458-26469	individuals	_
133-3	26470-26474	with	_
133-4	26475-26488	schizophrenia	_
133-5	26489-26491	in	_
133-6	26492-26495	the	_
133-7	26496-26504	elevated	_
133-8	26505-26511	versus	_
133-9	26512-26524	low-cytokine	_
133-10	26525-26530	group	_
133-11	26531-26535	were	_
133-12	26536-26538	on	_
133-13	26539-26546	average	_
133-14	26547-26548	4	_
133-15	26549-26554	years	_
133-16	26555-26560	older	_
133-17	26560-26561	.	_

#Text=Cytokine protein levels in the blood, with the possible exception of IL-1β, are known to increase with age.
134-1	26562-26570	Cytokine	_
134-2	26571-26578	protein	_
134-3	26579-26585	levels	_
134-4	26586-26588	in	_
134-5	26589-26592	the	_
134-6	26593-26598	blood	_
134-7	26598-26599	,	_
134-8	26600-26604	with	_
134-9	26605-26608	the	_
134-10	26609-26617	possible	_
134-11	26618-26627	exception	_
134-12	26628-26630	of	_
134-13	26631-26633	IL	_
134-14	26633-26634	-	_
134-15	26634-26636	1β	_
134-16	26636-26637	,	_
134-17	26638-26641	are	_
134-18	26642-26647	known	_
134-19	26648-26650	to	_
134-20	26651-26659	increase	_
134-21	26660-26664	with	_
134-22	26665-26668	age	_
134-23	26668-26669	.	_

#Text=As only IL-8 mRNA levels showed a statistically significant relationship with age in our patients, the age difference between the elevated and low-cytokine groups appears unlikely to have unduly influenced our results.
135-1	26670-26672	As	_
135-2	26673-26677	only	_
135-3	26678-26680	IL	_
135-4	26680-26681	-	_
135-5	26681-26682	8	_
135-6	26683-26687	mRNA	_
135-7	26688-26694	levels	_
135-8	26695-26701	showed	_
135-9	26702-26703	a	_
135-10	26704-26717	statistically	_
135-11	26718-26729	significant	_
135-12	26730-26742	relationship	_
135-13	26743-26747	with	_
135-14	26748-26751	age	_
135-15	26752-26754	in	_
135-16	26755-26758	our	_
135-17	26759-26767	patients	_
135-18	26767-26768	,	_
135-19	26769-26772	the	_
135-20	26773-26776	age	_
135-21	26777-26787	difference	_
135-22	26788-26795	between	_
135-23	26796-26799	the	_
135-24	26800-26808	elevated	_
135-25	26809-26812	and	_
135-26	26813-26825	low-cytokine	_
135-27	26826-26832	groups	_
135-28	26833-26840	appears	_
135-29	26841-26849	unlikely	_
135-30	26850-26852	to	_
135-31	26853-26857	have	_
135-32	26858-26864	unduly	_
135-33	26865-26875	influenced	_
135-34	26876-26879	our	_
135-35	26880-26887	results	_
135-36	26887-26888	.	_

#Text=Finally, it is possible that patients with more exaggerated cortical pathology and worse verbal fluency are more likely to have inflammatory changes in their blood owing to years of unremitting illness and to systematic differences in lifestyle factors like changes in diet, exercise and sleep, which could independently be associated with increases in markers of inflammation.
136-1	26889-26896	Finally	_
136-2	26896-26897	,	_
136-3	26898-26900	it	_
136-4	26901-26903	is	_
136-5	26904-26912	possible	_
136-6	26913-26917	that	_
136-7	26918-26926	patients	_
136-8	26927-26931	with	_
136-9	26932-26936	more	_
136-10	26937-26948	exaggerated	_
136-11	26949-26957	cortical	_
136-12	26958-26967	pathology	_
136-13	26968-26971	and	_
136-14	26972-26977	worse	_
136-15	26978-26984	verbal	_
136-16	26985-26992	fluency	_
136-17	26993-26996	are	_
136-18	26997-27001	more	_
136-19	27002-27008	likely	_
136-20	27009-27011	to	_
136-21	27012-27016	have	_
136-22	27017-27029	inflammatory	_
136-23	27030-27037	changes	_
136-24	27038-27040	in	_
136-25	27041-27046	their	_
136-26	27047-27052	blood	_
136-27	27053-27058	owing	_
136-28	27059-27061	to	_
136-29	27062-27067	years	_
136-30	27068-27070	of	_
136-31	27071-27082	unremitting	_
136-32	27083-27090	illness	_
136-33	27091-27094	and	_
136-34	27095-27097	to	_
136-35	27098-27108	systematic	_
136-36	27109-27120	differences	_
136-37	27121-27123	in	_
136-38	27124-27133	lifestyle	_
136-39	27134-27141	factors	_
136-40	27142-27146	like	_
136-41	27147-27154	changes	_
136-42	27155-27157	in	_
136-43	27158-27162	diet	_
136-44	27162-27163	,	_
136-45	27164-27172	exercise	_
136-46	27173-27176	and	_
136-47	27177-27182	sleep	_
136-48	27182-27183	,	_
136-49	27184-27189	which	_
136-50	27190-27195	could	_
136-51	27196-27209	independently	_
136-52	27210-27212	be	_
136-53	27213-27223	associated	_
136-54	27224-27228	with	_
136-55	27229-27238	increases	_
136-56	27239-27241	in	_
136-57	27242-27249	markers	_
136-58	27250-27252	of	_
136-59	27253-27265	inflammation	_
136-60	27265-27266	.	_

#Text=The challenges of determining to what extent blood biomarkers vary across the course of the illness and in response to factors such as antipsychotic exposure and symptom status emphasize the importance of studying the relationship of brain structural changes, clinical features and blood biomarkers of inflammation using a longitudinal design that includes the prodrome, first-episode psychosis and acute relapses.
137-1	27267-27270	The	_
137-2	27271-27281	challenges	_
137-3	27282-27284	of	_
137-4	27285-27296	determining	_
137-5	27297-27299	to	_
137-6	27300-27304	what	_
137-7	27305-27311	extent	_
137-8	27312-27317	blood	_
137-9	27318-27328	biomarkers	_
137-10	27329-27333	vary	_
137-11	27334-27340	across	_
137-12	27341-27344	the	_
137-13	27345-27351	course	_
137-14	27352-27354	of	_
137-15	27355-27358	the	_
137-16	27359-27366	illness	_
137-17	27367-27370	and	_
137-18	27371-27373	in	_
137-19	27374-27382	response	_
137-20	27383-27385	to	_
137-21	27386-27393	factors	_
137-22	27394-27398	such	_
137-23	27399-27401	as	_
137-24	27402-27415	antipsychotic	_
137-25	27416-27424	exposure	_
137-26	27425-27428	and	_
137-27	27429-27436	symptom	_
137-28	27437-27443	status	_
137-29	27444-27453	emphasize	_
137-30	27454-27457	the	_
137-31	27458-27468	importance	_
137-32	27469-27471	of	_
137-33	27472-27480	studying	_
137-34	27481-27484	the	_
137-35	27485-27497	relationship	_
137-36	27498-27500	of	_
137-37	27501-27506	brain	_
137-38	27507-27517	structural	_
137-39	27518-27525	changes	_
137-40	27525-27526	,	_
137-41	27527-27535	clinical	_
137-42	27536-27544	features	_
137-43	27545-27548	and	_
137-44	27549-27554	blood	_
137-45	27555-27565	biomarkers	_
137-46	27566-27568	of	_
137-47	27569-27581	inflammation	_
137-48	27582-27587	using	_
137-49	27588-27589	a	_
137-50	27590-27602	longitudinal	_
137-51	27603-27609	design	_
137-52	27610-27614	that	_
137-53	27615-27623	includes	_
137-54	27624-27627	the	_
137-55	27628-27636	prodrome	_
137-56	27636-27637	,	_
137-57	27638-27651	first-episode	_
137-58	27652-27661	psychosis	_
137-59	27662-27665	and	_
137-60	27666-27671	acute	_
137-61	27672-27680	relapses	_
137-62	27680-27681	.	_

#Text=Future studies should also attempt to systematically obtain data on lifestyle factors to aid in the interpretation of potentially increased cytokines.
138-1	27682-27688	Future	_
138-2	27689-27696	studies	_
138-3	27697-27703	should	_
138-4	27704-27708	also	_
138-5	27709-27716	attempt	_
138-6	27717-27719	to	_
138-7	27720-27734	systematically	_
138-8	27735-27741	obtain	_
138-9	27742-27746	data	_
138-10	27747-27749	on	_
138-11	27750-27759	lifestyle	_
138-12	27760-27767	factors	_
138-13	27768-27770	to	_
138-14	27771-27774	aid	_
138-15	27775-27777	in	_
138-16	27778-27781	the	_
138-17	27782-27796	interpretation	_
138-18	27797-27799	of	_
138-19	27800-27811	potentially	_
138-20	27812-27821	increased	_
138-21	27822-27831	cytokines	_
138-22	27831-27832	.	_

#Text=An interesting question raised by our study is the extent to which elevated peripheral cytokine levels reported here are indicative of the elevated brain cytokine mRNAs we reported previously using a post-mortem sample.
139-1	27833-27835	An	_
139-2	27836-27847	interesting	_
139-3	27848-27856	question	_
139-4	27857-27863	raised	_
139-5	27864-27866	by	_
139-6	27867-27870	our	_
139-7	27871-27876	study	_
139-8	27877-27879	is	_
139-9	27880-27883	the	_
139-10	27884-27890	extent	_
139-11	27891-27893	to	_
139-12	27894-27899	which	_
139-13	27900-27908	elevated	_
139-14	27909-27919	peripheral	_
139-15	27920-27928	cytokine	_
139-16	27929-27935	levels	_
139-17	27936-27944	reported	_
139-18	27945-27949	here	_
139-19	27950-27953	are	_
139-20	27954-27964	indicative	_
139-21	27965-27967	of	_
139-22	27968-27971	the	_
139-23	27972-27980	elevated	_
139-24	27981-27986	brain	_
139-25	27987-27995	cytokine	_
139-26	27996-28001	mRNAs	_
139-27	28002-28004	we	_
139-28	28005-28013	reported	_
139-29	28014-28024	previously	_
139-30	28025-28030	using	_
139-31	28031-28032	a	_
139-32	28033-28044	post-mortem	_
139-33	28045-28051	sample	_
139-34	28051-28052	.	_

#Text=The main boundary between peripheral circulation and the brain is the blood–brain barrier, which may be disrupted in the elevated cytokine schizophrenia group as can be found in other inflammatory conditions.
140-1	28053-28056	The	_
140-2	28057-28061	main	_
140-3	28062-28070	boundary	_
140-4	28071-28078	between	_
140-5	28079-28089	peripheral	_
140-6	28090-28101	circulation	_
140-7	28102-28105	and	_
140-8	28106-28109	the	_
140-9	28110-28115	brain	_
140-10	28116-28118	is	_
140-11	28119-28122	the	_
140-12	28123-28134	blood–brain	_
140-13	28135-28142	barrier	_
140-14	28142-28143	,	_
140-15	28144-28149	which	_
140-16	28150-28153	may	_
140-17	28154-28156	be	_
140-18	28157-28166	disrupted	_
140-19	28167-28169	in	_
140-20	28170-28173	the	_
140-21	28174-28182	elevated	_
140-22	28183-28191	cytokine	_
140-23	28192-28205	schizophrenia	_
140-24	28206-28211	group	_
140-25	28212-28214	as	_
140-26	28215-28218	can	_
140-27	28219-28221	be	_
140-28	28222-28227	found	_
140-29	28228-28230	in	_
140-30	28231-28236	other	_
140-31	28237-28249	inflammatory	_
140-32	28250-28260	conditions	_
140-33	28260-28261	.	_

#Text=Increased IL-1β leads to the induction of Nitric Oxide Synthase through activation of IL-1β receptors on brain vascular cells and the subsequent production of diffusible NO.
141-1	28262-28271	Increased	_
141-2	28272-28274	IL	_
141-3	28274-28275	-	_
141-4	28275-28277	1β	_
141-5	28278-28283	leads	_
141-6	28284-28286	to	_
141-7	28287-28290	the	_
141-8	28291-28300	induction	_
141-9	28301-28303	of	_
141-10	28304-28310	Nitric	_
141-11	28311-28316	Oxide	_
141-12	28317-28325	Synthase	_
141-13	28326-28333	through	_
141-14	28334-28344	activation	_
141-15	28345-28347	of	_
141-16	28348-28350	IL	_
141-17	28350-28351	-	_
141-18	28351-28353	1β	_
141-19	28354-28363	receptors	_
141-20	28364-28366	on	_
141-21	28367-28372	brain	_
141-22	28373-28381	vascular	_
141-23	28382-28387	cells	_
141-24	28388-28391	and	_
141-25	28392-28395	the	_
141-26	28396-28406	subsequent	_
141-27	28407-28417	production	_
141-28	28418-28420	of	_
141-29	28421-28431	diffusible	_
141-30	28432-28434	NO	_
141-31	28434-28435	.	_

#Text=Thus, elevated IL-1β in the periphery could cause blood–brain barrier disruption and change the active transport of cytokines across the blood–brain barrier, which may result in increased immune system communication between blood and brain in people with schizophrenia compared with controls.
142-1	28436-28440	Thus	_
142-2	28440-28441	,	_
142-3	28442-28450	elevated	_
142-4	28451-28453	IL	_
142-5	28453-28454	-	_
142-6	28454-28456	1β	_
142-7	28457-28459	in	_
142-8	28460-28463	the	_
142-9	28464-28473	periphery	_
142-10	28474-28479	could	_
142-11	28480-28485	cause	_
142-12	28486-28497	blood–brain	_
142-13	28498-28505	barrier	_
142-14	28506-28516	disruption	_
142-15	28517-28520	and	_
142-16	28521-28527	change	_
142-17	28528-28531	the	_
142-18	28532-28538	active	_
142-19	28539-28548	transport	_
142-20	28549-28551	of	_
142-21	28552-28561	cytokines	_
142-22	28562-28568	across	_
142-23	28569-28572	the	_
142-24	28573-28584	blood–brain	_
142-25	28585-28592	barrier	_
142-26	28592-28593	,	_
142-27	28594-28599	which	_
142-28	28600-28603	may	_
142-29	28604-28610	result	_
142-30	28611-28613	in	_
142-31	28614-28623	increased	_
142-32	28624-28630	immune	_
142-33	28631-28637	system	_
142-34	28638-28651	communication	_
142-35	28652-28659	between	_
142-36	28660-28665	blood	_
142-37	28666-28669	and	_
142-38	28670-28675	brain	_
142-39	28676-28678	in	_
142-40	28679-28685	people	_
142-41	28686-28690	with	_
142-42	28691-28704	schizophrenia	_
142-43	28705-28713	compared	_
142-44	28714-28718	with	_
142-45	28719-28727	controls	_
142-46	28727-28728	.	_

#Text=The present study was not designed to identify molecular mechanisms through which inflammation may mediate decreases in brain volumes, although we speculate that the mechanisms may be similar to those that cause cellular damage by peripheral chronic inflammation in other diseases (for review see).
143-1	28729-28732	The	_
143-2	28733-28740	present	_
143-3	28741-28746	study	_
143-4	28747-28750	was	_
143-5	28751-28754	not	_
143-6	28755-28763	designed	_
143-7	28764-28766	to	_
143-8	28767-28775	identify	_
143-9	28776-28785	molecular	_
143-10	28786-28796	mechanisms	_
143-11	28797-28804	through	_
143-12	28805-28810	which	_
143-13	28811-28823	inflammation	_
143-14	28824-28827	may	_
143-15	28828-28835	mediate	_
143-16	28836-28845	decreases	_
143-17	28846-28848	in	_
143-18	28849-28854	brain	_
143-19	28855-28862	volumes	_
143-20	28862-28863	,	_
143-21	28864-28872	although	_
143-22	28873-28875	we	_
143-23	28876-28885	speculate	_
143-24	28886-28890	that	_
143-25	28891-28894	the	_
143-26	28895-28905	mechanisms	_
143-27	28906-28909	may	_
143-28	28910-28912	be	_
143-29	28913-28920	similar	_
143-30	28921-28923	to	_
143-31	28924-28929	those	_
143-32	28930-28934	that	_
143-33	28935-28940	cause	_
143-34	28941-28949	cellular	_
143-35	28950-28956	damage	_
143-36	28957-28959	by	_
143-37	28960-28970	peripheral	_
143-38	28971-28978	chronic	_
143-39	28979-28991	inflammation	_
143-40	28992-28994	in	_
143-41	28995-29000	other	_
143-42	29001-29009	diseases	_
143-43	29010-29011	(	_
143-44	29011-29014	for	_
143-45	29015-29021	review	_
143-46	29022-29025	see	_
143-47	29025-29026	)	_
143-48	29026-29027	.	_

#Text=An interesting possibility is that increased peripheral inflammation leads to changes in tryptophan metabolism, resulting in increased kynurenine that can cross the blood–brain barrier, be converted to quinolinic acid and lead to neurotoxicity.
144-1	29028-29030	An	_
144-2	29031-29042	interesting	_
144-3	29043-29054	possibility	_
144-4	29055-29057	is	_
144-5	29058-29062	that	_
144-6	29063-29072	increased	_
144-7	29073-29083	peripheral	_
144-8	29084-29096	inflammation	_
144-9	29097-29102	leads	_
144-10	29103-29105	to	_
144-11	29106-29113	changes	_
144-12	29114-29116	in	_
144-13	29117-29127	tryptophan	_
144-14	29128-29138	metabolism	_
144-15	29138-29139	,	_
144-16	29140-29149	resulting	_
144-17	29150-29152	in	_
144-18	29153-29162	increased	_
144-19	29163-29173	kynurenine	_
144-20	29174-29178	that	_
144-21	29179-29182	can	_
144-22	29183-29188	cross	_
144-23	29189-29192	the	_
144-24	29193-29204	blood–brain	_
144-25	29205-29212	barrier	_
144-26	29212-29213	,	_
144-27	29214-29216	be	_
144-28	29217-29226	converted	_
144-29	29227-29229	to	_
144-30	29230-29240	quinolinic	_
144-31	29241-29245	acid	_
144-32	29246-29249	and	_
144-33	29250-29254	lead	_
144-34	29255-29257	to	_
144-35	29258-29271	neurotoxicity	_
144-36	29271-29272	.	_

#Text=Some individuals with an elevated cytokine expression pattern are also found in the healthy control group.
145-1	29273-29277	Some	_
145-2	29278-29289	individuals	_
145-3	29290-29294	with	_
145-4	29295-29297	an	_
145-5	29298-29306	elevated	_
145-6	29307-29315	cytokine	_
145-7	29316-29326	expression	_
145-8	29327-29334	pattern	_
145-9	29335-29338	are	_
145-10	29339-29343	also	_
145-11	29344-29349	found	_
145-12	29350-29352	in	_
145-13	29353-29356	the	_
145-14	29357-29364	healthy	_
145-15	29365-29372	control	_
145-16	29373-29378	group	_
145-17	29378-29379	.	_

#Text=This finding is not unexpected as slightly increased or chronic immune activation can be found because of a variety of causes that were not used as exclusion criteria in our study, including allergies, asthma or arthritis.
146-1	29380-29384	This	_
146-2	29385-29392	finding	_
146-3	29393-29395	is	_
146-4	29396-29399	not	_
146-5	29400-29410	unexpected	_
146-6	29411-29413	as	_
146-7	29414-29422	slightly	_
146-8	29423-29432	increased	_
146-9	29433-29435	or	_
146-10	29436-29443	chronic	_
146-11	29444-29450	immune	_
146-12	29451-29461	activation	_
146-13	29462-29465	can	_
146-14	29466-29468	be	_
146-15	29469-29474	found	_
146-16	29475-29482	because	_
146-17	29483-29485	of	_
146-18	29486-29487	a	_
146-19	29488-29495	variety	_
146-20	29496-29498	of	_
146-21	29499-29505	causes	_
146-22	29506-29510	that	_
146-23	29511-29515	were	_
146-24	29516-29519	not	_
146-25	29520-29524	used	_
146-26	29525-29527	as	_
146-27	29528-29537	exclusion	_
146-28	29538-29546	criteria	_
146-29	29547-29549	in	_
146-30	29550-29553	our	_
146-31	29554-29559	study	_
146-32	29559-29560	,	_
146-33	29561-29570	including	_
146-34	29571-29580	allergies	_
146-35	29580-29581	,	_
146-36	29582-29588	asthma	_
146-37	29589-29591	or	_
146-38	29592-29601	arthritis	_
146-39	29601-29602	.	_

#Text=This demonstrates that falling into the 'elevated cytokine' category as defined here is not in itself sufficient to cause schizophrenia.
147-1	29603-29607	This	_
147-2	29608-29620	demonstrates	_
147-3	29621-29625	that	_
147-4	29626-29633	falling	_
147-5	29634-29638	into	_
147-6	29639-29642	the	_
147-7	29643-29644	'	_
147-8	29644-29652	elevated	_
147-9	29653-29661	cytokine	_
147-10	29661-29662	'	_
147-11	29663-29671	category	_
147-12	29672-29674	as	_
147-13	29675-29682	defined	_
147-14	29683-29687	here	_
147-15	29688-29690	is	_
147-16	29691-29694	not	_
147-17	29695-29697	in	_
147-18	29698-29704	itself	_
147-19	29705-29715	sufficient	_
147-20	29716-29718	to	_
147-21	29719-29724	cause	_
147-22	29725-29738	schizophrenia	_
147-23	29738-29739	.	_

#Text=Rather it would appear that a specific type of brain-based susceptibility to immune activation may be needed to trigger the pathogenesis of schizophrenia.
148-1	29740-29746	Rather	_
148-2	29747-29749	it	_
148-3	29750-29755	would	_
148-4	29756-29762	appear	_
148-5	29763-29767	that	_
148-6	29768-29769	a	_
148-7	29770-29778	specific	_
148-8	29779-29783	type	_
148-9	29784-29786	of	_
148-10	29787-29798	brain-based	_
148-11	29799-29813	susceptibility	_
148-12	29814-29816	to	_
148-13	29817-29823	immune	_
148-14	29824-29834	activation	_
148-15	29835-29838	may	_
148-16	29839-29841	be	_
148-17	29842-29848	needed	_
148-18	29849-29851	to	_
148-19	29852-29859	trigger	_
148-20	29860-29863	the	_
148-21	29864-29876	pathogenesis	_
148-22	29877-29879	of	_
148-23	29880-29893	schizophrenia	_
148-24	29893-29894	.	_

#Text=Indeed, we have found evidence for the involvement of cytokines in the molecular and cellular neuropathology in people with schizophrenia with an elevated cytokine subgroup of people with schizophrenia found in two post-mortem cohorts.
149-1	29895-29901	Indeed	_
149-2	29901-29902	,	_
149-3	29903-29905	we	_
149-4	29906-29910	have	_
149-5	29911-29916	found	_
149-6	29917-29925	evidence	_
149-7	29926-29929	for	_
149-8	29930-29933	the	_
149-9	29934-29945	involvement	_
149-10	29946-29948	of	_
149-11	29949-29958	cytokines	_
149-12	29959-29961	in	_
149-13	29962-29965	the	_
149-14	29966-29975	molecular	_
149-15	29976-29979	and	_
149-16	29980-29988	cellular	_
149-17	29989-30003	neuropathology	_
149-18	30004-30006	in	_
149-19	30007-30013	people	_
149-20	30014-30018	with	_
149-21	30019-30032	schizophrenia	_
149-22	30033-30037	with	_
149-23	30038-30040	an	_
149-24	30041-30049	elevated	_
149-25	30050-30058	cytokine	_
149-26	30059-30067	subgroup	_
149-27	30068-30070	of	_
149-28	30071-30077	people	_
149-29	30078-30082	with	_
149-30	30083-30096	schizophrenia	_
149-31	30097-30102	found	_
149-32	30103-30105	in	_
149-33	30106-30109	two	_
149-34	30110-30121	post-mortem	_
149-35	30122-30129	cohorts	_
149-36	30129-30130	.	_

#Text=The present in vivo study supports the value of further research into a possible immunologically based mechanism of or contribution to the pathophysiology of schizophrenia.
150-1	30131-30134	The	_
150-2	30135-30142	present	_
150-3	30143-30145	in	_
150-4	30146-30150	vivo	_
150-5	30151-30156	study	_
150-6	30157-30165	supports	_
150-7	30166-30169	the	_
150-8	30170-30175	value	_
150-9	30176-30178	of	_
150-10	30179-30186	further	_
150-11	30187-30195	research	_
150-12	30196-30200	into	_
150-13	30201-30202	a	_
150-14	30203-30211	possible	_
150-15	30212-30227	immunologically	_
150-16	30228-30233	based	_
150-17	30234-30243	mechanism	_
150-18	30244-30246	of	_
150-19	30247-30249	or	_
150-20	30250-30262	contribution	_
150-21	30263-30265	to	_
150-22	30266-30269	the	_
150-23	30270-30285	pathophysiology	_
150-24	30286-30288	of	_
150-25	30289-30302	schizophrenia	_
150-26	30302-30303	.	_

#Text=Our finding that decreased verbal fluency and Broca's area volume is related to immune activation suggests that targeted treatment of some individuals with schizophrenia displaying the elevated cytokine biotype with anti-inflammatory agents may be beneficial for cognitive deficits, especially verbal fluency.
151-1	30304-30307	Our	_
151-2	30308-30315	finding	_
151-3	30316-30320	that	_
151-4	30321-30330	decreased	_
151-5	30331-30337	verbal	_
151-6	30338-30345	fluency	_
151-7	30346-30349	and	_
151-8	30350-30357	Broca's	_
151-9	30358-30362	area	_
151-10	30363-30369	volume	_
151-11	30370-30372	is	_
151-12	30373-30380	related	_
151-13	30381-30383	to	_
151-14	30384-30390	immune	_
151-15	30391-30401	activation	_
151-16	30402-30410	suggests	_
151-17	30411-30415	that	_
151-18	30416-30424	targeted	_
151-19	30425-30434	treatment	_
151-20	30435-30437	of	_
151-21	30438-30442	some	_
151-22	30443-30454	individuals	_
151-23	30455-30459	with	_
151-24	30460-30473	schizophrenia	_
151-25	30474-30484	displaying	_
151-26	30485-30488	the	_
151-27	30489-30497	elevated	_
151-28	30498-30506	cytokine	_
151-29	30507-30514	biotype	_
151-30	30515-30519	with	_
151-31	30520-30537	anti-inflammatory	_
151-32	30538-30544	agents	_
151-33	30545-30548	may	_
151-34	30549-30551	be	_
151-35	30552-30562	beneficial	_
151-36	30563-30566	for	_
151-37	30567-30576	cognitive	_
151-38	30577-30585	deficits	_
151-39	30585-30586	,	_
151-40	30587-30597	especially	_
151-41	30598-30604	verbal	_
151-42	30605-30612	fluency	_
151-43	30612-30613	.	_

#Text=As current treatments have little beneficial effect on language dysfunction in schizophrenia, anti-inflammatory agents may yield greater efficacy on this prominent deficit of the illness.
152-1	30614-30616	As	_
152-2	30617-30624	current	_
152-3	30625-30635	treatments	_
152-4	30636-30640	have	_
152-5	30641-30647	little	_
152-6	30648-30658	beneficial	_
152-7	30659-30665	effect	_
152-8	30666-30668	on	_
152-9	30669-30677	language	_
152-10	30678-30689	dysfunction	_
152-11	30690-30692	in	_
152-12	30693-30706	schizophrenia	_
152-13	30706-30707	,	_
152-14	30708-30725	anti-inflammatory	_
152-15	30726-30732	agents	_
152-16	30733-30736	may	_
152-17	30737-30742	yield	_
152-18	30743-30750	greater	_
152-19	30751-30759	efficacy	_
152-20	30760-30762	on	_
152-21	30763-30767	this	_
152-22	30768-30777	prominent	_
152-23	30778-30785	deficit	_
152-24	30786-30788	of	_
152-25	30789-30792	the	_
152-26	30793-30800	illness	_
152-27	30800-30801	.	_

#Text=In support of this, although Alzheimer's disease is a different disorder and any comparison with schizophrenia must be treated with caution, it is noteworthy that anti-inflammatory treatment resulted in a decrease in cytokine levels and improved verbal fluency.
153-1	30802-30804	In	_
153-2	30805-30812	support	_
153-3	30813-30815	of	_
153-4	30816-30820	this	_
153-5	30820-30821	,	_
153-6	30822-30830	although	_
153-7	30831-30842	Alzheimer's	_
153-8	30843-30850	disease	_
153-9	30851-30853	is	_
153-10	30854-30855	a	_
153-11	30856-30865	different	_
153-12	30866-30874	disorder	_
153-13	30875-30878	and	_
153-14	30879-30882	any	_
153-15	30883-30893	comparison	_
153-16	30894-30898	with	_
153-17	30899-30912	schizophrenia	_
153-18	30913-30917	must	_
153-19	30918-30920	be	_
153-20	30921-30928	treated	_
153-21	30929-30933	with	_
153-22	30934-30941	caution	_
153-23	30941-30942	,	_
153-24	30943-30945	it	_
153-25	30946-30948	is	_
153-26	30949-30959	noteworthy	_
153-27	30960-30964	that	_
153-28	30965-30982	anti-inflammatory	_
153-29	30983-30992	treatment	_
153-30	30993-31001	resulted	_
153-31	31002-31004	in	_
153-32	31005-31006	a	_
153-33	31007-31015	decrease	_
153-34	31016-31018	in	_
153-35	31019-31027	cytokine	_
153-36	31028-31034	levels	_
153-37	31035-31038	and	_
153-38	31039-31047	improved	_
153-39	31048-31054	verbal	_
153-40	31055-31062	fluency	_
153-41	31062-31063	.	_

#Text=The results of our study suggest that it may be possible to use a peripheral biomarker to identify a biological subgroup of individuals with schizophrenia whose disease process includes elevated indices of inflammation such as cytokines.
154-1	31064-31067	The	_
154-2	31068-31075	results	_
154-3	31076-31078	of	_
154-4	31079-31082	our	_
154-5	31083-31088	study	_
154-6	31089-31096	suggest	_
154-7	31097-31101	that	_
154-8	31102-31104	it	_
154-9	31105-31108	may	_
154-10	31109-31111	be	_
154-11	31112-31120	possible	_
154-12	31121-31123	to	_
154-13	31124-31127	use	_
154-14	31128-31129	a	_
154-15	31130-31140	peripheral	_
154-16	31141-31150	biomarker	_
154-17	31151-31153	to	_
154-18	31154-31162	identify	_
154-19	31163-31164	a	_
154-20	31165-31175	biological	_
154-21	31176-31184	subgroup	_
154-22	31185-31187	of	_
154-23	31188-31199	individuals	_
154-24	31200-31204	with	_
154-25	31205-31218	schizophrenia	_
154-26	31219-31224	whose	_
154-27	31225-31232	disease	_
154-28	31233-31240	process	_
154-29	31241-31249	includes	_
154-30	31250-31258	elevated	_
154-31	31259-31266	indices	_
154-32	31267-31269	of	_
154-33	31270-31282	inflammation	_
154-34	31283-31287	such	_
154-35	31288-31290	as	_
154-36	31291-31300	cytokines	_
154-37	31300-31301	.	_

#Text=Importantly, independent replication of these findings would support further clinical trials of anti-inflammatory drugs in this subgroup and could lead to effective novel treatments for some people with schizophrenia.
155-1	31302-31313	Importantly	_
155-2	31313-31314	,	_
155-3	31315-31326	independent	_
155-4	31327-31338	replication	_
155-5	31339-31341	of	_
155-6	31342-31347	these	_
155-7	31348-31356	findings	_
155-8	31357-31362	would	_
155-9	31363-31370	support	_
155-10	31371-31378	further	_
155-11	31379-31387	clinical	_
155-12	31388-31394	trials	_
155-13	31395-31397	of	_
155-14	31398-31415	anti-inflammatory	_
155-15	31416-31421	drugs	_
155-16	31422-31424	in	_
155-17	31425-31429	this	_
155-18	31430-31438	subgroup	_
155-19	31439-31442	and	_
155-20	31443-31448	could	_
155-21	31449-31453	lead	_
155-22	31454-31456	to	_
155-23	31457-31466	effective	_
155-24	31467-31472	novel	_
155-25	31473-31483	treatments	_
155-26	31484-31487	for	_
155-27	31488-31492	some	_
155-28	31493-31499	people	_
155-29	31500-31504	with	_
155-30	31505-31518	schizophrenia	_
155-31	31518-31519	.	_

#Text=Supplementary Information accompanies the paper on the Molecular Psychiatry website (http://www.nature.com/mp)
#Text=Heterogeneity of schizophrenia.
156-1	31520-31533	Supplementary	_
156-2	31534-31545	Information	_
156-3	31546-31557	accompanies	_
156-4	31558-31561	the	_
156-5	31562-31567	paper	_
156-6	31568-31570	on	_
156-7	31571-31574	the	_
156-8	31575-31584	Molecular	_
156-9	31585-31595	Psychiatry	_
156-10	31596-31603	website	_
156-11	31604-31605	(	_
156-12	31605-31609	http	_
156-13	31609-31610	:	_
156-14	31610-31611	/	_
156-15	31611-31612	/	_
156-16	31612-31626	www.nature.com	_
156-17	31626-31627	/	_
156-18	31627-31629	mp	_
156-19	31629-31630	)	_
156-20	31631-31644	Heterogeneity	_
156-21	31645-31647	of	_
156-22	31648-31661	schizophrenia	_
156-23	31661-31662	.	_

#Text=Conceptual models and analytic strategies
#Text=Immune system and schizophrenia
#Text=Prenatal infection and schizophrenia: a review of epidemiologic and translational studies
#Text=Recent progress in animal modeling of immune inflammatory processes in schizophrenia: implication of specific cytokines
#Text=Increased inflammatory markers identified in the dorsolateral prefrontal cortex of individuals with schizophrenia
#Text=The question of pro-inflammatory immune activity in schizophrenia and the potential importance of anti-inflammatory drugs
#Text=Plasma levels of interleukin-1β and interleukin-6 in schizophrenia, other psychoses, and affective disorders
#Text=Cytokine profiles in drug-naive schizophrenic patients
#Text=Serum IL-1beta, sIL-2 R, IL-6, IL-8 and TNF-alpha in schizophrenic patients, relation with symptomatology and responsiveness to risperidone treatment
#Text=Interleukin-6-(IL-6) plasma levels in depression and schizophrenia: comparison between the acute state and after remission
#Text=Serum interleukin-6 concentration in schizophrenia: elevation associated with duration of illness
#Text=Relationships between interleukins, neurotransmitters and psychopathology in drug-free male schizophrenics
#Text=Serum levels of IL-6, IL-10 and TNF-α in patients with bipolar disorder and schizophrenia: differences in pro- and anti-inflammatory balance
#Text=Elevated circulating levels of IL-6 in schizophrenia
#Text=Inflammatory cytokine alterations in schizophrenia: a systematic quantitative review
#Text=Increased interleukin-1 and interleukin-3 like activity in schizophrenic patients
#Text=Elevated interleukin-2, interleukin-6 and interleukin-8 serum levels in neuroleptic-free schizophrenia: association with psychopathology
#Text=Relationship between plasma analytes and SPARE-AD defined brain atrophy patterns in ADNI
#Text=The relation between inflammation and neuropsychological test performance
#Text=Rapid improvement in verbal fluency and aphasia following perispinal etanercept in Alzheimer's disease
#Text=Is quality of life associated with cognitive impairment in schizophrenia
#Text=The relationship between neurocognition and social cognition with functional outcomes in schizophrenia: a meta-analysis
#Text=A neuropsychological study of prefrontal lobe function in the positive and negative subtypes of schizophrenia
#Text=Cognitive impairments in patients with schizophrenia displaying preserved and compromised intellect
#Text=Analysis of neural mechanisms underlying verbal fluency in cytoarchitectonically defined stereotaxic space—the roles of Brodmann areas 44 and 45
#Text=Speech production: Wernicke, Broca and beyond
#Text=Functional specialization for semantic and phonological processing in the left inferior prefrontal cortex
#Text=Anatomically related grey and white matter abnormalities in adolescent-onset schizophrenia
#Text=Abnormal cortical folding patterns within Broca's area in schizophrenia: evidence from structural MRI
#Text=Brain volume in first-episode schizophrenia: systematic review and meta-analysis of magnetic resonance imaging studies
#Text=Postmortem studies in schizophrenia
#Text=Increased expression of astrocyte markers in schizophrenia: association with neuroinflammation
#Text=The relationship of structural alterations to cognitive deficits in schizophrenia: a voxel-based morphometry study
#Text=Grey and white matter abnormalities are associated with impaired spatial working memory ability in first-episode schizophrenia
#Text=Associations of cortical thickness and cognition in patients with schizophrenia and healthy controls
#Text=Hippocampal volume reduction and autobiographical memory deficits in chronic schizophrenia
#Text=Structural neurobiological correlates of Mayer-Salovery-Caruso Emotional Intelligence Test performance in early course schizophrenia
#Text=Social cognition and frontal lobe pathology in schizophrenia: a voxel-based morphometric study
#Text=Elevated levels of circulating IL-18BP and perturbed regulation of IL-18 in schizophrenia
#Text=
#Text=Indicators of conformance with guidelines of schizophrenia treatment in mental health services
#Text=Chlorpromazine equivalent doses for the newer atypical antipsychotics
#Text=
#Text=
#Text=
#Text=
#Text=The positive and negative syndrome scale (PANSS) for schizophrenia
#Text=
#Text=Procedures for detecting outlying observations in samples
#Text=Markers of inflammation and stress distinguish subsets of individuals with schizophrenia and bipolar disorder
#Text=SPSS twostep cluster: a first evaluation
#Text=Controlling the false discovery rate: a practical and powerful approach to multiple testing
#Text=Interleukin-1: a master regulator of neuroinflammation
#Text=Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects
#Text=Cytokines in schizophrenia and the effects of antipsychotic drugs
#Text=Progressive reduction in cortical thickness as psychosis develops: a multisite longitudinal neuroimaging study of youth at elevated clinical risk
#Text=Omental and subcutaneous adipose tissues of obese subjects release interleukin-6: depot difference and regulation by glucocorticoid
#Text=Adipose tissue, adipokines, and inflammation
#Text=Innate immunity in the central nervous system
#Text=Monocyte cytokine production in an elderly population: effect of age and inflammation
#Text=Gene expression profiling by mRNA sequencing reveals increased expression of immune/inflammation-related genes in the hippocampus of individuals with schizophrenia
#Text=Cytokines and the blood–brain barrier
#Text=Induction of nitric oxide synthase gene by interleukin in vascular smooth muscle cells
#Text=The role of inflammation in CNS injury and disease
#Text=Kynurenines in the mammalian brain: when physiology meets pathology
#Text=Gene expression analysis implicates a death receptor pathway in schizophrenia pathology
#Text=High white matter neuron density with elevated cortical cytokine expression in schizophrenia
#Text=A double-blind, randomized study of minocycline for the treatment of negative and cognitive symptoms in early-phase schizophrenia
#Text=Nonsteroidal anti-inflammatory drugs in Alzheimer's disease
#Text=Adjuvant aspirin therapy reduces symptoms of schizophrenia spectrum disorders: results from a randomized, double-blind, placebo-controlled trial
#Text=The path to personalized medicine
#Text=Supplementary Material
#Text=Cytokine mRNA expression levels in leukocyte cells from the blood of people with schizophrenia (red) and matched controls (blue).
157-1	31663-31673	Conceptual	_
157-2	31674-31680	models	_
157-3	31681-31684	and	_
157-4	31685-31693	analytic	_
157-5	31694-31704	strategies	_
157-6	31705-31711	Immune	_
157-7	31712-31718	system	_
157-8	31719-31722	and	_
157-9	31723-31736	schizophrenia	_
157-10	31737-31745	Prenatal	_
157-11	31746-31755	infection	_
157-12	31756-31759	and	_
157-13	31760-31773	schizophrenia	_
157-14	31773-31774	:	_
157-15	31775-31776	a	_
157-16	31777-31783	review	_
157-17	31784-31786	of	_
157-18	31787-31800	epidemiologic	_
157-19	31801-31804	and	_
157-20	31805-31818	translational	_
157-21	31819-31826	studies	_
157-22	31827-31833	Recent	_
157-23	31834-31842	progress	_
157-24	31843-31845	in	_
157-25	31846-31852	animal	_
157-26	31853-31861	modeling	_
157-27	31862-31864	of	_
157-28	31865-31871	immune	_
157-29	31872-31884	inflammatory	_
157-30	31885-31894	processes	_
157-31	31895-31897	in	_
157-32	31898-31911	schizophrenia	_
157-33	31911-31912	:	_
157-34	31913-31924	implication	_
157-35	31925-31927	of	_
157-36	31928-31936	specific	_
157-37	31937-31946	cytokines	_
157-38	31947-31956	Increased	_
157-39	31957-31969	inflammatory	_
157-40	31970-31977	markers	_
157-41	31978-31988	identified	_
157-42	31989-31991	in	_
157-43	31992-31995	the	_
157-44	31996-32008	dorsolateral	_
157-45	32009-32019	prefrontal	_
157-46	32020-32026	cortex	_
157-47	32027-32029	of	_
157-48	32030-32041	individuals	_
157-49	32042-32046	with	_
157-50	32047-32060	schizophrenia	_
157-51	32061-32064	The	_
157-52	32065-32073	question	_
157-53	32074-32076	of	_
157-54	32077-32093	pro-inflammatory	_
157-55	32094-32100	immune	_
157-56	32101-32109	activity	_
157-57	32110-32112	in	_
157-58	32113-32126	schizophrenia	_
157-59	32127-32130	and	_
157-60	32131-32134	the	_
157-61	32135-32144	potential	_
157-62	32145-32155	importance	_
157-63	32156-32158	of	_
157-64	32159-32176	anti-inflammatory	_
157-65	32177-32182	drugs	_
157-66	32183-32189	Plasma	_
157-67	32190-32196	levels	_
157-68	32197-32199	of	_
157-69	32200-32211	interleukin	_
157-70	32211-32212	-	_
157-71	32212-32214	1β	_
157-72	32215-32218	and	_
157-73	32219-32230	interleukin	_
157-74	32230-32231	-	_
157-75	32231-32232	6	_
157-76	32233-32235	in	_
157-77	32236-32249	schizophrenia	_
157-78	32249-32250	,	_
157-79	32251-32256	other	_
157-80	32257-32266	psychoses	_
157-81	32266-32267	,	_
157-82	32268-32271	and	_
157-83	32272-32281	affective	_
157-84	32282-32291	disorders	_
157-85	32292-32300	Cytokine	_
157-86	32301-32309	profiles	_
157-87	32310-32312	in	_
157-88	32313-32323	drug-naive	_
157-89	32324-32337	schizophrenic	_
157-90	32338-32346	patients	_
157-91	32347-32352	Serum	_
157-92	32353-32355	IL	_
157-93	32355-32356	-	_
157-94	32356-32361	1beta	_
157-95	32361-32362	,	_
157-96	32363-32366	sIL	_
157-97	32366-32367	-	_
157-98	32367-32368	2	_
157-99	32369-32370	R	_
157-100	32370-32371	,	_
157-101	32372-32374	IL	_
157-102	32374-32375	-	_
157-103	32375-32376	6	_
157-104	32376-32377	,	_
157-105	32378-32380	IL	_
157-106	32380-32381	-	_
157-107	32381-32382	8	_
157-108	32383-32386	and	_
157-109	32387-32396	TNF-alpha	_
157-110	32397-32399	in	_
157-111	32400-32413	schizophrenic	_
157-112	32414-32422	patients	_
157-113	32422-32423	,	_
157-114	32424-32432	relation	_
157-115	32433-32437	with	_
157-116	32438-32452	symptomatology	_
157-117	32453-32456	and	_
157-118	32457-32471	responsiveness	_
157-119	32472-32474	to	_
157-120	32475-32486	risperidone	_
157-121	32487-32496	treatment	_
157-122	32497-32508	Interleukin	_
157-123	32508-32509	-	_
157-124	32509-32510	6	_
157-125	32510-32511	-	_
157-126	32511-32512	(	_
157-127	32512-32514	IL	_
157-128	32514-32515	-	_
157-129	32515-32516	6	_
157-130	32516-32517	)	_
157-131	32518-32524	plasma	_
157-132	32525-32531	levels	_
157-133	32532-32534	in	_
157-134	32535-32545	depression	_
157-135	32546-32549	and	_
157-136	32550-32563	schizophrenia	_
157-137	32563-32564	:	_
157-138	32565-32575	comparison	_
157-139	32576-32583	between	_
157-140	32584-32587	the	_
157-141	32588-32593	acute	_
157-142	32594-32599	state	_
157-143	32600-32603	and	_
157-144	32604-32609	after	_
157-145	32610-32619	remission	_
157-146	32620-32625	Serum	_
157-147	32626-32637	interleukin	_
157-148	32637-32638	-	_
157-149	32638-32639	6	_
157-150	32640-32653	concentration	_
157-151	32654-32656	in	_
157-152	32657-32670	schizophrenia	_
157-153	32670-32671	:	_
157-154	32672-32681	elevation	_
157-155	32682-32692	associated	_
157-156	32693-32697	with	_
157-157	32698-32706	duration	_
157-158	32707-32709	of	_
157-159	32710-32717	illness	_
157-160	32718-32731	Relationships	_
157-161	32732-32739	between	_
157-162	32740-32752	interleukins	_
157-163	32752-32753	,	_
157-164	32754-32771	neurotransmitters	_
157-165	32772-32775	and	_
157-166	32776-32791	psychopathology	_
157-167	32792-32794	in	_
157-168	32795-32804	drug-free	_
157-169	32805-32809	male	_
157-170	32810-32824	schizophrenics	_
157-171	32825-32830	Serum	_
157-172	32831-32837	levels	_
157-173	32838-32840	of	_
157-174	32841-32843	IL	_
157-175	32843-32844	-	_
157-176	32844-32845	6	_
157-177	32845-32846	,	_
157-178	32847-32849	IL	_
157-179	32849-32850	-	_
157-180	32850-32852	10	_
157-181	32853-32856	and	_
157-182	32857-32862	TNF-α	_
157-183	32863-32865	in	_
157-184	32866-32874	patients	_
157-185	32875-32879	with	_
157-186	32880-32887	bipolar	_
157-187	32888-32896	disorder	_
157-188	32897-32900	and	_
157-189	32901-32914	schizophrenia	_
157-190	32914-32915	:	_
157-191	32916-32927	differences	_
157-192	32928-32930	in	_
157-193	32931-32934	pro	_
157-194	32934-32935	-	_
157-195	32936-32939	and	_
157-196	32940-32957	anti-inflammatory	_
157-197	32958-32965	balance	_
157-198	32966-32974	Elevated	_
157-199	32975-32986	circulating	_
157-200	32987-32993	levels	_
157-201	32994-32996	of	_
157-202	32997-32999	IL	_
157-203	32999-33000	-	_
157-204	33000-33001	6	_
157-205	33002-33004	in	_
157-206	33005-33018	schizophrenia	_
157-207	33019-33031	Inflammatory	_
157-208	33032-33040	cytokine	_
157-209	33041-33052	alterations	_
157-210	33053-33055	in	_
157-211	33056-33069	schizophrenia	_
157-212	33069-33070	:	_
157-213	33071-33072	a	_
157-214	33073-33083	systematic	_
157-215	33084-33096	quantitative	_
157-216	33097-33103	review	_
157-217	33104-33113	Increased	_
157-218	33114-33125	interleukin	_
157-219	33125-33126	-	_
157-220	33126-33127	1	_
157-221	33128-33131	and	_
157-222	33132-33143	interleukin	_
157-223	33143-33144	-	_
157-224	33144-33145	3	_
157-225	33146-33150	like	_
157-226	33151-33159	activity	_
157-227	33160-33162	in	_
157-228	33163-33176	schizophrenic	_
157-229	33177-33185	patients	_
157-230	33186-33194	Elevated	_
157-231	33195-33206	interleukin	_
157-232	33206-33207	-	_
157-233	33207-33208	2	_
157-234	33208-33209	,	_
157-235	33210-33221	interleukin	_
157-236	33221-33222	-	_
157-237	33222-33223	6	_
157-238	33224-33227	and	_
157-239	33228-33239	interleukin	_
157-240	33239-33240	-	_
157-241	33240-33241	8	_
157-242	33242-33247	serum	_
157-243	33248-33254	levels	_
157-244	33255-33257	in	_
157-245	33258-33274	neuroleptic-free	_
157-246	33275-33288	schizophrenia	_
157-247	33288-33289	:	_
157-248	33290-33301	association	_
157-249	33302-33306	with	_
157-250	33307-33322	psychopathology	_
157-251	33323-33335	Relationship	_
157-252	33336-33343	between	_
157-253	33344-33350	plasma	_
157-254	33351-33359	analytes	_
157-255	33360-33363	and	_
157-256	33364-33372	SPARE-AD	_
157-257	33373-33380	defined	_
157-258	33381-33386	brain	_
157-259	33387-33394	atrophy	_
157-260	33395-33403	patterns	_
157-261	33404-33406	in	_
157-262	33407-33411	ADNI	_
157-263	33412-33415	The	_
157-264	33416-33424	relation	_
157-265	33425-33432	between	_
157-266	33433-33445	inflammation	_
157-267	33446-33449	and	_
157-268	33450-33468	neuropsychological	_
157-269	33469-33473	test	_
157-270	33474-33485	performance	_
157-271	33486-33491	Rapid	_
157-272	33492-33503	improvement	_
157-273	33504-33506	in	_
157-274	33507-33513	verbal	_
157-275	33514-33521	fluency	_
157-276	33522-33525	and	_
157-277	33526-33533	aphasia	_
157-278	33534-33543	following	_
157-279	33544-33554	perispinal	_
157-280	33555-33565	etanercept	_
157-281	33566-33568	in	_
157-282	33569-33580	Alzheimer's	_
157-283	33581-33588	disease	_
157-284	33589-33591	Is	_
157-285	33592-33599	quality	_
157-286	33600-33602	of	_
157-287	33603-33607	life	_
157-288	33608-33618	associated	_
157-289	33619-33623	with	_
157-290	33624-33633	cognitive	_
157-291	33634-33644	impairment	_
157-292	33645-33647	in	_
157-293	33648-33661	schizophrenia	_
157-294	33662-33665	The	_
157-295	33666-33678	relationship	_
157-296	33679-33686	between	_
157-297	33687-33701	neurocognition	_
157-298	33702-33705	and	_
157-299	33706-33712	social	_
157-300	33713-33722	cognition	_
157-301	33723-33727	with	_
157-302	33728-33738	functional	_
157-303	33739-33747	outcomes	_
157-304	33748-33750	in	_
157-305	33751-33764	schizophrenia	_
157-306	33764-33765	:	_
157-307	33766-33767	a	_
157-308	33768-33781	meta-analysis	_
157-309	33782-33783	A	_
157-310	33784-33802	neuropsychological	_
157-311	33803-33808	study	_
157-312	33809-33811	of	_
157-313	33812-33822	prefrontal	_
157-314	33823-33827	lobe	_
157-315	33828-33836	function	_
157-316	33837-33839	in	_
157-317	33840-33843	the	_
157-318	33844-33852	positive	_
157-319	33853-33856	and	_
157-320	33857-33865	negative	_
157-321	33866-33874	subtypes	_
157-322	33875-33877	of	_
157-323	33878-33891	schizophrenia	_
157-324	33892-33901	Cognitive	_
157-325	33902-33913	impairments	_
157-326	33914-33916	in	_
157-327	33917-33925	patients	_
157-328	33926-33930	with	_
157-329	33931-33944	schizophrenia	_
157-330	33945-33955	displaying	_
157-331	33956-33965	preserved	_
157-332	33966-33969	and	_
157-333	33970-33981	compromised	_
157-334	33982-33991	intellect	_
157-335	33992-34000	Analysis	_
157-336	34001-34003	of	_
157-337	34004-34010	neural	_
157-338	34011-34021	mechanisms	_
157-339	34022-34032	underlying	_
157-340	34033-34039	verbal	_
157-341	34040-34047	fluency	_
157-342	34048-34050	in	_
157-343	34051-34072	cytoarchitectonically	_
157-344	34073-34080	defined	_
157-345	34081-34092	stereotaxic	_
157-346	34093-34102	space—the	_
157-347	34103-34108	roles	_
157-348	34109-34111	of	_
157-349	34112-34120	Brodmann	_
157-350	34121-34126	areas	_
157-351	34127-34129	44	_
157-352	34130-34133	and	_
157-353	34134-34136	45	_
157-354	34137-34143	Speech	_
157-355	34144-34154	production	_
157-356	34154-34155	:	_
157-357	34156-34164	Wernicke	_
157-358	34164-34165	,	_
157-359	34166-34171	Broca	_
157-360	34172-34175	and	_
157-361	34176-34182	beyond	_
157-362	34183-34193	Functional	_
157-363	34194-34208	specialization	_
157-364	34209-34212	for	_
157-365	34213-34221	semantic	_
157-366	34222-34225	and	_
157-367	34226-34238	phonological	_
157-368	34239-34249	processing	_
157-369	34250-34252	in	_
157-370	34253-34256	the	_
157-371	34257-34261	left	_
157-372	34262-34270	inferior	_
157-373	34271-34281	prefrontal	_
157-374	34282-34288	cortex	_
157-375	34289-34301	Anatomically	_
157-376	34302-34309	related	_
157-377	34310-34314	grey	_
157-378	34315-34318	and	_
157-379	34319-34324	white	_
157-380	34325-34331	matter	_
157-381	34332-34345	abnormalities	_
157-382	34346-34348	in	_
157-383	34349-34365	adolescent-onset	_
157-384	34366-34379	schizophrenia	_
157-385	34380-34388	Abnormal	_
157-386	34389-34397	cortical	_
157-387	34398-34405	folding	_
157-388	34406-34414	patterns	_
157-389	34415-34421	within	_
157-390	34422-34429	Broca's	_
157-391	34430-34434	area	_
157-392	34435-34437	in	_
157-393	34438-34451	schizophrenia	_
157-394	34451-34452	:	_
157-395	34453-34461	evidence	_
157-396	34462-34466	from	_
157-397	34467-34477	structural	_
157-398	34478-34481	MRI	_
157-399	34482-34487	Brain	_
157-400	34488-34494	volume	_
157-401	34495-34497	in	_
157-402	34498-34511	first-episode	_
157-403	34512-34525	schizophrenia	_
157-404	34525-34526	:	_
157-405	34527-34537	systematic	_
157-406	34538-34544	review	_
157-407	34545-34548	and	_
157-408	34549-34562	meta-analysis	_
157-409	34563-34565	of	_
157-410	34566-34574	magnetic	_
157-411	34575-34584	resonance	_
157-412	34585-34592	imaging	_
157-413	34593-34600	studies	_
157-414	34601-34611	Postmortem	_
157-415	34612-34619	studies	_
157-416	34620-34622	in	_
157-417	34623-34636	schizophrenia	_
157-418	34637-34646	Increased	_
157-419	34647-34657	expression	_
157-420	34658-34660	of	_
157-421	34661-34670	astrocyte	_
157-422	34671-34678	markers	_
157-423	34679-34681	in	_
157-424	34682-34695	schizophrenia	_
157-425	34695-34696	:	_
157-426	34697-34708	association	_
157-427	34709-34713	with	_
157-428	34714-34731	neuroinflammation	_
157-429	34732-34735	The	_
157-430	34736-34748	relationship	_
157-431	34749-34751	of	_
157-432	34752-34762	structural	_
157-433	34763-34774	alterations	_
157-434	34775-34777	to	_
157-435	34778-34787	cognitive	_
157-436	34788-34796	deficits	_
157-437	34797-34799	in	_
157-438	34800-34813	schizophrenia	_
157-439	34813-34814	:	_
157-440	34815-34816	a	_
157-441	34817-34828	voxel-based	_
157-442	34829-34840	morphometry	_
157-443	34841-34846	study	_
157-444	34847-34851	Grey	_
157-445	34852-34855	and	_
157-446	34856-34861	white	_
157-447	34862-34868	matter	_
157-448	34869-34882	abnormalities	_
157-449	34883-34886	are	_
157-450	34887-34897	associated	_
157-451	34898-34902	with	_
157-452	34903-34911	impaired	_
157-453	34912-34919	spatial	_
157-454	34920-34927	working	_
157-455	34928-34934	memory	_
157-456	34935-34942	ability	_
157-457	34943-34945	in	_
157-458	34946-34959	first-episode	_
157-459	34960-34973	schizophrenia	_
157-460	34974-34986	Associations	_
157-461	34987-34989	of	_
157-462	34990-34998	cortical	_
157-463	34999-35008	thickness	_
157-464	35009-35012	and	_
157-465	35013-35022	cognition	_
157-466	35023-35025	in	_
157-467	35026-35034	patients	_
157-468	35035-35039	with	_
157-469	35040-35053	schizophrenia	_
157-470	35054-35057	and	_
157-471	35058-35065	healthy	_
157-472	35066-35074	controls	_
157-473	35075-35086	Hippocampal	_
157-474	35087-35093	volume	_
157-475	35094-35103	reduction	_
157-476	35104-35107	and	_
157-477	35108-35124	autobiographical	_
157-478	35125-35131	memory	_
157-479	35132-35140	deficits	_
157-480	35141-35143	in	_
157-481	35144-35151	chronic	_
157-482	35152-35165	schizophrenia	_
157-483	35166-35176	Structural	_
157-484	35177-35192	neurobiological	_
157-485	35193-35203	correlates	_
157-486	35204-35206	of	_
157-487	35207-35228	Mayer-Salovery-Caruso	_
157-488	35229-35238	Emotional	_
157-489	35239-35251	Intelligence	_
157-490	35252-35256	Test	_
157-491	35257-35268	performance	_
157-492	35269-35271	in	_
157-493	35272-35277	early	_
157-494	35278-35284	course	_
157-495	35285-35298	schizophrenia	_
157-496	35299-35305	Social	_
157-497	35306-35315	cognition	_
157-498	35316-35319	and	_
157-499	35320-35327	frontal	_
157-500	35328-35332	lobe	_
157-501	35333-35342	pathology	_
157-502	35343-35345	in	_
157-503	35346-35359	schizophrenia	_
157-504	35359-35360	:	_
157-505	35361-35362	a	_
157-506	35363-35374	voxel-based	_
157-507	35375-35387	morphometric	_
157-508	35388-35393	study	_
157-509	35394-35402	Elevated	_
157-510	35403-35409	levels	_
157-511	35410-35412	of	_
157-512	35413-35424	circulating	_
157-513	35425-35427	IL	_
157-514	35427-35428	-	_
157-515	35428-35432	18BP	_
157-516	35433-35436	and	_
157-517	35437-35446	perturbed	_
157-518	35447-35457	regulation	_
157-519	35458-35460	of	_
157-520	35461-35463	IL	_
157-521	35463-35464	-	_
157-522	35464-35466	18	_
157-523	35467-35469	in	_
157-524	35470-35483	schizophrenia	_
157-525	35485-35495	Indicators	_
157-526	35496-35498	of	_
157-527	35499-35510	conformance	_
157-528	35511-35515	with	_
157-529	35516-35526	guidelines	_
157-530	35527-35529	of	_
157-531	35530-35543	schizophrenia	_
157-532	35544-35553	treatment	_
157-533	35554-35556	in	_
157-534	35557-35563	mental	_
157-535	35564-35570	health	_
157-536	35571-35579	services	_
157-537	35580-35594	Chlorpromazine	_
157-538	35595-35605	equivalent	_
157-539	35606-35611	doses	_
157-540	35612-35615	for	_
157-541	35616-35619	the	_
157-542	35620-35625	newer	_
157-543	35626-35634	atypical	_
157-544	35635-35649	antipsychotics	_
157-545	35654-35657	The	_
157-546	35658-35666	positive	_
157-547	35667-35670	and	_
157-548	35671-35679	negative	_
157-549	35680-35688	syndrome	_
157-550	35689-35694	scale	_
157-551	35695-35696	(	_
157-552	35696-35701	PANSS	_
157-553	35701-35702	)	_
157-554	35703-35706	for	_
157-555	35707-35720	schizophrenia	_
157-556	35722-35732	Procedures	_
157-557	35733-35736	for	_
157-558	35737-35746	detecting	_
157-559	35747-35755	outlying	_
157-560	35756-35768	observations	_
157-561	35769-35771	in	_
157-562	35772-35779	samples	_
157-563	35780-35787	Markers	_
157-564	35788-35790	of	_
157-565	35791-35803	inflammation	_
157-566	35804-35807	and	_
157-567	35808-35814	stress	_
157-568	35815-35826	distinguish	_
157-569	35827-35834	subsets	_
157-570	35835-35837	of	_
157-571	35838-35849	individuals	_
157-572	35850-35854	with	_
157-573	35855-35868	schizophrenia	_
157-574	35869-35872	and	_
157-575	35873-35880	bipolar	_
157-576	35881-35889	disorder	_
157-577	35890-35894	SPSS	_
157-578	35895-35902	twostep	_
157-579	35903-35910	cluster	_
157-580	35910-35911	:	_
157-581	35912-35913	a	_
157-582	35914-35919	first	_
157-583	35920-35930	evaluation	_
157-584	35931-35942	Controlling	_
157-585	35943-35946	the	_
157-586	35947-35952	false	_
157-587	35953-35962	discovery	_
157-588	35963-35967	rate	_
157-589	35967-35968	:	_
157-590	35969-35970	a	_
157-591	35971-35980	practical	_
157-592	35981-35984	and	_
157-593	35985-35993	powerful	_
157-594	35994-36002	approach	_
157-595	36003-36005	to	_
157-596	36006-36014	multiple	_
157-597	36015-36022	testing	_
157-598	36023-36034	Interleukin	_
157-599	36034-36035	-	_
157-600	36035-36036	1	_
157-601	36036-36037	:	_
157-602	36038-36039	a	_
157-603	36040-36046	master	_
157-604	36047-36056	regulator	_
157-605	36057-36059	of	_
157-606	36060-36077	neuroinflammation	_
157-607	36078-36091	Meta-analysis	_
157-608	36092-36094	of	_
157-609	36095-36103	cytokine	_
157-610	36104-36115	alterations	_
157-611	36116-36118	in	_
157-612	36119-36132	schizophrenia	_
157-613	36132-36133	:	_
157-614	36134-36142	clinical	_
157-615	36143-36149	status	_
157-616	36150-36153	and	_
157-617	36154-36167	antipsychotic	_
157-618	36168-36175	effects	_
157-619	36176-36185	Cytokines	_
157-620	36186-36188	in	_
157-621	36189-36202	schizophrenia	_
157-622	36203-36206	and	_
157-623	36207-36210	the	_
157-624	36211-36218	effects	_
157-625	36219-36221	of	_
157-626	36222-36235	antipsychotic	_
157-627	36236-36241	drugs	_
157-628	36242-36253	Progressive	_
157-629	36254-36263	reduction	_
157-630	36264-36266	in	_
157-631	36267-36275	cortical	_
157-632	36276-36285	thickness	_
157-633	36286-36288	as	_
157-634	36289-36298	psychosis	_
157-635	36299-36307	develops	_
157-636	36307-36308	:	_
157-637	36309-36310	a	_
157-638	36311-36320	multisite	_
157-639	36321-36333	longitudinal	_
157-640	36334-36346	neuroimaging	_
157-641	36347-36352	study	_
157-642	36353-36355	of	_
157-643	36356-36361	youth	_
157-644	36362-36364	at	_
157-645	36365-36373	elevated	_
157-646	36374-36382	clinical	_
157-647	36383-36387	risk	_
157-648	36388-36395	Omental	_
157-649	36396-36399	and	_
157-650	36400-36412	subcutaneous	_
157-651	36413-36420	adipose	_
157-652	36421-36428	tissues	_
157-653	36429-36431	of	_
157-654	36432-36437	obese	_
157-655	36438-36446	subjects	_
157-656	36447-36454	release	_
157-657	36455-36466	interleukin	_
157-658	36466-36467	-	_
157-659	36467-36468	6	_
157-660	36468-36469	:	_
157-661	36470-36475	depot	_
157-662	36476-36486	difference	_
157-663	36487-36490	and	_
157-664	36491-36501	regulation	_
157-665	36502-36504	by	_
157-666	36505-36519	glucocorticoid	_
157-667	36520-36527	Adipose	_
157-668	36528-36534	tissue	_
157-669	36534-36535	,	_
157-670	36536-36546	adipokines	_
157-671	36546-36547	,	_
157-672	36548-36551	and	_
157-673	36552-36564	inflammation	_
157-674	36565-36571	Innate	_
157-675	36572-36580	immunity	_
157-676	36581-36583	in	_
157-677	36584-36587	the	_
157-678	36588-36595	central	_
157-679	36596-36603	nervous	_
157-680	36604-36610	system	_
157-681	36611-36619	Monocyte	_
157-682	36620-36628	cytokine	_
157-683	36629-36639	production	_
157-684	36640-36642	in	_
157-685	36643-36645	an	_
157-686	36646-36653	elderly	_
157-687	36654-36664	population	_
157-688	36664-36665	:	_
157-689	36666-36672	effect	_
157-690	36673-36675	of	_
157-691	36676-36679	age	_
157-692	36680-36683	and	_
157-693	36684-36696	inflammation	_
157-694	36697-36701	Gene	_
157-695	36702-36712	expression	_
157-696	36713-36722	profiling	_
157-697	36723-36725	by	_
157-698	36726-36730	mRNA	_
157-699	36731-36741	sequencing	_
157-700	36742-36749	reveals	_
157-701	36750-36759	increased	_
157-702	36760-36770	expression	_
157-703	36771-36773	of	_
157-704	36774-36780	immune	_
157-705	36780-36781	/	_
157-706	36781-36801	inflammation-related	_
157-707	36802-36807	genes	_
157-708	36808-36810	in	_
157-709	36811-36814	the	_
157-710	36815-36826	hippocampus	_
157-711	36827-36829	of	_
157-712	36830-36841	individuals	_
157-713	36842-36846	with	_
157-714	36847-36860	schizophrenia	_
157-715	36861-36870	Cytokines	_
157-716	36871-36874	and	_
157-717	36875-36878	the	_
157-718	36879-36890	blood–brain	_
157-719	36891-36898	barrier	_
157-720	36899-36908	Induction	_
157-721	36909-36911	of	_
157-722	36912-36918	nitric	_
157-723	36919-36924	oxide	_
157-724	36925-36933	synthase	_
157-725	36934-36938	gene	_
157-726	36939-36941	by	_
157-727	36942-36953	interleukin	_
157-728	36954-36956	in	_
157-729	36957-36965	vascular	_
157-730	36966-36972	smooth	_
157-731	36973-36979	muscle	_
157-732	36980-36985	cells	_
157-733	36986-36989	The	_
157-734	36990-36994	role	_
157-735	36995-36997	of	_
157-736	36998-37010	inflammation	_
157-737	37011-37013	in	_
157-738	37014-37017	CNS	_
157-739	37018-37024	injury	_
157-740	37025-37028	and	_
157-741	37029-37036	disease	_
157-742	37037-37048	Kynurenines	_
157-743	37049-37051	in	_
157-744	37052-37055	the	_
157-745	37056-37065	mammalian	_
157-746	37066-37071	brain	_
157-747	37071-37072	:	_
157-748	37073-37077	when	_
157-749	37078-37088	physiology	_
157-750	37089-37094	meets	_
157-751	37095-37104	pathology	_
157-752	37105-37109	Gene	_
157-753	37110-37120	expression	_
157-754	37121-37129	analysis	_
157-755	37130-37140	implicates	_
157-756	37141-37142	a	_
157-757	37143-37148	death	_
157-758	37149-37157	receptor	_
157-759	37158-37165	pathway	_
157-760	37166-37168	in	_
157-761	37169-37182	schizophrenia	_
157-762	37183-37192	pathology	_
157-763	37193-37197	High	_
157-764	37198-37203	white	_
157-765	37204-37210	matter	_
157-766	37211-37217	neuron	_
157-767	37218-37225	density	_
157-768	37226-37230	with	_
157-769	37231-37239	elevated	_
157-770	37240-37248	cortical	_
157-771	37249-37257	cytokine	_
157-772	37258-37268	expression	_
157-773	37269-37271	in	_
157-774	37272-37285	schizophrenia	_
157-775	37286-37287	A	_
157-776	37288-37300	double-blind	_
157-777	37300-37301	,	_
157-778	37302-37312	randomized	_
157-779	37313-37318	study	_
157-780	37319-37321	of	_
157-781	37322-37333	minocycline	_
157-782	37334-37337	for	_
157-783	37338-37341	the	_
157-784	37342-37351	treatment	_
157-785	37352-37354	of	_
157-786	37355-37363	negative	_
157-787	37364-37367	and	_
157-788	37368-37377	cognitive	_
157-789	37378-37386	symptoms	_
157-790	37387-37389	in	_
157-791	37390-37401	early-phase	_
157-792	37402-37415	schizophrenia	_
157-793	37416-37428	Nonsteroidal	_
157-794	37429-37446	anti-inflammatory	_
157-795	37447-37452	drugs	_
157-796	37453-37455	in	_
157-797	37456-37467	Alzheimer's	_
157-798	37468-37475	disease	_
157-799	37476-37484	Adjuvant	_
157-800	37485-37492	aspirin	_
157-801	37493-37500	therapy	_
157-802	37501-37508	reduces	_
157-803	37509-37517	symptoms	_
157-804	37518-37520	of	_
157-805	37521-37534	schizophrenia	_
157-806	37535-37543	spectrum	_
157-807	37544-37553	disorders	_
157-808	37553-37554	:	_
157-809	37555-37562	results	_
157-810	37563-37567	from	_
157-811	37568-37569	a	_
157-812	37570-37580	randomized	_
157-813	37580-37581	,	_
157-814	37582-37594	double-blind	_
157-815	37594-37595	,	_
157-816	37596-37614	placebo-controlled	_
157-817	37615-37620	trial	_
157-818	37621-37624	The	_
157-819	37625-37629	path	_
157-820	37630-37632	to	_
157-821	37633-37645	personalized	_
157-822	37646-37654	medicine	_
157-823	37655-37668	Supplementary	_
157-824	37669-37677	Material	_
157-825	37678-37686	Cytokine	_
157-826	37687-37691	mRNA	_
157-827	37692-37702	expression	_
157-828	37703-37709	levels	_
157-829	37710-37712	in	_
157-830	37713-37722	leukocyte	_
157-831	37723-37728	cells	_
157-832	37729-37733	from	_
157-833	37734-37737	the	_
157-834	37738-37743	blood	_
157-835	37744-37746	of	_
157-836	37747-37753	people	_
157-837	37754-37758	with	_
157-838	37759-37772	schizophrenia	_
157-839	37773-37774	(	_
157-840	37774-37777	red	_
157-841	37777-37778	)	_
157-842	37779-37782	and	_
157-843	37783-37790	matched	_
157-844	37791-37799	controls	_
157-845	37800-37801	(	_
157-846	37801-37805	blue	_
157-847	37805-37806	)	_
157-848	37806-37807	.	_

#Text=A significant increase was observed in IL-1β mRNA expression in schizophrenia.
158-1	37808-37809	A	_
158-2	37810-37821	significant	_
158-3	37822-37830	increase	_
158-4	37831-37834	was	_
158-5	37835-37843	observed	_
158-6	37844-37846	in	_
158-7	37847-37849	IL	_
158-8	37849-37850	-	_
158-9	37850-37852	1β	_
158-10	37853-37857	mRNA	_
158-11	37858-37868	expression	_
158-12	37869-37871	in	_
158-13	37872-37885	schizophrenia	_
158-14	37885-37886	.	_

#Text=Other cytokines were not significantly changed but showed substantial expression variability.
159-1	37887-37892	Other	_
159-2	37893-37902	cytokines	_
159-3	37903-37907	were	_
159-4	37908-37911	not	_
159-5	37912-37925	significantly	_
159-6	37926-37933	changed	_
159-7	37934-37937	but	_
159-8	37938-37944	showed	_
159-9	37945-37956	substantial	_
159-10	37957-37967	expression	_
159-11	37968-37979	variability	_
159-12	37979-37980	.	_

#Text=Horizontal bars represent the median values.
160-1	37981-37991	Horizontal	_
160-2	37992-37996	bars	_
160-3	37997-38006	represent	_
160-4	38007-38010	the	_
160-5	38011-38017	median	_
160-6	38018-38024	values	_
160-7	38024-38025	.	_

#Text=Note the different scales on the y axes (**P<0.01).
161-1	38026-38030	Note	_
161-2	38031-38034	the	_
161-3	38035-38044	different	_
161-4	38045-38051	scales	_
161-5	38052-38054	on	_
161-6	38055-38058	the	_
161-7	38059-38060	y	_
161-8	38061-38065	axes	_
161-9	38066-38067	(	_
161-10	38067-38068	*	_
161-11	38068-38069	*	_
161-12	38069-38070	P	_
161-13	38070-38071	<	_
161-14	38071-38075	0.01	_
161-15	38075-38076	)	_
161-16	38076-38077	.	_

#Text=A recursive two-step clustering analysis of the mRNA levels of four cytokines (IL-1β, IL-18, IL-8, IL-2 in order of contribution) yields two subgroups in the optimal model.
162-1	38078-38079	A	_
162-2	38080-38089	recursive	_
162-3	38090-38098	two-step	_
162-4	38099-38109	clustering	_
162-5	38110-38118	analysis	_
162-6	38119-38121	of	_
162-7	38122-38125	the	_
162-8	38126-38130	mRNA	_
162-9	38131-38137	levels	_
162-10	38138-38140	of	_
162-11	38141-38145	four	_
162-12	38146-38155	cytokines	_
162-13	38156-38157	(	_
162-14	38157-38159	IL	_
162-15	38159-38160	-	_
162-16	38160-38162	1β	_
162-17	38162-38163	,	_
162-18	38164-38166	IL	_
162-19	38166-38167	-	_
162-20	38167-38169	18	_
162-21	38169-38170	,	_
162-22	38171-38173	IL	_
162-23	38173-38174	-	_
162-24	38174-38175	8	_
162-25	38175-38176	,	_
162-26	38177-38179	IL	_
162-27	38179-38180	-	_
162-28	38180-38181	2	_
162-29	38182-38184	in	_
162-30	38185-38190	order	_
162-31	38191-38193	of	_
162-32	38194-38206	contribution	_
162-33	38206-38207	)	_
162-34	38208-38214	yields	_
162-35	38215-38218	two	_
162-36	38219-38228	subgroups	_
162-37	38229-38231	in	_
162-38	38232-38235	the	_
162-39	38236-38243	optimal	_
162-40	38244-38249	model	_
162-41	38249-38250	.	_

#Text=Each cytokine mRNA expression is significantly elevated over the mean of all controls with the standard error (represented by bars) increasing as contribution weight decreases (a).
163-1	38251-38255	Each	_
163-2	38256-38264	cytokine	_
163-3	38265-38269	mRNA	_
163-4	38270-38280	expression	_
163-5	38281-38283	is	_
163-6	38284-38297	significantly	_
163-7	38298-38306	elevated	_
163-8	38307-38311	over	_
163-9	38312-38315	the	_
163-10	38316-38320	mean	_
163-11	38321-38323	of	_
163-12	38324-38327	all	_
163-13	38328-38336	controls	_
163-14	38337-38341	with	_
163-15	38342-38345	the	_
163-16	38346-38354	standard	_
163-17	38355-38360	error	_
163-18	38361-38362	(	_
163-19	38362-38373	represented	_
163-20	38374-38376	by	_
163-21	38377-38381	bars	_
163-22	38381-38382	)	_
163-23	38383-38393	increasing	_
163-24	38394-38396	as	_
163-25	38397-38409	contribution	_
163-26	38410-38416	weight	_
163-27	38417-38426	decreases	_
163-28	38427-38428	(	_
163-29	38428-38429	a	_
163-30	38429-38430	)	_
163-31	38430-38431	.	_

#Text=One subgroup contains elevated levels of cytokine mRNA expression (dark colors) and the other subgroup has lower levels compared with the control average (light colors).
164-1	38432-38435	One	_
164-2	38436-38444	subgroup	_
164-3	38445-38453	contains	_
164-4	38454-38462	elevated	_
164-5	38463-38469	levels	_
164-6	38470-38472	of	_
164-7	38473-38481	cytokine	_
164-8	38482-38486	mRNA	_
164-9	38487-38497	expression	_
164-10	38498-38499	(	_
164-11	38499-38503	dark	_
164-12	38504-38510	colors	_
164-13	38510-38511	)	_
164-14	38512-38515	and	_
164-15	38516-38519	the	_
164-16	38520-38525	other	_
164-17	38526-38534	subgroup	_
164-18	38535-38538	has	_
164-19	38539-38544	lower	_
164-20	38545-38551	levels	_
164-21	38552-38560	compared	_
164-22	38561-38565	with	_
164-23	38566-38569	the	_
164-24	38570-38577	control	_
164-25	38578-38585	average	_
164-26	38586-38587	(	_
164-27	38587-38592	light	_
164-28	38593-38599	colors	_
164-29	38599-38600	)	_
164-30	38600-38601	.	_

#Text=The elevated cytokine subgroups comprise 40% of the schizophrenia group (red) and 21% of the control group (blue) (b).
165-1	38602-38605	The	_
165-2	38606-38614	elevated	_
165-3	38615-38623	cytokine	_
165-4	38624-38633	subgroups	_
165-5	38634-38642	comprise	_
165-6	38643-38646	40%	_
165-7	38647-38649	of	_
165-8	38650-38653	the	_
165-9	38654-38667	schizophrenia	_
165-10	38668-38673	group	_
165-11	38674-38675	(	_
165-12	38675-38678	red	_
165-13	38678-38679	)	_
165-14	38680-38683	and	_
165-15	38684-38687	21%	_
165-16	38688-38690	of	_
165-17	38691-38694	the	_
165-18	38695-38702	control	_
165-19	38703-38708	group	_
165-20	38709-38710	(	_
165-21	38710-38714	blue	_
165-22	38714-38715	)	_
165-23	38716-38717	(	_
165-24	38717-38718	b	_
165-25	38718-38719	)	_
165-26	38719-38720	.	_

#Text=Z-Scores for the 10 neurocognitive domains tested.
166-1	38721-38729	Z-Scores	_
166-2	38730-38733	for	_
166-3	38734-38737	the	_
166-4	38738-38740	10	_
166-5	38741-38755	neurocognitive	_
166-6	38756-38763	domains	_
166-7	38764-38770	tested	_
166-8	38770-38771	.	_

#Text=Significance levels for diagnosis are indicated on the upper portion of the figure.
167-1	38772-38784	Significance	_
167-2	38785-38791	levels	_
167-3	38792-38795	for	_
167-4	38796-38805	diagnosis	_
167-5	38806-38809	are	_
167-6	38810-38819	indicated	_
167-7	38820-38822	on	_
167-8	38823-38826	the	_
167-9	38827-38832	upper	_
167-10	38833-38840	portion	_
167-11	38841-38843	of	_
167-12	38844-38847	the	_
167-13	38848-38854	figure	_
167-14	38854-38855	.	_

#Text=All tests with the exception of the Controlled Oral Word Association Test (COWAT) and the similarities subtest of the WAIS-III were significantly changed between schizophrenia and control groups when covaried for premorbid IQ (Wechsler Test of Adult Reading).
168-1	38856-38859	All	_
168-2	38860-38865	tests	_
168-3	38866-38870	with	_
168-4	38871-38874	the	_
168-5	38875-38884	exception	_
168-6	38885-38887	of	_
168-7	38888-38891	the	_
168-8	38892-38902	Controlled	_
168-9	38903-38907	Oral	_
168-10	38908-38912	Word	_
168-11	38913-38924	Association	_
168-12	38925-38929	Test	_
168-13	38930-38931	(	_
168-14	38931-38936	COWAT	_
168-15	38936-38937	)	_
168-16	38938-38941	and	_
168-17	38942-38945	the	_
168-18	38946-38958	similarities	_
168-19	38959-38966	subtest	_
168-20	38967-38969	of	_
168-21	38970-38973	the	_
168-22	38974-38982	WAIS-III	_
168-23	38983-38987	were	_
168-24	38988-39001	significantly	_
168-25	39002-39009	changed	_
168-26	39010-39017	between	_
168-27	39018-39031	schizophrenia	_
168-28	39032-39035	and	_
168-29	39036-39043	control	_
168-30	39044-39050	groups	_
168-31	39051-39055	when	_
168-32	39056-39064	covaried	_
168-33	39065-39068	for	_
168-34	39069-39078	premorbid	_
168-35	39079-39081	IQ	_
168-36	39082-39083	(	_
168-37	39083-39091	Wechsler	_
168-38	39092-39096	Test	_
168-39	39097-39099	of	_
168-40	39100-39105	Adult	_
168-41	39106-39113	Reading	_
168-42	39113-39114	)	_
168-43	39114-39115	.	_

#Text=The COWAT revealed significantly poorer performance in individuals with schizophrenia who have elevated cytokine levels compared with those with low cytokine levels as shown by the bracket in the lower portion of the figure.
169-1	39116-39119	The	_
169-2	39120-39125	COWAT	_
169-3	39126-39134	revealed	_
169-4	39135-39148	significantly	_
169-5	39149-39155	poorer	_
169-6	39156-39167	performance	_
169-7	39168-39170	in	_
169-8	39171-39182	individuals	_
169-9	39183-39187	with	_
169-10	39188-39201	schizophrenia	_
169-11	39202-39205	who	_
169-12	39206-39210	have	_
169-13	39211-39219	elevated	_
169-14	39220-39228	cytokine	_
169-15	39229-39235	levels	_
169-16	39236-39244	compared	_
169-17	39245-39249	with	_
169-18	39250-39255	those	_
169-19	39256-39260	with	_
169-20	39261-39264	low	_
169-21	39265-39273	cytokine	_
169-22	39274-39280	levels	_
169-23	39281-39283	as	_
169-24	39284-39289	shown	_
169-25	39290-39292	by	_
169-26	39293-39296	the	_
169-27	39297-39304	bracket	_
169-28	39305-39307	in	_
169-29	39308-39311	the	_
169-30	39312-39317	lower	_
169-31	39318-39325	portion	_
169-32	39326-39328	of	_
169-33	39329-39332	the	_
169-34	39333-39339	figure	_
169-35	39339-39340	.	_

#Text=Error bars indicate standard error (T; P=0.06, *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001, *****P<0.0000001).
170-1	39341-39346	Error	_
170-2	39347-39351	bars	_
170-3	39352-39360	indicate	_
170-4	39361-39369	standard	_
170-5	39370-39375	error	_
170-6	39376-39377	(	_
170-7	39377-39378	T	_
170-8	39378-39379	;	_
170-9	39380-39381	P	_
170-10	39381-39382	=	_
170-11	39382-39386	0.06	_
170-12	39386-39387	,	_
170-13	39388-39389	*	_
170-14	39389-39390	P	_
170-15	39390-39391	<	_
170-16	39391-39395	0.05	_
170-17	39395-39396	,	_
170-18	39397-39398	*	_
170-19	39398-39399	*	_
170-20	39399-39400	P	_
170-21	39400-39401	<	_
170-22	39401-39405	0.01	_
170-23	39405-39406	,	_
170-24	39407-39408	*	_
170-25	39408-39409	*	_
170-26	39409-39410	*	_
170-27	39410-39411	P	_
170-28	39411-39412	<	_
170-29	39412-39417	0.001	_
170-30	39417-39418	,	_
170-31	39419-39420	*	_
170-32	39420-39421	*	_
170-33	39421-39422	*	_
170-34	39422-39423	*	_
170-35	39423-39424	P	_
170-36	39424-39425	<	_
170-37	39425-39431	0.0001	_
170-38	39431-39432	,	_
170-39	39433-39434	*	_
170-40	39434-39435	*	_
170-41	39435-39436	*	_
170-42	39436-39437	*	_
170-43	39437-39438	*	_
170-44	39438-39439	P	_
170-45	39439-39440	<	_
170-46	39440-39449	0.0000001	_
170-47	39449-39450	)	_
170-48	39450-39451	.	_

#Text=Language-related brain areas influenced by elevated cytokine levels in schizophrenia.
171-1	39452-39468	Language-related	_
171-2	39469-39474	brain	_
171-3	39475-39480	areas	_
171-4	39481-39491	influenced	_
171-5	39492-39494	by	_
171-6	39495-39503	elevated	_
171-7	39504-39512	cytokine	_
171-8	39513-39519	levels	_
171-9	39520-39522	in	_
171-10	39523-39536	schizophrenia	_
171-11	39536-39537	.	_

#Text=Significant volumetric changes in areas associated with verbal fluency were found in the left hemisphere (a).
172-1	39538-39549	Significant	_
172-2	39550-39560	volumetric	_
172-3	39561-39568	changes	_
172-4	39569-39571	in	_
172-5	39572-39577	areas	_
172-6	39578-39588	associated	_
172-7	39589-39593	with	_
172-8	39594-39600	verbal	_
172-9	39601-39608	fluency	_
172-10	39609-39613	were	_
172-11	39614-39619	found	_
172-12	39620-39622	in	_
172-13	39623-39626	the	_
172-14	39627-39631	left	_
172-15	39632-39642	hemisphere	_
172-16	39643-39644	(	_
172-17	39644-39645	a	_
172-18	39645-39646	)	_
172-19	39646-39647	.	_

#Text=The pars opercularis, part of Broca's area, showed significantly diminished volume in individuals with schizophrenia compared with controls (upper brackets).
173-1	39648-39651	The	_
173-2	39652-39656	pars	_
173-3	39657-39668	opercularis	_
173-4	39668-39669	,	_
173-5	39670-39674	part	_
173-6	39675-39677	of	_
173-7	39678-39685	Broca's	_
173-8	39686-39690	area	_
173-9	39690-39691	,	_
173-10	39692-39698	showed	_
173-11	39699-39712	significantly	_
173-12	39713-39723	diminished	_
173-13	39724-39730	volume	_
173-14	39731-39733	in	_
173-15	39734-39745	individuals	_
173-16	39746-39750	with	_
173-17	39751-39764	schizophrenia	_
173-18	39765-39773	compared	_
173-19	39774-39778	with	_
173-20	39779-39787	controls	_
173-21	39788-39789	(	_
173-22	39789-39794	upper	_
173-23	39795-39803	brackets	_
173-24	39803-39804	)	_
173-25	39804-39805	.	_

#Text=There was also a significantly decreased average brain volume in the elevated cytokine schizophrenia group as compared with the low-cytokine group in this brain area (lower brackets).
174-1	39806-39811	There	_
174-2	39812-39815	was	_
174-3	39816-39820	also	_
174-4	39821-39822	a	_
174-5	39823-39836	significantly	_
174-6	39837-39846	decreased	_
174-7	39847-39854	average	_
174-8	39855-39860	brain	_
174-9	39861-39867	volume	_
174-10	39868-39870	in	_
174-11	39871-39874	the	_
174-12	39875-39883	elevated	_
174-13	39884-39892	cytokine	_
174-14	39893-39906	schizophrenia	_
174-15	39907-39912	group	_
174-16	39913-39915	as	_
174-17	39916-39924	compared	_
174-18	39925-39929	with	_
174-19	39930-39933	the	_
174-20	39934-39946	low-cytokine	_
174-21	39947-39952	group	_
174-22	39953-39955	in	_
174-23	39956-39960	this	_
174-24	39961-39966	brain	_
174-25	39967-39971	area	_
174-26	39972-39973	(	_
174-27	39973-39978	lower	_
174-28	39979-39987	brackets	_
174-29	39987-39988	)	_
174-30	39988-39989	.	_

#Text=The supramarginal gyrus in the right hemisphere showed a significant interaction effect between diagnosis and cytokine group, but there were no significant differences between diagnostic group or cytokine group.
175-1	39990-39993	The	_
175-2	39994-40007	supramarginal	_
175-3	40008-40013	gyrus	_
175-4	40014-40016	in	_
175-5	40017-40020	the	_
175-6	40021-40026	right	_
175-7	40027-40037	hemisphere	_
175-8	40038-40044	showed	_
175-9	40045-40046	a	_
175-10	40047-40058	significant	_
175-11	40059-40070	interaction	_
175-12	40071-40077	effect	_
175-13	40078-40085	between	_
175-14	40086-40095	diagnosis	_
175-15	40096-40099	and	_
175-16	40100-40108	cytokine	_
175-17	40109-40114	group	_
175-18	40114-40115	,	_
175-19	40116-40119	but	_
175-20	40120-40125	there	_
175-21	40126-40130	were	_
175-22	40131-40133	no	_
175-23	40134-40145	significant	_
175-24	40146-40157	differences	_
175-25	40158-40165	between	_
175-26	40166-40176	diagnostic	_
175-27	40177-40182	group	_
175-28	40183-40185	or	_
175-29	40186-40194	cytokine	_
175-30	40195-40200	group	_
175-31	40200-40201	.	_

#Text=Error bars indicate calculated standard error (*P<0.05, **P<0.01).
176-1	40202-40207	Error	_
176-2	40208-40212	bars	_
176-3	40213-40221	indicate	_
176-4	40222-40232	calculated	_
176-5	40233-40241	standard	_
176-6	40242-40247	error	_
176-7	40248-40249	(	_
176-8	40249-40250	*	_
176-9	40250-40251	P	_
176-10	40251-40252	<	_
176-11	40252-40256	0.05	_
176-12	40256-40257	,	_
176-13	40258-40259	*	_
176-14	40259-40260	*	_
176-15	40260-40261	P	_
176-16	40261-40262	<	_
176-17	40262-40266	0.01	_
176-18	40266-40267	)	_
176-19	40267-40268	.	_

#Text=Increases in IL-1β mRNA in schizophrenia are a significant predictor of poorer COWAT scores (b).
177-1	40269-40278	Increases	_
177-2	40279-40281	in	_
177-3	40282-40284	IL	_
177-4	40284-40285	-	_
177-5	40285-40287	1β	_
177-6	40288-40292	mRNA	_
177-7	40293-40295	in	_
177-8	40296-40309	schizophrenia	_
177-9	40310-40313	are	_
177-10	40314-40315	a	_
177-11	40316-40327	significant	_
177-12	40328-40337	predictor	_
177-13	40338-40340	of	_
177-14	40341-40347	poorer	_
177-15	40348-40353	COWAT	_
177-16	40354-40360	scores	_
177-17	40361-40362	(	_
177-18	40362-40363	b	_
177-19	40363-40364	)	_
177-20	40364-40365	.	_

#Text=Similarly, increases in IL-1β mRNA also predict decreased volumes of the left hemisphere pars opercularis in schizophrenia (c).
178-1	40366-40375	Similarly	_
178-2	40375-40376	,	_
178-3	40377-40386	increases	_
178-4	40387-40389	in	_
178-5	40390-40392	IL	_
178-6	40392-40393	-	_
178-7	40393-40395	1β	_
178-8	40396-40400	mRNA	_
178-9	40401-40405	also	_
178-10	40406-40413	predict	_
178-11	40414-40423	decreased	_
178-12	40424-40431	volumes	_
178-13	40432-40434	of	_
178-14	40435-40438	the	_
178-15	40439-40443	left	_
178-16	40444-40454	hemisphere	_
178-17	40455-40459	pars	_
178-18	40460-40471	opercularis	_
178-19	40472-40474	in	_
178-20	40475-40488	schizophrenia	_
178-21	40489-40490	(	_
178-22	40490-40491	c	_
178-23	40491-40492	)	_
178-24	40492-40493	.	_

#Text=Individuals in the elevated cytokine group are represented by dark red points and those in the low-cytokine group indicated by lighter red points.
179-1	40494-40505	Individuals	_
179-2	40506-40508	in	_
179-3	40509-40512	the	_
179-4	40513-40521	elevated	_
179-5	40522-40530	cytokine	_
179-6	40531-40536	group	_
179-7	40537-40540	are	_
179-8	40541-40552	represented	_
179-9	40553-40555	by	_
179-10	40556-40560	dark	_
179-11	40561-40564	red	_
179-12	40565-40571	points	_
179-13	40572-40575	and	_
179-14	40576-40581	those	_
179-15	40582-40584	in	_
179-16	40585-40588	the	_
179-17	40589-40601	low-cytokine	_
179-18	40602-40607	group	_
179-19	40608-40617	indicated	_
179-20	40618-40620	by	_
179-21	40621-40628	lighter	_
179-22	40629-40632	red	_
179-23	40633-40639	points	_
179-24	40639-40640	.	_

#Text=Demographics of study participants
#Text= \tBlood and cognitive testing\tMRI scanning\t \tDemographic\tSchizophrenia (n=43)\tControl (n=43)\tDifference\tSchizophrenia (n=33)\tControl (n=43)\tDifference\t \tAge in years (range)\t33.6 (20–48)\t32.5 (22–48)\tns\t33.4 (20–48)\t32.5 (22–48)\tns\t \tEducation in years (range)\t12.8 (8–19)\t15.5 (10–20)\tt(84)=–5.78, p<0.001\t13.1 (8–19)\t15.5 (10–20)\tt(74)=−4.75, p<0.001\t \tHandedness % right\t77.1±49.1\t87.1±28.2\tns\t77.3±48.3\t87.1±28.2\tns\t \tGender\t18 F: 25M\t22 F: 21M\tns\t13 F: 20M\t22 F: 21M\tns\t \tRIN±s.d.\t7.94±0.65\t7.78±1.17\tns\t7.89±0.67\t7.78±1.18\tns\t \tAge of onset (in years and range)\t22.3 (15–32)\t \t \t22.7 (15–31)\t \t \t \tDuration of illness in years±s.d.\t11.7±6.18\t \t \t11.2±6.73\t \t \t \tPANSS positive±s.d.\t15.8±4.82\t \t \t15.8±4.92\t \t \t \tPANSS negative±s.d.\t14.3±6.98\t \t \t14.0±6.49\t \t \t \tPANSS general±s.d.\t33.1±10.2\t \t \t33.3±10.4\t \t \t \tPANSS total±s.d.\t63.2±19.5\t \t \t63.1±19.4\t \t \t \tChlorpromazine mean equivalent dose (mg)±s.d.\t627±501\t \t \t632±460\t \t \t \tBody mass index (n, mean±s.d.)\t33, 30.6±6.65\t \t \t26, 30.9±6.67\t \t \t \tAntipsychotic (frequency in total cohort)\tamisulpride=8, aripripazole=6, clozapine=14, olazapine=8, paliperidone=3, quetiapine=8, risperidone=8, ziprasidone=2, zuclopentixol=1\t \t \tamisulpride=5, aripripazole=5, clozapine=9, olazapine=7, paliperidone=2, quetiapine=7, risperidone=6, ziprasidone=1, zuclopentixol=1\t \t \t \t
#Text=Abbreviations: ns, not significant; PANSS, Positive and Negative Syndrome Scale; RIN, RNA integrity number; s.d., standard deviation.
180-1	40641-40653	Demographics	_
180-2	40654-40656	of	_
180-3	40657-40662	study	_
180-4	40663-40675	participants	_
180-5	40676-40677	 	_
180-6	40678-40683	Blood	_
180-7	40684-40687	and	_
180-8	40688-40697	cognitive	_
180-9	40698-40705	testing	_
180-10	40706-40709	MRI	_
180-11	40710-40718	scanning	_
180-12	40721-40732	Demographic	_
180-13	40733-40746	Schizophrenia	_
180-14	40747-40748	(	_
180-15	40748-40749	n	_
180-16	40749-40750	=	_
180-17	40750-40752	43	_
180-18	40752-40753	)	_
180-19	40754-40761	Control	_
180-20	40762-40763	(	_
180-21	40763-40764	n	_
180-22	40764-40765	=	_
180-23	40765-40767	43	_
180-24	40767-40768	)	_
180-25	40769-40779	Difference	_
180-26	40780-40793	Schizophrenia	_
180-27	40794-40795	(	_
180-28	40795-40796	n	_
180-29	40796-40797	=	_
180-30	40797-40799	33	_
180-31	40799-40800	)	_
180-32	40801-40808	Control	_
180-33	40809-40810	(	_
180-34	40810-40811	n	_
180-35	40811-40812	=	_
180-36	40812-40814	43	_
180-37	40814-40815	)	_
180-38	40816-40826	Difference	_
180-39	40829-40832	Age	_
180-40	40833-40835	in	_
180-41	40836-40841	years	_
180-42	40842-40843	(	_
180-43	40843-40848	range	_
180-44	40848-40849	)	_
180-45	40850-40854	33.6	_
180-46	40855-40856	(	_
180-47	40856-40858	20	_
180-48	40858-40859	–	_
180-49	40859-40861	48	_
180-50	40861-40862	)	_
180-51	40863-40867	32.5	_
180-52	40868-40869	(	_
180-53	40869-40871	22	_
180-54	40871-40872	–	_
180-55	40872-40874	48	_
180-56	40874-40875	)	_
180-57	40876-40878	ns	_
180-58	40879-40883	33.4	_
180-59	40884-40885	(	_
180-60	40885-40887	20	_
180-61	40887-40888	–	_
180-62	40888-40890	48	_
180-63	40890-40891	)	_
180-64	40892-40896	32.5	_
180-65	40897-40898	(	_
180-66	40898-40900	22	_
180-67	40900-40901	–	_
180-68	40901-40903	48	_
180-69	40903-40904	)	_
180-70	40905-40907	ns	_
180-71	40910-40919	Education	_
180-72	40920-40922	in	_
180-73	40923-40928	years	_
180-74	40929-40930	(	_
180-75	40930-40935	range	_
180-76	40935-40936	)	_
180-77	40937-40941	12.8	_
180-78	40942-40943	(	_
180-79	40943-40944	8	_
180-80	40944-40945	–	_
180-81	40945-40947	19	_
180-82	40947-40948	)	_
180-83	40949-40953	15.5	_
180-84	40954-40955	(	_
180-85	40955-40957	10	_
180-86	40957-40958	–	_
180-87	40958-40960	20	_
180-88	40960-40961	)	_
180-89	40962-40963	t	_
180-90	40963-40964	(	_
180-91	40964-40966	84	_
180-92	40966-40967	)	_
180-93	40967-40968	=	_
180-94	40968-40969	–	_
180-95	40969-40973	5.78	_
180-96	40973-40974	,	_
180-97	40975-40976	p	_
180-98	40976-40977	<	_
180-99	40977-40982	0.001	_
180-100	40983-40987	13.1	_
180-101	40988-40989	(	_
180-102	40989-40990	8	_
180-103	40990-40991	–	_
180-104	40991-40993	19	_
180-105	40993-40994	)	_
180-106	40995-40999	15.5	_
180-107	41000-41001	(	_
180-108	41001-41003	10	_
180-109	41003-41004	–	_
180-110	41004-41006	20	_
180-111	41006-41007	)	_
180-112	41008-41009	t	_
180-113	41009-41010	(	_
180-114	41010-41012	74	_
180-115	41012-41013	)	_
180-116	41013-41014	=	_
180-117	41014-41015	−	_
180-118	41015-41019	4.75	_
180-119	41019-41020	,	_
180-120	41021-41022	p	_
180-121	41022-41023	<	_
180-122	41023-41028	0.001	_
180-123	41031-41041	Handedness	_
180-124	41042-41043	%	_
180-125	41044-41049	right	_
180-126	41050-41054	77.1	_
180-127	41054-41055	±	_
180-128	41055-41059	49.1	_
180-129	41060-41064	87.1	_
180-130	41064-41065	±	_
180-131	41065-41069	28.2	_
180-132	41070-41072	ns	_
180-133	41073-41077	77.3	_
180-134	41077-41078	±	_
180-135	41078-41082	48.3	_
180-136	41083-41087	87.1	_
180-137	41087-41088	±	_
180-138	41088-41092	28.2	_
180-139	41093-41095	ns	_
180-140	41098-41104	Gender	_
180-141	41105-41107	18	_
180-142	41108-41109	F	_
180-143	41109-41110	:	_
180-144	41111-41114	25M	_
180-145	41115-41117	22	_
180-146	41118-41119	F	_
180-147	41119-41120	:	_
180-148	41121-41124	21M	_
180-149	41125-41127	ns	_
180-150	41128-41130	13	_
180-151	41131-41132	F	_
180-152	41132-41133	:	_
180-153	41134-41137	20M	_
180-154	41138-41140	22	_
180-155	41141-41142	F	_
180-156	41142-41143	:	_
180-157	41144-41147	21M	_
180-158	41148-41150	ns	_
180-159	41153-41156	RIN	_
180-160	41156-41157	±	_
180-161	41157-41160	s.d	_
180-162	41160-41161	.	_
180-163	41162-41166	7.94	_
180-164	41166-41167	±	_
180-165	41167-41171	0.65	_
180-166	41172-41176	7.78	_
180-167	41176-41177	±	_
180-168	41177-41181	1.17	_
180-169	41182-41184	ns	_
180-170	41185-41189	7.89	_
180-171	41189-41190	±	_
180-172	41190-41194	0.67	_
180-173	41195-41199	7.78	_
180-174	41199-41200	±	_
180-175	41200-41204	1.18	_
180-176	41205-41207	ns	_
180-177	41210-41213	Age	_
180-178	41214-41216	of	_
180-179	41217-41222	onset	_
180-180	41223-41224	(	_
180-181	41224-41226	in	_
180-182	41227-41232	years	_
180-183	41233-41236	and	_
180-184	41237-41242	range	_
180-185	41242-41243	)	_
180-186	41244-41248	22.3	_
180-187	41249-41250	(	_
180-188	41250-41252	15	_
180-189	41252-41253	–	_
180-190	41253-41255	32	_
180-191	41255-41256	)	_
180-192	41257-41260	 	 	_
180-193	41261-41265	22.7	_
180-194	41266-41267	(	_
180-195	41267-41269	15	_
180-196	41269-41270	–	_
180-197	41270-41272	31	_
180-198	41272-41273	)	_
180-199	41274-41277	 	 	_
180-200	41280-41288	Duration	_
180-201	41289-41291	of	_
180-202	41292-41299	illness	_
180-203	41300-41302	in	_
180-204	41303-41308	years	_
180-205	41308-41309	±	_
180-206	41309-41312	s.d	_
180-207	41312-41313	.	_
180-208	41314-41318	11.7	_
180-209	41318-41319	±	_
180-210	41319-41323	6.18	_
180-211	41324-41327	 	 	_
180-212	41328-41332	11.2	_
180-213	41332-41333	±	_
180-214	41333-41337	6.73	_
180-215	41338-41341	 	 	_
180-216	41344-41349	PANSS	_
180-217	41350-41358	positive	_
180-218	41358-41359	±	_
180-219	41359-41362	s.d	_
180-220	41362-41363	.	_
180-221	41364-41368	15.8	_
180-222	41368-41369	±	_
180-223	41369-41373	4.82	_
180-224	41374-41377	 	 	_
180-225	41378-41382	15.8	_
180-226	41382-41383	±	_
180-227	41383-41387	4.92	_
180-228	41388-41391	 	 	_
180-229	41394-41399	PANSS	_
180-230	41400-41408	negative	_
180-231	41408-41409	±	_
180-232	41409-41412	s.d	_
180-233	41412-41413	.	_
180-234	41414-41418	14.3	_
180-235	41418-41419	±	_
180-236	41419-41423	6.98	_
180-237	41424-41427	 	 	_
180-238	41428-41432	14.0	_
180-239	41432-41433	±	_
180-240	41433-41437	6.49	_
180-241	41438-41441	 	 	_
180-242	41444-41449	PANSS	_
180-243	41450-41457	general	_
180-244	41457-41458	±	_
180-245	41458-41461	s.d	_
180-246	41461-41462	.	_
180-247	41463-41467	33.1	_
180-248	41467-41468	±	_
180-249	41468-41472	10.2	_
180-250	41473-41476	 	 	_
180-251	41477-41481	33.3	_
180-252	41481-41482	±	_
180-253	41482-41486	10.4	_
180-254	41487-41490	 	 	_
180-255	41493-41498	PANSS	_
180-256	41499-41504	total	_
180-257	41504-41505	±	_
180-258	41505-41508	s.d	_
180-259	41508-41509	.	_
180-260	41510-41514	63.2	_
180-261	41514-41515	±	_
180-262	41515-41519	19.5	_
180-263	41520-41523	 	 	_
180-264	41524-41528	63.1	_
180-265	41528-41529	±	_
180-266	41529-41533	19.4	_
180-267	41534-41537	 	 	_
180-268	41540-41554	Chlorpromazine	_
180-269	41555-41559	mean	_
180-270	41560-41570	equivalent	_
180-271	41571-41575	dose	_
180-272	41576-41577	(	_
180-273	41577-41579	mg	_
180-274	41579-41580	)	_
180-275	41580-41581	±	_
180-276	41581-41584	s.d	_
180-277	41584-41585	.	_
180-278	41586-41589	627	_
180-279	41589-41590	±	_
180-280	41590-41593	501	_
180-281	41594-41597	 	 	_
180-282	41598-41601	632	_
180-283	41601-41602	±	_
180-284	41602-41605	460	_
180-285	41606-41609	 	 	_
180-286	41612-41616	Body	_
180-287	41617-41621	mass	_
180-288	41622-41627	index	_
180-289	41628-41629	(	_
180-290	41629-41630	n	_
180-291	41630-41631	,	_
180-292	41632-41636	mean	_
180-293	41636-41637	±	_
180-294	41637-41640	s.d	_
180-295	41640-41641	.	_
180-296	41641-41642	)	_
180-297	41643-41645	33	_
180-298	41645-41646	,	_
180-299	41647-41651	30.6	_
180-300	41651-41652	±	_
180-301	41652-41656	6.65	_
180-302	41657-41660	 	 	_
180-303	41661-41663	26	_
180-304	41663-41664	,	_
180-305	41665-41669	30.9	_
180-306	41669-41670	±	_
180-307	41670-41674	6.67	_
180-308	41675-41678	 	 	_
180-309	41681-41694	Antipsychotic	_
180-310	41695-41696	(	_
180-311	41696-41705	frequency	_
180-312	41706-41708	in	_
180-313	41709-41714	total	_
180-314	41715-41721	cohort	_
180-315	41721-41722	)	_
180-316	41723-41734	amisulpride	_
180-317	41734-41735	=	_
180-318	41735-41736	8	_
180-319	41736-41737	,	_
180-320	41738-41750	aripripazole	_
180-321	41750-41751	=	_
180-322	41751-41752	6	_
180-323	41752-41753	,	_
180-324	41754-41763	clozapine	_
180-325	41763-41764	=	_
180-326	41764-41766	14	_
180-327	41766-41767	,	_
180-328	41768-41777	olazapine	_
180-329	41777-41778	=	_
180-330	41778-41779	8	_
180-331	41779-41780	,	_
180-332	41781-41793	paliperidone	_
180-333	41793-41794	=	_
180-334	41794-41795	3	_
180-335	41795-41796	,	_
180-336	41797-41807	quetiapine	_
180-337	41807-41808	=	_
180-338	41808-41809	8	_
180-339	41809-41810	,	_
180-340	41811-41822	risperidone	_
180-341	41822-41823	=	_
180-342	41823-41824	8	_
180-343	41824-41825	,	_
180-344	41826-41837	ziprasidone	_
180-345	41837-41838	=	_
180-346	41838-41839	2	_
180-347	41839-41840	,	_
180-348	41841-41854	zuclopentixol	_
180-349	41854-41855	=	_
180-350	41855-41856	1	_
180-351	41857-41860	 	 	_
180-352	41861-41872	amisulpride	_
180-353	41872-41873	=	_
180-354	41873-41874	5	_
180-355	41874-41875	,	_
180-356	41876-41888	aripripazole	_
180-357	41888-41889	=	_
180-358	41889-41890	5	_
180-359	41890-41891	,	_
180-360	41892-41901	clozapine	_
180-361	41901-41902	=	_
180-362	41902-41903	9	_
180-363	41903-41904	,	_
180-364	41905-41914	olazapine	_
180-365	41914-41915	=	_
180-366	41915-41916	7	_
180-367	41916-41917	,	_
180-368	41918-41930	paliperidone	_
180-369	41930-41931	=	_
180-370	41931-41932	2	_
180-371	41932-41933	,	_
180-372	41934-41944	quetiapine	_
180-373	41944-41945	=	_
180-374	41945-41946	7	_
180-375	41946-41947	,	_
180-376	41948-41959	risperidone	_
180-377	41959-41960	=	_
180-378	41960-41961	6	_
180-379	41961-41962	,	_
180-380	41963-41974	ziprasidone	_
180-381	41974-41975	=	_
180-382	41975-41976	1	_
180-383	41976-41977	,	_
180-384	41978-41991	zuclopentixol	_
180-385	41991-41992	=	_
180-386	41992-41993	1	_
180-387	41994-41997	 	 	_
180-388	42001-42014	Abbreviations	_
180-389	42014-42015	:	_
180-390	42016-42018	ns	_
180-391	42018-42019	,	_
180-392	42020-42023	not	_
180-393	42024-42035	significant	_
180-394	42035-42036	;	_
180-395	42037-42042	PANSS	_
180-396	42042-42043	,	_
180-397	42044-42052	Positive	_
180-398	42053-42056	and	_
180-399	42057-42065	Negative	_
180-400	42066-42074	Syndrome	_
180-401	42075-42080	Scale	_
180-402	42080-42081	;	_
180-403	42082-42085	RIN	_
180-404	42085-42086	,	_
180-405	42087-42090	RNA	_
180-406	42091-42100	integrity	_
180-407	42101-42107	number	_
180-408	42107-42108	;	_
180-409	42109-42112	s.d	_
180-410	42112-42113	.	_
180-411	42113-42114	,	_
180-412	42115-42123	standard	_
180-413	42124-42133	deviation	_
180-414	42133-42134	.	_

#Text=Individuals may be on one or more antipsychotics.
181-1	42135-42146	Individuals	_
181-2	42147-42150	may	_
181-3	42151-42153	be	_
181-4	42154-42156	on	_
181-5	42157-42160	one	_
181-6	42161-42163	or	_
181-7	42164-42168	more	_
181-8	42169-42183	antipsychotics	_
181-9	42183-42184	.	_
